

Molecular and Functional Characterisation of Lysine-11-Linked Ubiquitination in Pattern Recognition Receptor Signalling



Doctoral thesis

for

the award of the doctoral degree

of the Faculty of Mathematics and Natural Sciences

of the University of Cologne

submitted by

Muhammed Talha Cinko

2026

Table of content

Abstract	4
Zusammenfassung	6
1 Introduction	8
1.1 Ubiquitin and the Ubiquitination System	8
1.1.1 E3 Ubiquitin Ligases and Their Functions in Gene Regulation and Cell Death	13
1.1.2 Deubiquitinases	16
1.2 The TNF Signalling Pathway	17
1.3 PRR	20
1.3.1 NLRs	21
1.3.2 ALRs	22
1.3.3 CLRs	22
1.3.4 TLRs	23
1.3.4.1 TLR3 Signalling Pathway	24
1.3.4.2 TLR4 Signalling Pathway	28
1.3.5 RLRs	32
1.3.6 cGAS-STING	35
1.4 IFN Signalling	38
1.4.1 IFN-I	38
1.4.2 IFN-II	41
1.4.3 IFN-III	42
1.5 Cell Death	44
1.5.1 Apoptosis	44
1.5.2 Necroptosis	47
1.5.3 Pyroptosis	48
1.6 ANKIB1	49
1.7 Aim of the study	54
2 Materials and Methods	56
2.1 Generation of ANKIB1 Expression Constructs	56
2.2 Recombinant proteins, cells and cell lines	56
2.3 SDS-PAGE and Western blotting	57
2.4 Cell Activation and Immunoprecipitation	58
2.5 Production of Tandem Ubiquitin Binding Entity (TUBE) and Deubiquitinases	58
2.6 <i>In vitro</i> Ubiquitin Assay	59
2.7 K11-Ub Specific Antibody Production	59
2.8 Tandem Ubiquitin Binding Entity Pulldown (TUBE PD) and <i>In vitro</i> Deubiquitination Assay	59

2.9	K11-Ub IP	60
2.10	Mice	60
2.11	Isolation of Bone Marrow Derived Macrophages (BMDMs) and splenocytes	61
2.12	RNA Isolation and RT-qPCR.....	61
2.13	RNA sequencing.....	61
2.14	ELISA	62
2.15	HSV-1 Infection and Disease Monitoring.....	62
2.16	Secondary HLH and <i>E. coli</i> sepsis model.....	62
2.17	IAV Infection	63
2.18	<i>In vitro</i> Infection Assays.....	63
2.19	nCounter RNA Analysis.....	63
2.20	Cytokine/Chemokine Quantification	63
2.21	Ubiquitin Linkage Type Identification.....	64
2.22	Statistics, Reproducibility and Softwares.....	64
2.23	Data Availability	65
2.24	Declaration of Artificial Intelligence Usage.....	65
3	Results.....	66
4	Discussion	93
5	References	101
6	Appendix	118
6.1	Abbreviations	118
6.2	List of the Figures	123

Abstract

Pattern recognition receptor (PRR)-mediated interferon (IFN) production is essential for host defence against invading pathogens. Among PRRs, Toll-like receptor 3 (TLR3), TLR4, Retinoic Acid-Inducible Gene I (RIG-I) / Mitochondrial Antiviral-Signalling (MAVS) and the cyclic GMP–AMP synthase–stimulator of interferon genes (cGAS–STING) pathways signal through TANK-binding kinase 1 (TBK1), which activates the transcription factor IFN regulatory factor 3 (IRF3) via its phosphorylation, thereby inducing type I and type III IFN production. Beyond its role in innate immune signalling, TBK1 also functions within the TNF pathway, where it phosphorylates receptor-interacting protein kinase 1 (RIPK1) to suppress cell death. Previous studies demonstrated that TBK1 recruitment to the TNF receptor 1 signalling complex (TNFR1-SC) depends on the linear ubiquitin ligase activity of HOIP, which promotes the recruitment of NEMO and subsequent association of TBK1 through the adaptor proteins TRAF family member-Associated NF- κ B Activator (TANK), NAK-Associated Protein 1 (NAP1). However, the molecular mechanisms governing TBK1 recruitment and activation downstream of PRRs have remained poorly understood. This study identifies lysine 11-linked ubiquitin chains (K11-Ub) as critical regulators of TBK1 activation downstream of TLR3, TLR4, and cGAS–STING signalling, but not the RIG-I/MAVS pathway. The RBR E3 ubiquitin ligase Ankyrin repeat and IBR domain-containing protein 1 (ANKIB1) catalyses the formation of K11-linked ubiquitin chains on components of the TLR3- and cGAS–STING-associated signalosomes, thereby promoting the recruitment of Optineurin (OPTN), while not affecting the recruitment of TANK, NAP1, or Similar to NAP1 TBK1 Adaptor (SINTBAD). OPTN recruitment subsequently enables TBK1 activation, defining a previously unrecognized signalling axis. Mechanistically, ANKIB1 is recruited to the respective signalling complexes through its ubiquitin-interacting motif (UIM), where it mediates K11-linked ubiquitination of TRIF, OPTN, NEMO, and STING. ANKIB1 itself also undergoes auto-ubiquitination under basal conditions, which is further enhanced following TLR3 or STING activation. Importantly, the RING1, but not RING2, domain of ANKIB1, is required for these ubiquitination events and for subsequent TBK1 activation unlike other RBR group E3 ligases. In addition, loss of ANKIB1 severely impairs TBK1/IRF3 activation, and subsequent IFN production, following TLR3/4 cGAS–STING stimulation. In contrast, RIG-I/MAVS-dependent signalling and IFN induction remain unaltered. Biochemical analyses revealed that RIG-I/MAVS signalling primarily relies on TANK, NAP1, and SINTBAD for TBK1 activation, whereas TLR3/4- and cGAS–STING-mediated TBK1 activation is governed by OPTN, establishing ANKIB1 as a central regulator of TBK1 activation in OPTN-dependent PRR pathways. *In vivo* studies further manifested that ANKIB1 deficiency attenuates IFN production downstream of TLR3 signalling, thereby alleviating interferonopathy and improving survival in a secondary haemophagocytic lymphohistiocytosis (HLH) model. Conversely, ANKIB1 depletion compromises type I IFN responses and antiviral immunity, resulting in increased susceptibility to herpes simplex virus 1 (HSV-1) infection, which primarily activates cGAS–STING signalling. Collectively,

these findings reveal an unexpected and indispensable role for K11-linked ubiquitin signalling in PRR-mediated IFN production and immune responses, both *in vitro* and *in vivo*.

Zusammenfassung

Die durch Mustererkennungsrezeptoren (PRR) vermittelte Interferon (IFN)-Produktion ist für die Abwehr eindringender Krankheitserreger durch den Wirt von entscheidender Bedeutung. Zu den PRRs gehören der Toll-like-Rezeptor 3 (TLR3), TLR4, Retinsäure-induzierbares Gen-I (RIG-I)/ Mitochondrialer Antiviraler-Signalweg (MAVS) sowie die zyklische GMP–AMP Synthase–Stimulator-von-Interferon-Genen (cGAS-STING)-Signalwege. Diese Signalwege vermitteln ihre Signale über die TANK-bindende Kinase 1 (TBK1), welche den Transkriptionsfaktor IFN-Regulationsfaktor 3 (IRF3) durch dessen Phosphorylierung aktiviert und dadurch die Produktion von Typ-I- und Typ-III-IFN induziert. Neben seiner Rolle in der angeborenen Immunantwort ist TBK1 auch im TNF-Signalweg aktiv, wo es die Rezeptor-interagierende Proteinkinase 1 (RIPK1) phosphoryliert und so den Zelltod hemmt. Frühere Studien haben gezeigt, dass die Rekrutierung von TBK1 an den TNF-Rezeptor-1-Signalkomplex (TNFR1-SC) von der linearen Ubiquitin-Ligase-Aktivität von HOIP abhängt. HOIP fördert hierbei die Rekrutierung von NEMO und die anschließende Assoziation von TBK1 über die Adapterproteine TRAF-Familienmitglied-assoziiierter NF- κ B-Aktivator (TANK) und NAK-assoziiertes Protein 1 (NAP1). Die molekularen Mechanismen, die die Rekrutierung und Aktivierung von TBK1 nach Aktivierung von PRRs steuern, sind jedoch bislang kaum verstanden. Diese Studie identifiziert Lysin-11-verknüpfte Ubiquitinketten (K11-Ub) als entscheidende Regulatoren der TBK1-Aktivierung im Anschluss an die Aktivierung der TLR3-, TLR4- und cGAS-STING-Signalwege, nicht jedoch des RIG-I/ MAVS-Signalwegs. Das RBR-E3-Ubiquitinligase Ankyrin-Repeat- und IBR-Domänen-haltiges Protein 1 (ANKIB1) katalysiert die Bildung von K11-verknüpften Ubiquitinketten an Komponenten der TLR3- und cGAS-STING-assoziierten Signalosomen und fördert dadurch die Rekrutierung von Optineurin (OPTN), ohne jedoch die Rekrutierung von TANK, NAP1 oder dem NAP1-ähnlichen TBK1-Adaptor (SINTBAD) zu beeinflussen. Die OPTN-Rekrutierung ermöglicht anschließend die TBK1-Aktivierung und definiert so einen bisher unbekannten Signalweg. Mechanistisch gesehen wird ANKIB1 über sein Ubiquitin-Interaktionsmotiv (UIM) an die jeweiligen Signalkomplexe rekrutiert, wo es die K11-verknüpfte Ubiquitinierung von TRIF, OPTN, NEMO und STING vermittelt. ANKIB1 selbst unterliegt unter basalen Bedingungen einer Autoubiquitinierung, die nach Aktivierung von TLR3 oder STING weiter verstärkt wird. Wichtig ist, dass im Gegensatz zu anderen E3-Ligasen der RBR-Familie die RING1-Domäne von ANKIB1 - nicht jedoch die RING2-Domäne - für diese Ubiquitinierungsvorgänge und die anschließende TBK1-Aktivierung erforderlich ist. Darüber hinaus beeinträchtigt der Verlust von ANKIB1 die TBK1/ IRF3-Aktivierung und die nachfolgende IFN-Produktion nach TLR3/ 4/ cGAS-STING-Stimulation erheblich. Im Gegensatz dazu bleiben die RIG-I/ MAVS-abhängige Signalübertragung und die IFN-Induktion unverändert. Biochemische Analysen haben gezeigt, dass die RIG-I/ MAVS-Signalübertragung für die TBK1-Aktivierung primär auf TANK, NAP1 und SINTBAD angewiesen ist, während die TLR3/ 4- und cGAS-STING-vermittelte TBK1-Aktivierung durch OPTN gesteuert wird. Dies etabliert ANKIB1 als zentralen Regulator der TBK1-Aktivierung in OPTN-abhängigen PRR-Signalwegen. In-vivo-Studien haben weiterhin gezeigt, dass ein

Mangel an ANKIB1 die IFN-Produktion TLR3- nachgeschalteter Signalübertragung abschwächt, wodurch Interferonopathie gemildert sowie die Überlebensrate in einem sekundären hämophagozytischen Lymphohistiozytose (HLH)-Modell verbessert werden kann. Umgekehrt beeinträchtigt die Reduktion von ANKIB1 die Typ-I-IFN-Antworten und die antivirale Immunität, was zu einer erhöhten Anfälligkeit für eine Infektion mit dem Herpes-simplex-Virus Typ 1 (HSV-1) führt, welches primär die cGAS-STING-Signalübertragung aktiviert. Zusammenfassend zeigen diese Ergebnisse eine unerwartete und unverzichtbare Rolle der K11-verknüpften Ubiquitin-Signalgebung bei der PRR-vermittelten IFN-Produktion und den Immunantworten, sowohl *in vitro* als auch *in vivo*.

1 Introduction

Advances in biochemical profiling have increasingly linked cellular pathogenesis to aberrant biochemical reactions. Upon exposure to extracellular stimuli, such as signalling molecules or infectious agents, cells initiate biochemical cascades that govern essential outcomes, including proliferation, phenotypic behaviour, fate determination, and host defence. These complex networks incorporate stringent checkpoints regulated by physical or chemical modifications of core constituents, predominantly mediated by regulatory proteins and post-translational modifications (PTMs). PTMs involve the covalent conjugation of functional moieties to indispensable proteins within these networks. Consequently, functional impairments in regulatory proteins or genetic mutations at PTM target sites can disrupt the molecular "on-off" switches governing signalling and metabolic pathways, frequently resulting in elevated morbidity or lethality.

Regulatory proteins operate through two primary mechanistic modalities: scaffolding and enzymatic activity. Scaffolding induces conformational changes that modulate the functionality of associated pathway proteins, whereas enzymatic activity catalyses PTMs such as phosphorylation, glycosylation, and ubiquitination (Ub)¹. While protein phosphorylation is a classically characterised PTM, Ub—the covalent ligation of ubiquitin to substrate proteins—is comparably abundant and integral to nearly all cellular events. Empirical evidence has demonstrated the indispensable role of Ub in orchestrating signal transduction, fundamental cellular processes, inflammatory responses, and programmed cell death. Accordingly, the dysregulation of Ub pathways is established as a primary driver in the pathogenesis of various conditions, notably cancer, autoimmune disorders, and neurodegenerative diseases².

1.1 Ubiquitin and the Ubiquitination System

Ubiquitin is a highly conserved, compact, and globular 8.6 kDa protein comprising 76 amino acids that is ubiquitously expressed across all cell types. In mammalian systems, it is encoded by four distinct genes: *UBB*, *UBC*, *RPS27*, and *UBA52*. *UBB* and *UBC* are polycistronic genes and responsible for the expression of polyubiquitin precursors whereas the expression and translation of *RPS27*, and *UBA52* genes result in ubiquitin-ribosomal fusion proteins which provide a single ubiquitin after processed³. As one of the most prevalent PTMs, Ub is critically involved in regulating virtually all signalling pathways by modulating protein activity, physiological persistence, and subcellular localisation.

The foundational understanding of the ubiquitin system and its mechanisms was established through the pioneering work of Avram Hershko, Aaron Ciechanover, and Irwin Rose between 1978 and 1980. Their investigations into *in vitro* proteolysis, utilising lysosome-deficient rabbit reticulocyte lysates, yielded several critical observations: first, substrate degradation was strictly dependent on Adenosine Triphosphate (ATP) hydrolysis; second, the process required the presence of a small, heat-stable

proteinaceous factor; and third, target substrates exhibited an increase in molecular weight prior to their degradation⁴⁻⁶. Although initially designated as ATP-dependent proteolysis factor 1 (APF-1), this heat-stable molecule was subsequently recognised as ubiquitin, a protein previously implicated in promoting lymphocyte differentiation^{7, 8}. Later structural and biochemical analyses revealed that ubiquitin's remarkable heat stability arises from its extensive intramolecular interactions. Furthermore, the observed increase in substrate size was attributed to the covalent conjugation of a minimum of four ubiquitin moieties prior to the ATP-dependent degradation of the target^{4, 5, 9}.

While Ub was originally characterised solely as a mechanism to promote proteasomal degradation, subsequent research has illuminated its extensive non-proteolytic functions. Consequently, ubiquitinated proteins can experience vastly different cellular fates. This functional diversity—despite a conserved fundamental conjugation mechanism—is dictated by structural variations among ubiquitination machinery components and the inherent complexity of the ubiquitin code, which distinguishes between monoubiquitination and diverse polyubiquitin chains¹⁰.

Mechanistically, Ub typically involves the formation of an isopeptide bond between the alpha-carboxyl group at the C-terminus of ubiquitin and the epsilon-amino group of a target lysine residue on the substrate protein¹¹. Substrates can undergo monoubiquitination, which is the attachment of a single ubiquitin moiety. Alternatively, they can be multi-monoubiquitinated, wherein individual ubiquitin molecules are conjugated to multiple distinct lysine residues on the same target protein. Both of these configurations are frequently implicated in regulatory processes such as deoxyribonucleic acid (DNA) repair, viral budding, and transcriptional regulation. Finally, polyubiquitination is characterised by the sequential attachment of multiple ubiquitin molecules to a single substrate lysine residue, forming a chain linked by isopeptide bonds, as illustrated in Figure 1.1¹¹.




Figure 1.1: Structural Architecture of Ubiquitin and Modalities of Ubiquitination. **A)** Schematic representation of the molecular structure of ubiquitin, highlighting the spatial distribution and specific positions of its internal lysine residues. **B)** Categorisation of ubiquitination patterns, including monoubiquitination (top), polyubiquitination (centre), and multi-monoubiquitination (bottom). Adapted from^{12, 13}.

A single ubiquitin molecule contains eight potential amine groups for conjugation: its N-terminal methionine (M1) and seven internal lysine residues (K6, K11, K27, K29, K33, K48, and K63). Any of these sites can act as an acceptor for subsequent ubiquitin attachment, resulting in the formation of structurally distinct polyubiquitin chains, or linkages (e.g., K48- or K63-linked chains)¹⁴. The topological nature of the specific polyubiquitin chain dictates its physiological role, as summarised in Figure 1.2. For example, K48-linked chains as the most abundant type classically target substrates for proteasomal degradation. In contrast, K63-linked chains predominantly function as scaffolds to mediate downstream protein-protein interactions or induce allosteric conformational changes in the target protein. Alternatively, M1-linked (also known as linear) chains act as recruitment platforms for effector proteins, such as kinases, thereby initiating signal transduction cascades. Furthermore, it was documented that K6-Ub involves radiation-induced DNA damage response and mitophagy process¹⁵. Even though there are only few studies about K27-Ub, it was suggested that K27-Ub is capable of both, targeting proteins for autophagic degradation and enhancing autophagic flux through its association with autophagy receptors^{16, 17}. K29-Ub is associated with the regulation of proteasome by preventing substrate protein engagement to the proteasome¹⁸. Furthermore, despite the presence of few studies current evidences suggested that K33-Ub plays a role in endomembrane trafficking, particularly in regulating protein localisation to the trans-Golgi network¹⁹. Moreover, K11-linked chains mostly correspond with proteasomal degradation in cell cycle²⁰ and endoplasmic reticulum (ER) related misfolded protein response²¹ in spite of some indication of its role in signalling²². Nonetheless, a recent report showed that K11/K48 branch chains provide faster and more robust degradation of the target proteins compared to K11- chains alone²³. Another study also showed that homotypic K11 chains are not engaged with 26S proteasome in contrast to K11/K48 hybrid chain²⁴. In addition, presence of K11/K63 hybrid chains were documented as signal for a receptor internalisation²⁵. Despite these established paradigms, the precise biological functions of several atypical linkage types and mixed chains remain incompletely elucidated^{14, 26}.




Figure 1.2: Diversity of Polyubiquitin Chain Topologies and Their Established Biological Functions. Summary of the various polyubiquitin linkage types and their respective physiological implications as characterized to date. Redrawn and adapted from¹⁴.

The enzymatic cascade of Ub is orchestrated by three sequential classes of enzymes: the ubiquitin-activating enzyme (E1), the ubiquitin-conjugating enzyme (E2), and the ubiquitin-protein ligase (E3). As illustrated in Figure 1.3, the process initiates with the ATP-dependent activation of ubiquitin by E1, which results in the formation of adenylated ubiquitin and a subsequent thioester bond between the C-terminal carboxyl group of ubiquitin and a catalytic cysteine residue within the E1 active site²⁷. Subsequently, the ubiquitin moiety is translocated to a cysteine residue on an E2 enzyme via a transthioesterification reaction. In the final stage, the E3 ligase facilitates the Ub of the target substrate. Depending on the structural class of the E3 ligase, the ubiquitin moiety is transferred either directly from the E2 to the substrate or through a covalent E3-ubiquitin intermediate²⁸.

Current genomic data and classification studies indicate that the human proteome contains approximately two E1s, Ubiquitin Like Modifier Activating Enzyme (UBA) 1 and UBA6^{29, 30}, approximately 40 E2s for ubiquitin and ubiquitin-like proteins (UBLs)³¹, and 672 E3s³². This hierarchical expansion determines that substrate specificity is primarily determined by the diverse array of E3 ligases. Furthermore, the specific E3 ligase involved governs the architectural characteristics of the ubiquitin modifications, including the length and linkage composition of the chains. Given their substrate-specific activities and differential regulatory roles, a comprehensive characterisation of E3

ligases and their associated ubiquitin modifications are essential for elucidating specific cellular functions and gaining profound mechanistic insights into the broader Ub machinery¹¹.




Figure 1.3: General Overview of Ubiquitination Mechanism. Ubiquitin (Ub), ubiquitin-activating enzyme (E1), ubiquitin-conjugating enzyme (E2), and ubiquitin protein ligase (E3). Adapted from³³.

In addition to lysine residues of ubiquitin, the high conservation of its amino acid (aa) sequence from yeast to humans indicates that the structural topology of ubiquitin is equally critical for its biological function. Ubiquitin contains three prominent and characteristic hydrophobic surface patches centered around Phe4, Ile36, and Ile44. The Phe4 patch plays a particularly important role in mediating interactions with the Ubiquitin-Binding in ABIN and NEMO (UBAN) domain as well as with deubiquitinating enzymes. The Ile36 patch is closely associated with the recognition of DUBs and ubiquitin-binding domains (UBDs) present in various proteins. In contrast, the Ile44 patch is primarily required for interactions with the proteasome³⁴. Also, recently emerging data indicated that the modification of ubiquitin molecule itself modulate Ub reaction pipeline. For instance, it was reported that lysine residues of the ubiquitin could be decorated by acetyl groups (Acs), which do not block E1-mediated E2 charging, but instead interfere the ubiquitin transfer to the substrates and polyubiquitin chains elongation as evidenced using K6-AcUb and K48-AcUb³⁵. However, physiological function and molecular mechanism of ubiquitin acetylation remain to be elucidated. Phosphorylation represents another PTM of ubiquitin. Proteomic analyses have identified multiple ubiquitin phosphorylation sites, including Thr7, Thr12, Thr14, Ser20, Thr22, Thr55, Tyr59, Thr66, and Ser65¹⁵. However, among these modifications, only Ser65-phosphorylated ubiquitin has been functionally characterized in detail. Ser65-phosphorylated ubiquitin exists in two dynamic conformational states. The predominant conformation closely resembles native ubiquitin but exhibits altered surface charge properties. In contrast, in the less abundant conformation, it shows distinct surface charge distributions, but also C-terminus of the ubiquitin is folded into the ubiquitin core. This structural arrangement can hinder the extension of

polyubiquitin chains while not impairing ubiquitin charging of E2 enzymes by E1^{36, 37}. Despite these insights, the biological significance of ubiquitin phosphorylation, its interacting partners, impact on association with E3 ligases and broader functional roles remain incompletely understood and require further investigation.

1.1.1 E3 Ubiquitin Ligases and Their Functions in Gene Regulation and Cell Death

Following the initial characterisation of the ubiquitin molecule, the first comprehensive biochemical delineation of the ubiquitin system was conducted in the early 1980s by Hershko and colleagues. Their critical work identified three distinct classes of enzymes—designated E1, E2, and E3—which were defined by their sequential roles in the protein degradation pathway³⁸. However, the detailed investigation of a specific E3 ubiquitin ligase did not occur until 1990, with the study of UBR1 in *Saccharomyces cerevisiae*. This research was pivotal in establishing the biochemical significance of E3 enzymes. Since then, a multitude of E3 ligases has been identified across diverse species and categorised based on their conserved structural architectures^{2, 32, 39}.

An active E3 ligase is defined as a protein capable of interacting with an E2-Ubiquitin or E2 UBL intermediate. Based on the structural configuration of this domain and the specific mechanism, the E3 must possess the catalytic capacity to facilitate the transfer of the ubiquitin or UBL moiety from the E2 onto a specific target substrate or the E3 protein itself as illustrated in Figure 1.4.

E3 ligases are classified into four primary groups according to their structure and catalytic mechanism: (i) Really Interesting New Gene (RING), (ii) degenerate RING (dRING), (iii) Homologous to the E6-AP Carboxyl Terminus (HECT), and (iv) RING-Between-RING (RBR). Each class possesses unique conserved domains and catalytic residues³².

RING-type E3 ligases are defined by the presence of either a RING or a U-box catalytic domain. This class facilitates the direct transfer of ubiquitin from the E2-conjugating enzyme to the target substrate. Comprising more than 450 identified genes, RING-type ligases represent the largest E3 family in the human genome. While certain RING E3s function as monomers by simultaneously binding the E2 and the substrate, others operate as complex multimeric assemblies. Their RING domains utilise conserved cysteine and histidine residues to coordinate Zn^{2+} ions, a structural requirement for stabilising the conformation necessary for enzymatic activity⁴⁰. On the other hand, dRING E3s have a U-box catalytic domain, that shares significant structural homology with the canonical RING domain. The primary distinction lies in the stabilisation of the domain's fold. U-box domains rely on a network of hydrogen bonds and salt bridges to maintain their architecture, rather than zinc ion coordination, as is the case for the RING domains. Despite this difference in stabilisation, U-box E3s function mechanistically as RING-type E3 ligases⁴¹. However, both E3 types rely on certain E2 enzymes to determine the polyubiquitin linkage specificity because of the closed conformation of E2-Ub, mediated by RING

E3s³⁴. For example, BRCA1 generates K63-linked polyubiquitin chains in coordination with E2 enzymes, Ube2N-Uev1A, whereas it builds K48-linked polyubiquitin chains with Ube2K⁴². Also, Ube2S emerged as K11-Ub-generating E2 enzyme in coordination with RING E3 ligase, anaphase promoting complex (APC/C)⁴³.

In contrast, HECT E3 ligases exhibit a binary structural organization characterised by an N-terminal E2-binding domain and C terminal HECT domain, bearing a catalytic cysteine residue. Unlike the RING class, HECT enzymes form a covalent E3-ubiquitin thioester intermediate during the reaction. In this mechanism, ubiquitin is first transferred from the E2 to the catalytic cysteine within the HECT domain before the final formation of an isopeptide bond with the target substrate. Because of ubiquitin-E3 intermediate, HECT E3 ligases determine the type of polyubiquitin chains independently of E2s. To date, only 28 genes encoding HECT ligases have been identified in the human proteome^{44, 45}.

The fourth class, RBR E3 ligases, employs a hybrid catalytic mechanism that distinguishes them from both the RING and HECT types. RBR E3s are characterised by a modular architecture, consisting of a RING1 domain, an "In-Between-RING" (IBR) domain, and a RING2 domain, and each domain coordinates with two Zn^{2+} ions for the stability of their structure. The RING1 domain facilitates E2 binding through conserved cysteine and histidine residues, similar to the RING-type ligases, albeit it was reported that RBR-RING1 allows for an open conformation of the E2-Ub complex rather than a closed stage, which canonical RING E3s enable for E2-mediated polyubiquitin linkage specificity. Consequently, a different mechanism of action in E2-E3 association⁴⁶ was suggested. On the contrary, the RING2 domain is both structurally and functionally distinct from RING1 and contains a catalytic cysteine that forms a covalent ubiquitin-E3 intermediate, a process analogous to the HECT mechanism. This intermediate, which also designates the polyubiquitin chain topology, subsequently catalyses Ub of the substrate. IBR domains are structurally similar to RING2 domains despite their unknown function⁴⁶. Also, a small subgroup of RBR E3 ligases, including heme-oxidized IRP2 ubiquitin ligase-1 (HOIL-1)-interacting protein (HOIP), Parkin, Ariadne RBR E3 Ubiquitin Protein Ligase (ARIH) 1, ARIH2 and Ankyrin Repeat And IBR Domain Containing 1 (ANKIB1) carry an autoinhibitory Ariadne domain, physically masking the catalytic cysteine of RING2, keeping apart RING1 and RING2 domains and ultimately interfering any E3-Ub intermediate formation. To relieve this autoinhibitory state, specific protein-protein interactions are required, which results in a major conformational rearrangement of catalytic RBR domain. For example, HOIP must associate with HOIL-1 and SHANK-associated RH-domain-interacting protein (SHARPIN) to achieve activation^{47, 48}. Similarly, Parkin activation involves binding to Ser65-phosphorylated ubiquitin, followed by PINK1-mediated phosphorylation of its UBL domain, which together promote the release of autoinhibition¹⁵. Compared to the other classes, only 14 RBR E3 genes have been defined hitherto. While the biological roles of specific members—such as HOIL-1 and HOIP—have been established in immune signalling, the biochemical functions of most RBR family members, such as ANKIB1, remain poorly understood^{49, 50}.

Consequently, further research is required to fully dissect the functional importance of the remaining RBR E3 ligases.




Figure 1.4: Comparative Schematic of E3 Ubiquitin Ligase Classes. Overview of the structural and functional diversity among E3 ligase families, including Ubiquitin (Ub), the ubiquitin-conjugating enzyme (E2), the Homologous to the E6-AP Carboxyl Terminus (HECT), Really Interesting New Gene (RING), and the RING1-IBR-RING2 (RBR) classes. **A)** Detailed illustration of the catalytic mechanisms employed by RING-type and HECT-type E3 ligases. **B)** Schematic representation of the ubiquitination mechanism specific to the RBR-type E3 ligase family. Adapted from⁵¹.

To exploit the multifaceted functionalities of diverse protein ubiquitination linkages and mechanisms, eukaryotic cells express numerous E3 ubiquitin ligases. These enzymes provide an extensive repertoire of substrate recognition modules and regulatory components. The unique biochemical properties of each E3 ligase modulate the stability and conformational state of their target proteins, thereby orchestrating a wide array of cellular activities. One of the primary roles of these ligases is the regulation of gene activation, achieved through the direct ubiquitination of proteins involved in transcriptional pathways. Alternatively, E3 ligases can exert indirect control upon extracellular stimuli by triggering the K48-linked polyubiquitination and subsequent proteasomal degradation of either transcription factors or their respective inhibitors, effectively serving as molecular switches for gene expression⁵². Also, they can build a unique polyubiquitin platform that can recruit a variety of effector proteins, allowing downstream pathway activation. Furthermore, specific E3 ligases, such as HOIP and cellular inhibitor of the apoptosis proteins 1 and 2 (cIAP1/2), govern cell death transitions by regulating pathways such as programmed cell death (apoptosis) and regulated necrosis (necroptosis). These enzymes function as

"double-edged swords": they may enhance the stability of receptor complexes through various types of polyubiquitination such as K63 and linear-Ub, to favour pro-survival gene activation or, conversely, promote cell death signalling and cellular disintegration²⁶. This dual regulatory capacity is particularly prominent in immune signalling, where E3 ligases maintain the balance between inflammation and cell death, as observed in the tumour necrosis factor receptor superfamily-tumour necrosis factor superfamily (TNFRSF-TNFSF) and PRR signalling pathways⁵³, which would be discussed in the following sections in detail.

1.1.2 Deubiquitinases

As with other PTMs, Ub is a reversible process. The precise removal of ubiquitin is fundamental to prevent aberrant signalling that could otherwise compromise cellular homeostasis. This regulated excision is mediated by a specialised protease family known as deubiquitinases (DUBs), of which approximately 100 distinct members have been identified in humans. Parallel to the selectivity of E3 ligases, DUBs exhibit specific activities that are contingent upon the nature of the substrate and the topology of the ubiquitin chain targeted for degradation⁵⁴.

DUBs are categorised into two main classes as cysteine(thiol)-based ubiquitin proteases and ubiquitin metalloproteases. While Jab1/Mov34/MPN protease (JAMM) family members are zinc-binding ubiquitin metalloproteases, thiol ubiquitin proteases are further divided into six different subgroups on the basis of their various structures, including Ub C-terminal hydrolases (UCHs), Ub-specific proteases (USPs), Machado-Josephin domain proteases (MJDs), ovarian tumour proteases (OTUs), motif interacting with Ub-containing novel DUB family (MINDY), and zinc-finger-containing Ub peptidase (ZUP1). Despite their structural divergence, these enzymes operate via a conserved catalytic mechanism mediated by a classic catalytic triad. Within this triad, a neighbouring histidine residue decreases the pKa of the cysteine, thereby enhancing its nucleophilicity. Concurrently, an acidic residue—typically asparagine, aspartic acid, or glutamic acid—facilitates the further polarization and electrostatic stabilization of the histidine intermediate⁵⁵. Ultimately, a nucleophilic thiol group attacks the carbonyl group of the ubiquitin, breaking the isopeptide or peptide bond between two ubiquitin moieties. However, a few mechanistic differences were recently reported. For example, USP30 carries a unique catalytic triad, comprised of Cys-His-Ser, wherein serine residue facilitates the proper association of histidine residues. Thus, it was suggested that this could be a general mechanism for the USP family as it is also documented for USP16 and USP45^{56, 57}. In contrast, MINDY1/2 use a distinct, non-canonical mechanism that coordinates a water molecule via a Thr residue in the position of a traditional acidic residue⁵⁸. Nonetheless, catalytic mechanism of JAMM metalloproteases variously rely on zinc ion coordination with two histidine, an aspartate and a water molecule, which acts as a nucleophile upon its activation by a zinc ion⁵⁹. In general, DUBs also differ from each other on basis of their substrate specificity determined by the ubiquitin chain linkage type and length, but all mainly interacts with Ile44

patch of the ubiquitin⁵⁵. OTU deubiquitinase with linear linkage specificity (OTULIN) is illustrated as a linear ubiquitin specific DUB since its rigid binding interface solely allows linear ubiquitin chains and does not tolerate even a slightly rotated structure of K63-linked chains⁶⁰. Conversely, USP DUB, cylindromatosis (CYLD), is more tolerant than OTULIN, enabling its accommodation on K63-M1 ubiquitin chains and their cleavage⁶¹.

In consideration of their specificity and unique function, DUBs are implicated in numerous physiological processes, including protein quality control, DNA damage response, immune signalling, and autophagy. USP30 opposes Parkin mediated ubiquitination of the mitochondria, thereby interfering the mitophagy⁶². Also, Associated Molecule with the SH3 domain of STAM (AMSH) removes K63-linked polyubiquitin chains from epidermal growth factor receptor (EGFR) and limits its subsequent lysosomal degradation⁶³. Moreover, A20 catalyses the K63-linked deubiquitination of TNF receptor-associated factor (TRAF) 6 and negatively regulates lipopolysaccharides (LPS)-induced nuclear factor κ light-chain enhancer of the activated B cells (NF- κ B) activation⁶⁴. Besides, OTU7B (Cezanne) cleaves K11-linked ubiquitin chains associated with APC/C substrates and reverses their proteasomal degradation⁶⁵. Intriguingly, it has been demonstrated that Cezanne prolongs Hypoxia-Inducible Factor 1- α (HIF1- α) turnover proteasome independent manner by removing its K11-Ub⁶⁶. Despite some established function of the DUBs on specific ubiquitin linkage types, many DUBs can cleave more than one type of ubiquitin chains with varying degree of preferences. Consequently, the underlying mechanisms by which DUBs exert their catalytic functions, as well as the specific molecular parameters that dictate their linkage specificity, require further clarification.

1.2 The TNF Signalling Pathway

In response to infection or pathogenic challenge, cells synthesise and secrete a variety of cytokines and chemokines to recruit and activate immune cells, thereby initiating a robust inflammatory response. TNFRSF members, which comprise 26 receptors, including TNFR1, CD95 (Fas), and the TNF-related apoptosis-inducing ligand (TRAIL) receptors 1/2 (TRAIL-R1/2), are central in this process^{67, 68}. These "death receptors" (DRs) possess a cytoplasmic death domain (DD) that allows them to trigger inflammatory gene activation or execute cell death signals, such as apoptosis or necroptosis, contributing to host defence. The transition between these divergent signalling outcomes is stringently regulated.

The TNFR1 signalling complex (TNFR1-SC), also known as Complex I, represents a well-characterised model of this system. Upon binding the TNF ligand, TNFR1 undergoes trimerisation, leading to the concerted recruitment of several adapter proteins. Specifically, TNFR-associated via death domain (TRADD) associates with the receptor, facilitating the recruitment of receptor interacting serine/threonine protein kinase 1 (RIPK1), TRAF2, and the E3 ligases, cIAP1/2⁶⁸⁻⁷⁰. Once localised to the complex, cIAP1/2 catalyse the formation of K63-linked ubiquitin chains on various components,

including RIPK1 and themselves⁷¹. This auto-ubiquitination facilitates the recruitment of the Linear Ubiquitin Chain Assembly Complex (LUBAC)⁷². LUBAC—composed of HOIP, HOIL-1, and SHARPIN—is unique in its ability to generate linear ubiquitin chains on substrates such as TNFR1, TRADD, and RIPK1^{69, 73}.

RIPK1 serves as a central scaffold within the TNFR1-SC, essential for the recruitment of downstream effectors that activate the mitogen-activated protein kinase (MAPK or MKK) and NF- κ B pathways. The MAPK pathway promotes cellular proliferation by activating transcription factor, Activator Protein 1 (AP-1), and inducing the expression of pro-survival genes through the coordinated signalling of p38, Extracellular Signal-Regulated Kinase (ERK) and c-Jun N-terminal kinase (JNK)^{74, 75}. Simultaneously, NF- κ B transcription factor serves as a master regulator of inflammatory cytokine production. In the early signalling phase, cIAP1/2 generated-K63-Ub on RIPK1 recruit the transforming growth factor- β -activated kinase 1 (TAK1) via TAK1-binding proteins 2 and 3 (TAB2/TAB3). TAK1 initiates the MAPK cascade by activating MKK3/4/6/7, which results in the downstream phosphorylation and activation of p38, JNK, and ERK, while concurrently contributing to the activation of the Inhibitor of κ B (I κ B) kinase (IKK) complex (consisting of IKK α , IKK β , and NF- κ B essential modulator [NEMO])^{76, 77}. NEMO is preferentially recruited to linear ubiquitin chains via its UBAN domain^{78, 79}. Subsequently, TAK1 phosphorylates IKK β (S177), triggering IKK β autophosphorylation (S181) and full complex activation⁸⁰. Active IKK β then phosphorylates I κ B, marking it for K48-linked ubiquitination and proteasomal turnover, which releases the NF- κ B (p50-p65) heterodimer for nuclear translocation⁸¹. Furthermore, linear ubiquitin chains on RIPK1 recruit Tumour Necrosis Factor Receptor-Associated Factor (TRAF) family member-associated NF- κ B activator (TANK) in an early phase of the signalling and later NAK-associated protein 1 (NAP1) through NEMO or A20, respectively. Both are necessary for the recruitment and activation of non-canonical IKKs (IKK ϵ and TBK1). These kinases play a pivotal role in restricting RIPK1 activity to prevent TNF-induced cell death by phosphorylating RIPK1 inhibitory manner^{79, 82}. Notably, it was evidenced that cIAP1 can catalyse K11-Ub of RIPK1 in complex I and that NEMO is able to bind these chains. In spite of the fact that precise nature and functionality of these chains are currently elusive, it indicates that K11-Ub serves as a scaffold rather than degradation signal²².

In the absence of sufficient RIPK1 ubiquitination or phosphorylation, the TNFR1-SC transitions into a cytosolic, death-inducing complex known as Complex II. This complex incorporates Fas-associated death domain (FADD), which utilises its Death Effector Domain (DED), associated with RIPK1 to recruit and facilitate the auto-processing of pro cysteine-aspartic acid protease (caspase) 8. The resulting active caspase 8 tetramer initiates the executioner caspase (caspases 3/6/7) cascade, leading to apoptosis^{83, 84}. Alternatively, if caspase 8 is inhibited, RIPK1 interacts with RIPK3 via their respective RHIM domains. This interaction leads to the activation of RIPK3 and the subsequent phosphorylation of Mixed Lineage Kinase Domain like pseudokinase (MLKL), the terminal executioner of necroptosis⁸⁵⁻

⁸⁷. RIPK3 can also be activated independently of RIPK1 by other RIP Homotypic Interaction Motif (RHIM)-containing proteins, such as Z-DNA-binding protein 1 (ZBP1) or TIR-domain-containing adapter-inducing interferon- β (TRIF)^{88, 89}. However, which interaction partners are needed for RIPK3 activation is highly context-dependent. Also, whether these interactions differentially regulate RIPK3 activity and eventually initiation of necroptosis remains elusive. This process is further regulated by cellular FLICE-like inhibitory protein (c-FLIP) large isoform, which forms heterodimers with procaspase 8 to prevent its full activation and inhibit apoptosis as well as necroptosis by mediating the cleavage of RIPK1 and RIPK3⁹⁰⁻⁹².

Ultimately, the PTM patterns on RIPK1 determine the signalling outcome. While its scaffolding function is protective to the cell death, its kinase activity is pro-apoptotic/necroptotic. To prevent cell death, RIPK1 must bear inhibitory phosphorylation at specific residues; for instance, Mitogen-activated protein kinase-activated protein kinase 2 (MK2) phosphorylates RIPK1 at S320 following TAK1 activation^{93, 94}, while IKKs and non-canonical IKKs mediate pro-survival phosphorylations that block the pro-death autophosphorylation of RIPK1 at S166^{95, 96}.

Finally, DUBs such as CYLD, A20, and OTULIN provide critical counter-regulation within the TNFR1-SC^{97, 98}. CYLD cleaves K63/M1-linked chains on RIPK1 to terminate inflammatory gene activation and promote cell death signalling, whereas A20 binds and protects M1-linked chains to stabilize Complex I^{98, 99}. On the other hand, OTULIN, specifically targets M1-linked chains, clears aberrant linear Ub of several LUBAC components, allowing its efficient recruitment to complex I rather than removing linear-Ub on the complex I¹⁰⁰.




Figure 1.5: Schematic Overview of Tumour Necrosis Factor Receptor 1 (TNFR1) Signalling Complexes and Regulatory Mechanisms. Comprehensive illustration of the TNFR1-SC landscape, depicting the transition between pro-survival and pro-death signalling. Key components include: Complex I (Pro-survival/Inflammatory): Mitogen-activated protein kinase (MAPK), nuclear factor κ light-chain enhancer of the activated B cells (NF- κ B), TNFR1-associated via death domain (TRADD), TNF receptor-associated factor 2 (TRAF2), and cellular inhibitor of the apoptosis proteins 1 and 2 (cIAP1/2), receptor-interacting protein kinase 1/3 (RIPK1/3), transforming growth factor- β -activated kinase 1 (TAK1), TAK1-binding proteins 2 and 3 (TAB2/TAB3), inhibitor of the nuclear factor κ B kinase subunit α and β (IKK α /IKK β), NF- κ B essential modulator (NEMO), TANK-binding kinase 1 (TBK1), linear ubiquitin chain-assembly complex (LUBAC), SHANK-associated RH-domain-interacting protein (SHARPIN), heme-oxidized IRP2 ubiquitin ligase-1 (HOIL-1), and HOIL-1-interacting protein (HOIP). Complex II (Pro-death): The cytosolic transition involving death effector domain (DED) Fas-associated death domain (DD) (FADD), and procaspase 8 (leading to apoptosis) or the RIPK1/RIPK3/MLKL necrosome (leading to necroptosis). Regulatory Factors: Modulators such as the deubiquitinase CYLD, the inhibitor c-FLIP, and RHIM-domain interactors like Z-DNA-binding protein 1 (ZBP1), MAPK-activated protein kinase 2 (MK2). Adapted from⁶⁹.

1.3 PRR

In vertebrates, the immune system is bifurcated into two specialised subgroups: adaptive immunity and innate immunity. While adaptive immunity utilises antigen-specific receptors for a sophisticated and

delayed defence, the innate immune system serves as the primary line of defence, relying on the recognition of conserved molecular motifs. These motifs are categorised as pathogen-associated molecular patterns (PAMPs)—molecules of exogenous origin, such as bacterial LPS, viral single-stranded ribonucleic acids (RNAs) (ssRNAs) double-stranded RNAs (dsRNAs)—and damage-associated molecular patterns (DAMPs), which are host-derived molecules released during tissue injury or cellular stress (e.g., DNA or RNA from necrotic cells)¹⁰¹. All these molecules are detected by pattern recognition receptors (PRRs) expressed in both immune and non-immune cells, which initiates inflammatory responses^{67, 102}.

PRRs consists of two types of receptors that are either cytosolic or membrane-bound. The cytosolic receptors include Retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs), Nucleotide Oligomerization Domain (NOD)-like receptors (NLRs), Absent in Melanoma 2 (AIM2)-like receptors (ALRs), and cyclic guanosine monophosphate–adenosine monophosphate synthase (cGAS) DNA sensor. The transmembrane receptors include C-type lectin receptors (CLRs) and Toll-like receptors (TLRs)¹⁰¹.

1.3.1 NLRs

NLRs represent a phylogenetically conserved class of innate immune sensors traditionally characterised by their capacity to detect intracellular pathogens and endogenous debris associated with tissue damage. To date, 22 distinct human NLRs have been identified, exhibiting a broad spectrum of physiological functions¹⁰³. Structurally, the NLR architecture is defined by a tripartite domain organisation: a central nucleotide-binding domain, termed the NACHT domain—an acronym derived from the four constituent members: NLR family apoptosis inhibitory protein (NAIP, also known as NLRB1), class II major histocompatibility complex trans-activator (CIITA, also known as NLRA), hydroxy eicosatetraenoic (HETE), and telomerase-associated protein 1 (TEP1, also known as TP1). This domain is a universal feature of the family, facilitating both nucleic acid binding and receptor oligomerization. This is flanked by a C-terminal leucine-rich repeat (LRR) region responsible for ligand detection, and an N-terminal effector domain, such as the caspase recruitment domain (CARD) or the pyrin domain (PYD), which serves as a scaffold for protein-protein interactions¹⁰⁴.

Within this family, the proteins, nucleotide-binding oligomerisation domain containing 1 (NOD1) and NOD2, respectively—have been the subject of extensive characterisation. Despite their lack of intrinsic transmembrane domains, NOD1 and NOD2 are actively recruited to the plasma and endosomal membranes through palmitoylation, which enables these receptors to initiate robust NF- κ B and MAPK signalling cascades in response to bacterial peptidoglycans¹⁰⁵. These regulatory mechanisms highlight the pivotal role of PTMs in modulating PRR-mediated innate immunity and provide critical insights into the functional dynamics governing host defence¹⁰⁶.

In addition to those, specific NLR subsets are specialised to facilitate the assembly of inflammasomes, which are intracellular multi-protein complexes and initiate another modality of cell death, called pyroptosis. Inflammasomes assemble in response to numerous PAMPs or cellular stress^{107, 108}. While distinct NLRs may initiate the assembly of different inflammasomes, these complexes typically converge on the activation of pro-caspase-1. The resulting active caspase-1 cleaves pro-interleukin (IL)-1 β and pro-IL-18 into their mature, biologically active forms. Upon their secretion into the extracellular space, these pro-inflammatory cytokines establish a potent inflammatory environment, thereby amplifying and enforcing the systemic immune response¹⁰⁶.

1.3.2 ALRs

ALRs are comprised of a specialised class of cytosolic PRRs that modulate immunometabolism through the detection of intracellular DNA. As the most comprehensively characterised member of the ALR family, AIM2 is structurally defined by an N-terminal PYD and a C-terminal hematopoietic interferon-inducible nuclear (HIN)-200 domain. Under homeostatic physiological conditions, AIM2 is maintained in an autoinhibited state via intramolecular interactions between these two domains, a mechanism that effectively prevents aberrant inflammasome assembly¹⁰⁹.

Activation is initiated when the HIN-200 domain directly engages with dsDNA, disrupting this autoinhibition and releasing the N-terminal PYD, which facilitates the recruitment of the adapter protein apoptosis-associated speck-like protein containing a CARD (ASC). Through homotypic PYD-PYD interactions, ASC molecules aggregate and utilise their CARD domains to link with the CARD of procaspase-1, resulting in the assembly of the multi-protein AIM2 inflammasome complex. Similarly to NLR-dependent inflammasome, this triggers the proteolytic activation of caspase-1, which subsequently catalyses the maturation of the proinflammatory cytokines proIL-1 β and IL-18, alongside the cleavage of GSDMD to execute downstream effector functions and ultimately pyroptosis¹¹⁰.

Beyond its fundamental role in sensing microbial DNA during infection, the inflammasome-dependent activity of AIM2 is a critical determinant in tumorigenesis and the pathogenesis of various inflammatory and autoimmune conditions, such as neuroinflammation, dermatitis, systemic lupus erythematosus (SLE), liver disease. Nevertheless, the precise molecular mechanisms governing AIM2 activation, its subsequent regulation and its therapeutic potential remains to be elucidated^{111, 112}.

1.3.3 CLRs

In the early 2000s, the discovery of CLRs expanded the known repertoire of PRRs. CLRs were uncovered during research which aimed at elucidating the mechanisms of phagocytosis—the cellular process by which immune cells engulf and internalise solid particles, including pathogens, dead cells, and debris. Specifically, Brown and colleagues utilised an expression cloning screen to identify a

macrophage receptor capable of phagocytosing zymosan, a yeast cell wall particle. This screen led to the identification of a protein initially designated as dendritic cell (DC)-associated C-type lectin-1 (Dectin-1). Subsequent investigations demonstrated that Dectin-1 binds to β -glucan, a structural carbohydrate polymer found within fungal cell walls, establishing Dectin-1 as a classical PRR^{113, 114}.

CLRs are traditionally composed of a class of receptors that recognise carbohydrates on the surfaces of pathogenic microorganisms in a Ca^{2+} dependent manner¹¹⁵. To date, over one thousand members of the CLRs have been identified, including annotations derived solely from genomic sequencing. However, structural and functional analyses have also uncovered numerous C-type lectin-like domains (CTLDs) that function independently of Ca^{2+} and lack the conventional motifs required for carbohydrate recognition. Reflecting this structural versatility, CTLDs bind a broad spectrum of ligands beyond carbohydrates, including proteins, lipids (such as glycolipids), fungal melanin, and inorganic molecules like uric acid (UA)¹¹⁶. Even though the majority of CLRs are not well studied to determine the associated signal transduction pathways, upon the ligand recognition, some of them activate NF- κ B, MAPK, and numerous immune cell specific signalling¹¹⁷.

CLRs are primarily expressed on antigen-presenting cells (APCs) such as macrophages and dendritic cells (DCs), as well as certain tissue cells, CLRs utilise CTLD to distinguish between self and non-self structures^{103, 118}. Based on their cellular localisation, CLRs are classified as either secretory receptors or transmembrane receptors. The primary representatives of the secretory class are the collagen lectin family. Transmembrane CLRs are further subdivided into type I and type II receptors based on their topology: type I receptors feature an extracellular N-terminus and contain multiple CTLDs, whereas type II receptors possess an intracellular N-terminus and a single, isolated CTLD. The vast majority of these membrane-associated receptors actively participate in antigen processing and presentation^{115, 116}.

Because many CLRs exhibit distinct expression patterns across myeloid lineages, they also serve as valuable biomarkers for identifying specific myeloid subpopulations, either alone or in combination with other cellular markers. For example, characterisation via single-cell RNA sequencing has demonstrated that mannose receptor C-type 1 (MRC1) functions as a definitive marker for a distinct subset of "immunosuppressive macrophages"¹¹⁹. Leveraging these highly specific expression profiles holds significant potential for designing targeted therapeutic and research strategies to modulate immune responses.

1.3.4 TLRs

Toll-like receptors (TLRs) represent the most extensively characterised class of pattern recognition receptors (PRRs), a field of study that originated with the discovery that mutations in the *Drosophila melanogaster* Toll receptor resulted in profound vulnerability to fungal infections. Following this milestone, Janeway and Medzhitov identified a mammalian homolog, subsequently designated as TLR4,

paving the way for the identification of a broader TLR family comprising TLR1–10 in humans and TLR1–13 in mice¹¹². Notably, TLR10 remains non-functional in the murine model due to the genomic insertion of retroelements. These receptors are broadly categorised by their subcellular compartmentalisation; TLR1, TLR2, TLR4, TLR5, TLR6, and TLR10 are localised to the cell surface to facilitate the recognition of microbial proteins and lipids, whereas the endosomal TLRs, including TLR3, TLR7, TLR8, and TLR9, are specialised for the detection of pathogen-derived nucleic acids.¹⁰³

Structurally, TLRs are defined as type I transmembrane proteins characterised by an extracellular ectodomain containing various leucine-rich repeats (LRRs) for pattern recognition, a transmembrane domain, and a cytosolic Toll-interleukin-1 receptor (TIR) domain¹²⁰. The TIR domain is essential for the activation of downstream signalling cascades that induce the expression of proinflammatory cytokines, chemokines, and, in particular cases, interferons (IFN)¹⁰². Upon ligand engagement, TLRs function as either homodimers (TLR3, 4, 5, 7, 8, 9) or heterodimers (TLR1, 2, 6). This dimerisation determines precise molecular specificity, as seen in the detection of tri-acylated or di-acylated lipoproteins by TLR1-2 and TLR2-6 heterodimers, respectively. Among the homodimeric receptors, TLR4 is specialised for LPS binding¹²¹, TLR5 is activated by bacterial flagellin¹²². Within the endosomal compartment, TLR3 recognises double-stranded RNA (dsRNA)¹²³, while TLR7 and TLR8 engage with single-stranded RNA (ssRNA) through distinct nucleotide-binding patterns¹²⁴. Additionally, TLR9 recognises unmethylated cytosine-phosphate-guanine (CpG) motifs in both ssDNA and dsDNA¹²⁵. Although TLR10 is comparatively less characterised regarding its associated signalling, it has been shown to bind dsRNA in acidic pH conditions *in vitro*¹⁰³.

Given their physiological prominence, TLR3 and TLR4 are relatively well studied within the TLR family and serve as the primary focus of the present study.

1.3.4.1 TLR3 Signalling Pathway

TLR3 is particularly critical for the recognition of viral dsRNA and the subsequent initiation of the antiviral response. Following its translation into ER, the chaperone Unc-93 homolog B1 (UNC93B1) guides trafficking of TLR3 to the endosomal compartment via the Golgi apparatus where its N-glycosylation takes place^{126, 127}. In the endosomal compartment, LRR of glycosylated-TLR3 is cleaved by cathepsins B and H to enhance its affinity to dsRNA and prolong its half-life¹²⁸. Nevertheless, in some cell types, such as human fibroblasts and mast cells, TLR3 is localised within the plasma membrane¹²⁹. Yet, because high affinity binding of dsRNA to TLR3 mainly occurs in acidic pH, it is still elusive whether TLR3 localised on the cell surface can induce robust signalling cascades¹³⁰.

As illustrated in Figure 1.6, upon ligand binding, TLR3 forms homodimers and recruits the adapter protein TRIF, which is in auto-inhibited state in resting condition, through its TIR-TIR domain interaction to propagate downstream signalling¹³¹. As a central scaffold, TRIF facilitates the assembly

of the TLR3 signalling complex (TLR3-SC) by orchestrating the recruitment of RIPK1, and three RING-type E3 ubiquitin ligases: Pellino-1, TRAF6, and TRAF3¹³². At this turning point, the pathway bifurcates into two distinct functional arms: a pro-inflammatory branch governed by TRAF6 and RIPK1, which drives the MAPK and NF- κ B pathways¹³³, and an antiviral branch regulated by TRAF3, which culminates in the production of type I interferons (IFN α/β) and type III IFN (λ)¹³⁴. However, recent studies have demonstrated that TRAF2 can also interact with TRIF, collaborating with TRAF6 to contribute to the induction of IFN β , though it is incapable of driving this activation independently¹³⁵. Conversely, alternative findings reveal that TRAF6 and its associated catalytic activity are dispensable for the IFN signalling arm¹³⁶. Additionally, it has been reported that TRAF2 may participate redundantly in murine immune cell IFN α/β production; however, the precise contributions of TRAF2 and TRAF3 exhibit cell-type specificity and remain to be fully elucidated¹³⁷.

The pro-inflammatory cascade is initiated through the association of TRAF6 with the N-terminus of TRIF and the interaction between RIPK1 and TRIF via their respective RHIM domains¹³³. Subsequent K63-linked polyubiquitination of both proteins is essential for the recruitment of the TAB2/3-TAK1 complex, thereby activating the MAPK and indirectly IKK α/β cascades¹³⁸. While TRAF6 can induce its own K63-linked autoubiquitination alongside the K63-Ub of RIPK1—thereby enhancing complex stability and overall signalling efficiency, RIPK1 likely necessitates the involvement of additional E3 ligases¹³¹. For instance, Pellino-1 is recruited to RIPK1 and decorates it K63 ubiquitin chains, further reinforcing NF- κ B signalling¹³⁹. Substantially, analogous to the TNFR1-SC, the LUBAC complex is recruited to the TLR3-SC to generate linear ubiquitin chains on RIPK1 and several other signalling modules¹⁴⁰. This modification promotes MAPK pathways and efficient IKK complex recruitment, leading to I κ B degradation and the nuclear translocation of NF- κ B, although the specific substrates of LUBAC within the TLR3-SC remain to be fully characterised¹²³.

Simultaneously, the antiviral arm is activated as TRAF3 undergoes K63-linked auto-ubiquitination¹³⁴, providing a docking platform for NEMO, TANK, and/or NAP1, followed by the recruitment of the kinases TBK1/IKK ϵ ¹⁴¹. Also, it has been proposed that E3 ligase RNF128 promotes TBK1 activation via executing its K63-Ub, downstream of TLR3/4, cGAS and RLRs¹⁴². Following activation through auto- or trans-autophosphorylation, TBK1 phosphorylates the pLxIS motif on TRIF, where 'p' represents a hydrophilic amino acid and 'x' denotes any amino acid. This latter facilitates the recruitment of interferon regulatory factor 3 (IRF3)¹⁴³. Subsequent phosphorylation of IRF3 at S386 by TBK1/ IKK ϵ induces its homodimerisation and nuclear translocation¹⁴⁴ where it binds to IFN-stimulated response elements (ISRE) to drive IFN transcription. In addition, although TBK1 is capable of activating IRF7, the higher constitutive expression of IRF3 renders it the primary regulator of this antiviral response¹⁴⁵.¹⁴⁶ However, growing evidences indicate potential redundancy, dispensability and cell type specific effects in this signalling arm. For example, IKK ϵ expression is inducible and high in immune compartment, albeit non-immune cells usually express low level of IKK ϵ in unstimulated conditions

despite the ubiquitous and constitutive expression of TBK1¹⁴⁷. Besides it was asserted that deficiency of IKK ϵ alone does not affect IRF3 activation in murine bone-marrow-derived macrophages (BMDMs)¹⁴⁸. Consequently, IKK ϵ could have a redundant function in IRF3 activation. Though canonical interaction partner for NAP1 is TBK1, rather than IKK ϵ , another study indicated that NAP1 and Similar to NAP1 TBK1 Adapter Domain (SINTBAD), which share a certain homology with NAP1 and TANK for binding to TBK1, could be dispensable for TLR3/4-induced TBK1 activation and IFN production^{149, 150}. Besides, Optineurin (OPTN) was suggested as another adaptor protein for TBK1 in TLR3/4-TRIF signalling and polyubiquitin binding ability OPTN in its UBAN is crucial for the respective signalling activation¹⁵¹. Subsequent research asserted a cooperative functionality, demonstrating that concurrent TANK deficiency and mutation of the OPTN-UBAN domain—which compromises its ability to bind polyubiquitin chains—exhibits a synergistic inhibitory effect, significantly diminishing TBK1/IRF3 activation and subsequent IFN β transcription compared to either disruption alone¹⁴⁸. Hence, TBK1 is predominantly responsible for IRF3 activation, but deficiency of neither adaptor alone completely abolishes IRF3 activation and subsequent IFN β transcription according to the current literature. In spite of accumulating data, differential requirement of TBK1 adaptor proteins and the mechanism of how TBK1 is activated in TLR3/4-TRIF signalling remain controversial and unclear.

The regulation of TLR3 signalling is achieved through the coordinated actions of E3 ligases and DUBs. For instance, K48-Ub of TBK1 is executed by TRAF-interacting protein (TRIP), leading its proteasomal degradation to terminate TLR3-induced IRF3 signalling and IFN production¹⁵². Some studies also showed that A20 can block TLR3-induced NF- κ B and IRF3 activation^{64, 153}, yet how A20 mechanistically accomplishes this negative regulation require further research. Besides, another study revealed that Deubiquitinating Enzyme A (DUBA) cleaves K63-linked ubiquitin chains on TRAF3 to block downstream IRF3 signalling¹⁵⁴. Furthermore, USP19 has been implicated as a negative regulator of TLR3/4-TRIF signalling, reportedly executing the deubiquitination of cullin 3 generated-K27-ubiquitin chains on TRIF to terminate downstream signalling. However, while certain *in vitro* and *in vivo* data partially support this claim, the physiological relevance of TRIF K27-ubiquitination and the precise mechanism of action of USP19 remain controversial, as these findings are predominantly based on overexpression models lacking physiological stimuli¹⁵⁵. Complementing these regulatory mechanisms, another finding demonstrated that RNF182 promotes the K48-linked ubiquitination (K48-Ub) of TLR3-induced p65, targeting it for degradation to terminate NF- κ B signalling and suppress pro-inflammatory cytokine production¹⁵⁶. Despite extensive characterisation studies of TLR3 signalling, the precise positive and negative regulatory mechanisms governing the TLR3 signalling complex (TLR3-SC) along with several mechanistic discrepancies, particularly in the mechanism of TBK1 activation, need to be further investigated.

Beyond gene activation, TLR3 serves as a critical mediator of programmed cell death. During viral pathogenesis, viruses often attempt to circumvent host immunity by inhibiting proinflammatory

cytokine production or interfering with functional components of the TLR3-SC. As a counter-defence, infected cells can initiate cell death pathways to block the viral replication cycle and propagate inflammatory signals to neighbouring cells⁶⁷. Current research indicates that, analogous to the transition to Complex II in TNF signalling, a TLR3-induced DISC-like structure can assemble through FADD, RIPK1, procaspase 8, procaspase 10 (if expressed) and c-FLIP, named after “ripiptosome” . Nonetheless, the role of procaspase 10 is still elusive. While some models suggest this complex originates in cytosol and later engages with TLR3-TRIF, other studies suggest the formation of ripoptosome in TLR3-TRIF directly as a sequential event yet independent assembly mechanisms^{92, 157}. Further empirical elucidation is required to resolve these kinetic models.




Figure 1.6: Toll-like receptor 3 (TLR3) signalling pathway. Following the binding of double-stranded ribonucleic acid (dsRNA) to Toll-like receptor 3 (TLR3), receptor dimerization is triggered, leading to the recruitment of TIR-domain-containing adapter-inducing interferon- β (TRIF) through the Toll/interleukin-1 receptor (TIR) domain. The tumour necrosis factor receptor-associated factor 6 (TRAF6)–receptor-interacting protein 1 (RIPK1) axis is responsible for the activation of the nuclear factor kappa B (NF- κ B) and mitogen-activated protein kinase (MAPK) pathways, whereas the tumour necrosis factor receptor-associated factor 3 (TRAF3)–TANK-binding kinase 1 (TBK1) axis is involved in interferon production through the activation of the transcription factor interferon regulatory factor 3 (IRF3). Created with BioRender.

The formation of the TLR3-induced ripoptosome becomes particularly prominent under conditions in which the primary TLR3-SC is insufficiently regulated, often due to impaired post-translational

modifications or the absence of key regulatory components, such as during viral interference. Mechanistically, TLR3 sequentially recruits TRIF and RIPK1, thereby facilitating the interaction of RIPK1 with FADD. This scaffold subsequently enables the recruitment of procaspase-8, resulting in a complex that is structurally and functionally analogous to TNF-induced Complex II. The proximity-induced auto-catalytic cleavage of procaspase-8 leads to its activation and initiates the downstream executioner caspase cascade, ultimately culminating in apoptotic cell death. Nevertheless, it was suggested that FADD may not be required for ripoptosome to execute cell death, demonstrating equally activated caspase 8 and 3 in control and FADD depleted cells¹⁵⁷. Also, several studies corroborated that RIPK1 is indispensable in this process^{92, 157}. The regulation of TLR3-induced DISC formation and signalling is tightly controlled at multiple levels. cIAPs can be recruited to the ripoptosome, where they suppress apoptosis by promoting K48-linked ubiquitination of RIPK1, targeting it for proteasomal degradation⁹². In parallel, LUBAC indirectly antagonises cell death by stabilising the pro-survival TLR3-SC¹²³. This stabilisation enhances the expression of c-FLIP, which acts as a direct inhibitor of procaspase-8 activation, thereby limiting ripoptosome-mediated apoptosis. Under the conditions of caspase inhibition, cells can shift the modality of the cell death to necroptosis. In this cascade, RIPK1 interacts with RIPK3 through their respective RHIM domains. As a result, RIPK1 either directly phosphorylates RIPK3 or facilitates its autophosphorylation, though the exact initiating mechanism remains to be fully elucidated. Activated RIPK3 subsequently phosphorylates MLKL, inducing a conformational change that drives MLKL oligomerisation and translocation to the plasma membrane, where it forms pores and causes the leakage of intracellular contents⁶⁷. However, procaspase 8-c-FLIP (large isoform) heterodimer can halt necroptosis initiation via cleavage of RIPK1 and RIPK3. Even though several studies claim opposite results^{89, 157}, under specific conditions—particularly within TLR3 and TLR4 signalling pathways—necroptosis can be executed independently of RIPK1 via a direct RIPK3-TRIF RHIM interaction axis, which culminates autophosphorylation of RIPK3¹⁵⁸. The involvement of TRIF could be prevented by caspases through its cleavage¹⁵⁹. In spite of these recent discoveries, the precise regulatory mechanisms governing TLR3-induced cell death remain poorly understood and warrant further investigation.

1.3.4.2 TLR4 Signalling Pathway

TLR4 serves as a specialised PRR dedicated to detecting LPS, a prominent glycolipid component within the outer membrane of gram-negative bacteria, thereby initiating downstream immune signalling cascades. Structurally, TLR4 is composed of an extracellular LRR-containing domain, a transmembrane domain, and a cytoplasmic TIR domain¹⁶⁰. Following its translation in the ER, TLR4 undergoes N-glycosylation and is fully folded by the chaperones glycoprotein 96 (gp96) and protein associated with TLR4 (PRAT4A) prior to trafficking to the plasma membrane via the Golgi apparatus. Within the ER, TLR4 also establishes a strong association with myeloid differentiation 2 (MD2), which is functionally critical, as TLR4 alone is incapable of binding LPS^{161, 162}.

The ligand engagement cascade begins when LPS binds to LPS-binding protein (LBP), which subsequently transfers the glycolipid to cluster of differentiation 14 (CD14), and ultimately to the MD2-TLR4 co-receptor complex, driving receptor homodimerisation. Notably, both LBP and membrane-bound CD14 are absolutely required for efficient TLR4-MD2-LPS dimerisation and robust signal transduction^{121, 163}. With the exception of TLR3, all TLRs initiate downstream signalling through the adaptor protein myeloid differentiation primary response 88 (MyD88). In contrast, TLR4 uniquely utilises both MyD88- and TRIF-dependent pathways. In this context, CD14 is indispensable for the subsequent endocytosis of the TLR4-MD2-LPS homodimer, an internalising process that facilitates the assembly of the TRIF-mediated signalling complex¹⁶⁴.

As shown in Figure 1.7, receptor dimerisation at the plasma membrane promotes the recruitment of TIR Domain Containing Adaptor Protein (TIRAP), which serves as a scaffold for MyD88. The assembly of this MyD88-dependent signalling complex is biochemically distinct from the TRIF-mediated complexes formed by endocytosed TLR4 and TLR3. Downstream MyD88 signalling initiates with the sequential recruitment of IL-1R-associated kinase 4 (IRAK4) and the subsequent recruitment of IRAK1 and IRAK2. Upon recruitment, IRAK4 activates IRAK1 and IRAK2 by their phosphorylation. These two downstream kinases operate with functional redundancy and are directly responsible for the recruitment of TRAF6¹⁶⁵. Similar to the cascade observed in TLR3 signalling, TRAF6 undergoes K63-linked auto-ubiquitination. This modification establishes a molecular platform that recruits the TAB2/TAB3 regulatory subunits, the kinase TAK1, and the IKK complex via adaptor protein NEMO, ultimately driving the activation of the MAPK pathways via the phosphorylation of p38, JNK and ERK 1/2 and NF- κ B signalling, which lead to release of pro-inflammatory cytokines like TNF- α and IL-6¹²¹. Additionally, it has been demonstrated that the catalytic activity of IRAK4 is strictly required for MyD88-dependent NF- κ B and MAPK induction¹⁶⁶.

On the other hand, following the relocalisation of the TLR4-MD2-LPS complex into the endosome via CD14-dependent, clathrin-mediated endocytosis, TLR4 associates with the TRIF-related adaptor molecule (TRAM). TRAM subsequently recruits TRIF, initiating a signalling cascade analogous to TLR3 signalling. Acting as a central scaffold, TRIF coordinates the recruitment of RIPK1 alongside the E3 ubiquitin ligases Pellino-1, TRAF6, and TRAF3 to assemble the TLR4-TRIF SC¹³⁹. At this junction, the cascade diverges into two functionally distinct branches: a pro-inflammatory arm, mediated by TRAF6 and RIPK1, which activates the MAPK and NF- κ B pathways through TAK1 and IKK complex respectively, and an antiviral arm, governed by TRAF3, which induces type I and type III interferons via TBK1/IKK ϵ and subsequent IRF3 activation¹⁶⁰. It was also claimed that the scaffolding function of IRAK4 is essential for TRIF-dependent NF- κ B and MAPK, but not IRF3 activation, though the underlying mechanism governing this alternative pathway remains to be elucidated¹⁶⁶. Additionally, it was shown that LUBAC activity is crucial to trigger TLR4-mediated NF- κ B and MAPK activation as

evidence in SHARPIN-deficient or HOIP-catalytically inactive expression cells^{167, 168}, albeit LUBAC contributes to TLR4-MyD88, TLR4-TRIF or both signalling remains elusive.

This TLR4-TRIF cascade operates independently of TLR4-MyD88 signalling, as evidenced by the impaired but persistent LPS-induced signalling observed in MyD88-deficient cells^{169, 170}. While the TLR4-MyD88 pathway mediates the early activation of MAPK and NF- κ B, the TLR4-TRIF pathway drives the late signalling response¹⁶⁹. Furthermore, despite the presence of TBK1/IKK ϵ in both arms, only TLR4-TRIF signalling is capable of inducing type I and III IFN production via IRF3 due to specific regulatory and structural divergence in the recruitment and activation of non-canonical IKKs. Several critical factors modulate these distinct outcomes within the signalling framework. During MyD88 signalling, TRAF3 is initially recruited to the TLR4-MyD88 SC but undergoes rapid degradation via cIAP1/2-mediated K48-linked ubiquitination which could be reversed by the DUB USP25 in a particular context. Because TRAF3 restricts the association of TRAF6 with the TLR4-MyD88 complex, its degradation facilitates more robust MAPK and NF- κ B activation^{171, 172}. Furthermore, MyD88 lacks the specific IRF3-binding motif (pLxIS) required to recruit IRF3 to the signalosome¹⁴⁶. Also, it was suggested that TBK1 and IKK ϵ are recruited to the MyD88 complex through TRAF6-K63Ub-NEMO-TANK signalling axis, positioning TBK1/IKK ϵ in close proximity to the IKK complex and unlike activating IRF3, TBK1 and IKK ϵ serve as negative feedback regulators of canonical IKK activation by phosphorylating them in an inhibitory manner, which limits NF- κ B activation^{173, 174}. Notably, TANK deletion completely abolishes IKK ϵ activation while only marginally reducing TBK1 phosphorylation following TLR4 stimulation. Conversely, TRIF-mediated IRF3 activation remains unimpaired in the absence of TANK¹⁷³. This demonstrates that TANK is required for IKK ϵ activation, but IKK ϵ is dispensable for type I/III IFN production, suggesting TBK1 recruitment and activation during TRIF signalling relies on alternative adaptor proteins. Interestingly, the deletion of NAP1 does not alter gene expression following LPS stimulation, indicating that NAP1 does not share this regulatory role in MyD88 and TRIF-mediated TLR4 signalling¹⁴⁹. Nonetheless, similarly to TLR3 signalling, it was reported that OPTN-UBAN mutant is associated with impaired TLR4-induced TBK1 activation and IFN production, suggesting that OPTN is required adaptor for TBK1 in TLR4-TRIF signalling¹⁵¹.




Figure 1.7: MyD88 and TRIF-dependent TLR4 signalling pathway. Upon LPS binding-induced dimerisation of TLR4-MD2, TIRAP is recruited to the receptor, facilitating the assembly of the MyD88-dependent signalling complex. Subsequently, IRAK4, and IRAK1/2, are associated with MyD88 and TRAF6, leading to the activation of the NF- κ B and MAPK pathways. At the same time, TRAF3 is rapidly degraded by cIAP1/2, thereby preventing its incorporation into the signalling complex. TBK1 and IKK ϵ are recruited in proximity to the canonical IKK complex through the adaptor protein TANK, which interacts with NEMO. Once CD14-mediated internalisation initiated, TLR4-MD2-LPS recruits TRAM and TRIF, which triggers the formation of TRAF6, RIPK1 and TRAF3 containing signalosome that induce NF- κ B, MAPK, and IFN-producing IRF3 pathways. Created with BioRender.

In addition to those, functional separation is also observed in pathological contexts; during many viral infections, the upregulation of MyD88 is associated with an impaired type I IFN response, whereas MyD88 inhibition results in elevated IFN response, suppresses viral replication, and improves survival in mouse models of multiple viral diseases¹⁷⁵. TLR4 signalling has also been recognised as a major contributor to bacterial sepsis-induced lethality. Experimental septic shock or sepsis can be triggered by LPS administration, *E. coli* injection, or cecal ligation and puncture (CLP), respectively and is characterised by excessive production of inflammatory cytokines such as TNF α and IL-6, disruption of splenic architecture, systemic inflammation, multi-organ failure, and high mortality in mice and human^{176, 177}. Several studies have demonstrated that caspase-1/11 and TLR4-MyD88-dependent signalling are the principal mediators of sepsis pathogenesis, as deficiency of caspase-1/11 or MyD88 markedly reduces systemic inflammation and improves survival although the consequence of IL1 β and IL18, downstream effectors of caspase-1/11, remains controversial¹⁷⁷⁻¹⁸⁰. The major distinction between

these studies lies in the experimental model employed. In sterile, LPS-induced septic shock, deficiency of caspase-11, IL-1 β , or IL-18 confers significant protection. In contrast, in CLP- or *E. coli*-induced sepsis models, depletion of these mediators does not result in a substantial improvement in survival or a marked reduction in inflammatory cytokine production. In addition, another study reported that STING- and TRIF-dependent signalling pathways partially contribute to the pathogenesis of severe, but not moderate, CLP-induced sepsis, although their contribution appears to be less prominent than that of MyD88- and caspase-1/11-mediated signalling¹⁸¹. The contribution of currently unidentified effector proteins and their potential roles in driving aberrant immune responses remain to be elucidated in future studies.

1.3.5 RLRs

Members of the RLR family are crucial for cytosolic dsRNA recognition and consist of RIG-I, melanoma differentiation-associated gene 5 (MDA5), and laboratory of genetics and physiology 2 (LGP2) receptors. Structurally, all three RLR family members share a central RNA-dependent ATPase motor or helicase domain, containing Hel1, Hel2 and Hel2i, and a conserved carboxy-terminal domain (CTD) that include an RNA-binding motif. However, only RIG-I and MDA5 possess two tandem Caspase activation and recruitment domains (CARDs) at their N-termini, which are essential for downstream signalling. In resting condition, RIG-I is maintained in autoinhibited conformation because of the structural restriction of CARD domain by Hel2i. Even though RIG-I weakly and transiently binds to the cellular RNA, it does not result in the release of CARD domain and initiation of the signalling. On the contrary, RIG-I preferentially recognises 5'-di/triphosphate (5'-PP/5'-PPP) short dsRNA or stem loop RNAs of viral and bacterial origin. This ligand binding culminates the conformational rearrangement of RIG-I, embedding RNA within the RIG-I and dislodging the CARD domain¹⁸². It has also been reported that RNA polymerase III can produce 5'-PPP dsRNA, engaging with RIG-I, but this process is tightly counteracted by phosphatase DUSP31^{183, 184}. Moreover, ATP-binding and hydrolysis in RIG-I serve as a proofreading mechanism, allowing only high affinity dsRNAs and blocking persistent engagement with host-RNA in general¹⁸². Upon release of the CARD domain, RIG-I requires the removal of inhibitory phosphorylation that are mediated by protein phosphatase (PP)1 α and γ , which enhances its association with TRIM25, culminating K63-Ub of the CARD domain and subsequent oligomerisation of RIG-I¹⁸⁵⁻¹⁸⁷. In contrast to RIG-I, MDA5 detects long dsRNA structures, typically generated during viral replication without the requirement of di- or triphosphate end, and self-methylated RNA, characteristic of mammalian transcripts, fails to activate this receptor. Moreover, unlike RIG-I, CARD domain of MDA5 is held in open conformation in the steady state and upon the engagement with long dsRNA, MDA5 undergoes oligomerisation through cooperative binding¹⁸². Despite its less characterisation compared to RIG-I, MDA5 activation similarly depends on PP1 α and γ -mediated removal of inhibitory phosphorylations alongside an ATP-reliant proofreading¹⁸⁸. Also, TRIM65-mediated K63-Ub of its helicase domain has been reported to promote its oligomerisation¹⁸⁹. LGP2 lacks

the signalling CARDs and is therefore unable to autonomously initiate downstream signalling pathways. Despite this, LGP2 functions as a critical regulator of the other two receptors. It serves as a feedback inhibitor to suppress RNA recognition by RIG-I, while simultaneously promoting nucleation and oligomerisation of MDA5 on long dsRNA through cooperative binding¹⁹⁰. The physiological relevance of this regulation is underscored by the observation that LGP2-deficient mice fail to mount an adequate interferon response following infection with encephalomyocarditis virus (EMCV)¹⁹¹. After the oligomerisation of RIG-I or MDA5, they build homotypic CARD-mediated interactions with the mitochondrial antiviral-signaling protein (MAVS) adaptor, containing CARD, proline rich domain (PRD) and transmembrane domain. This engagement initiates a prion-like aggregation of MAVS oligomers, which serves as the platform for the subsequent activation of the downstream NF- κ B and IRF3 signalling cascades. As depicted in Figure 1.8, mechanistically, MAVS recruits TRAF2/TRAF3/ TRAF5/TRAF6 via distinct TRAF-binding motifs. This recruitment results in the K63-linked polyubiquitination (K63-Ub) of MAVS and the assembly of downstream signalling complexes. Specifically, the recruitment of the NEMO-IKK α / β complex leads to the activation of the NF- κ B pathway, which drives the expression of pro-inflammatory cytokines. Concurrently, NEMO-TBK1/IKK ϵ module that were bridged through TANK, NAP1, and SINTBAD were also recruited to the MAVS signalosome, which leads to first phosphorylation of MAVS within its conserved pLxIS consensus motif, licensing the subsequent recruitment and phosphorylation of IRF3^{143, 192}, ultimately triggering the induction of type I and type III IFN gene expression. Within this framework, TBK1 and IKK ϵ are functionally redundant similar to other signalling. Although the underlying mechanism of TRAF proteins contribution is incompletely understood, biochemical studies have demonstrated that TRAF2, TRAF3, TRAF5, and TRAF6 function redundantly in mediating NF- κ B and IRF3 activation, as significant reductions in cytokine and type I interferon production were observed only upon simultaneous depletion of all three proteins. The E3 ligase activities of both TRAF2 and TRAF6 contribute to these signalling pathways; however, TRAF2 catalytic activity becomes dispensable in the presence of LUBAC. In TRAF5/6-deficient mouse embryonic fibroblasts (MEFs), concurrent disruption of TRAF2 and LUBAC catalytic activities impaired NF- κ B and IRF3 activation more severely than disruption of either component alone. Furthermore, the study revealed that the UBAN domain of NEMO is essential for NF- κ B- and IRF3-dependent gene expression, whereas ubiquitination of NEMO at various lysine residues is not required for these signalling responses^{193, 194}. Beyond the canonical signalling cascade, a TRAF-dependent, NEMO-independent mechanism of TBK1 and IRF3 activation has been proposed to drive IFN- β expression in spite of the limited mechanistic data. In contrast to previous reports, it was asserted that combined deficiency of TANK, NAP1, and SINTBAD does not affect TBK1-IRF3 activation or the induction of IFN production^{150, 194}. Additionally, IKK α and IKK β have been implicated in facilitating TBK1 and IRF3 activation, highlighting further complexity within antiviral signalling networks¹⁹⁴. Nevertheless, a recent study documented that HOIP, HOIL-1, but not SHARPIN, along with linear ubiquitin generating activity of LUBAC are required to induce robust IRF3

and NF- κ B signalling. In contrast to proposed redundant function of LUBAC with TRAF2, single HOIP or HOIL-1 deficiency was sufficient to impair respective pathways. Furthermore, NEMO deficiency completely blunted proinflammatory cytokine and IFN production upon Sendai virus infection, underscoring a contradiction with earlier reports and further research is required for the clarification of the mechanism behind TBK1 activation and downstream cascades.




Figure 1.8: Schematic representation of RIG-I/MAVS pathway. Upon recognition of 5'-triphosphorylated short double-stranded RNA (5'ppp-dsRNA) by RIG-I or long double-stranded RNA by MDA5, these receptors undergo self-oligomerisation and subsequently promote MAVS oligomerisation through CARD–CARD interactions. MAVS oligomers then recruit TRAF2, TRAF3, TRAF5, and TRAF6, leading to the assembly of downstream signalling complexes that are stabilised by non-degradative ubiquitin chains generated by TRAF proteins and the Linear Ubiquitin Chain Assembly Complex (LUBAC). NEMO directly recruits the canonical IKK complex (IKK α /IKK β), thereby activating NF- κ B signalling. In parallel, NEMO associates with the adaptor proteins TANK, NAP1, or SINTBAD to facilitate the recruitment of the non-canonical IKKs, TBK1 and IKK ϵ , resulting in MAVS phosphorylation, IRF3 activation and the induction of type I/III IFN production. Created in BioRender.

In addition to these regulatory mechanisms, several other E3 ligases have implications in RIG-I/MAVS signalling. TRIM21 is responsible for K27-Ub of MAVS, mediating TBK1 recruitment to the MAVS signalosome¹⁹⁵, albeit MARCH8-dependent K27-Ub of MAVS results in its autophagic degradation¹⁹⁶. Besides, RNF5, ANKIB1 and MARCH5 have been proposed to induce MAVS proteasomal degradation through K48-Ub of its distinct lysine residues^{197–199}, thereby not only restraining excessive RIG-I/MAVS signalling but also leading to signal termination as a negative feedback mechanism.

1.3.6 cGAS-STING

cGAS represents a more recently identified member of the PRR family. Functioning as a nucleotidyl transferase, cGAS detects and binds cytosolic long dsDNA derived from diverse sources, including viral, bacterial, and self-DNA derived from endogenous retroelements or genomic DNA because of the mitotic genotoxic stress in the tumour cells as well as the mitochondrial DNA after released to the cytosol in certain pathological conditions, which can be counteracted by effector caspases through the cleavage of cGAS²⁰⁰. Notably, recent studies have demonstrated that cGAS also reside within the nucleus and is present in membrane-bound form, albeit functionality of the cGAS compartmentalisation and how cGAS activation is regulated particularly in nucleus remain elusive. As illustrated in Figure 1.9, upon engaging with dsDNA, cGAS undergoes a conformational change to an open state, initiating the synthesis of the second messenger 2'3'-cyclic Guanosine Monophosphate (GMP)- Adenosine Monophosphate (AMP) (2'3'-cGAMP), using ATP and Guanosine Triphosphate (GTP). This secondary messenger is subsequently recognised at the ER by the cyclic-dinucleotide sensor known as stimulator of interferon genes (STING), triggering its lateral oligomerisation and activation of TBK1. Notably, 2'3'-cGAMP can also operate in an autocrine and paracrine manner through exports via ATP-binding cassette sub-family C member 1 (ABCC1) and unknown transporter(s) as well as through gap junctions. Subsequently, it is imported to the recipient cells from extracellular environment by SLC19A1, SLC46A2, and LRRC8 transporters and associates with STING, yet the abundance of 2'3'-cGAMP is intracellularly and extracellularly orchestrated by 2'3'-cGAMP-degrading enzymes²⁰¹. Essentially, structural and biochemical data have been suggested that TBK1 is bound to STING in a low affinity via PLPLRT/SD motif in C terminal tail (CTT) of STING, albeit TBK1 activation requires at least two STING molecules in close proximity and conformational rearrangement of STING upon 2'3'-cGAMP binding, enhancing binding affinity of TBK1 to STING and allowing trans-autophosphorylation of TBK1^{202, 203}. Activated TBK1 phosphorylates adjacent STING at the S366 position (in human), which is part of pLxIS motif, allowing the recruitment of IRF3 and its subsequent phosphorylation by TBK1. Consistently with mechanisms observed in RLR and various TLR signalling pathways, IRF3 undergoes homodimerisation and translocates into the nucleus to drive the transcription of type I/III IFN production²⁰⁴. Beyond the induction of IFN, STING has been implicated in promoting NF- κ B and MAPK pathways. It was initially proposed that cGAS-STING signalling relies on TBK1 to directly phosphorylate canonical IKKs, thereby activating these downstream effector proteins²⁰⁵. Nonetheless, subsequent comprehensive studies established that TBK1 and IKK ϵ act redundantly to activate IKK α/β , as the deficiency of both TBK1 and IKK ϵ results in a significant reduction in NF- κ B signaling. Intriguingly, these same studies indicated that IKK α/β contributes to the phosphorylation of IRF3, either directly—as evidenced in murine BMDMs—or via boosting TBK1 phosphorylation, as observed in human Tohoku Hospital Pediatrics-1 (THP-1) cells^{206, 207}. Furthermore, while IRF3 activation predominantly requires TBK1 in murine BMDMs, both IKK ϵ and TBK1 act redundantly to mediate its activation in THP-1 cells. It has also been proposed that TAK1 is required for the activation of TBK1

and IRF3, and to an even greater extent, IKK α / β activation. Moreover, NEMO and its UBAN domain have been asserted as crucial for both TBK1 and IKK α / β activation, thereof subsequent NF- κ B-dependent cytokine production and IFN production within the cGAS-STING signalling cascade²⁰⁷. Despite the growing evidences, the precise underlying mechanisms driving cGAS-STING-dependent pathway activation, the crosstalk between canonical and non-canonical IKKs regulating these pathways, and whether they are differentially regulated across distinct cell types or species remain to be fully elucidated.




Figure 1.9: Overview of cGAS-STING pathway. Cyclic GMP–AMP synthase (cGAS) functions as a nucleotidyl transferase that detects cytosolic dsDNA originating from viral, bacterial, or endogenous sources and initiates the synthesis of the second messenger cyclic GMP–AMP (2'3'cGAMP) that could also be exported or imported for autocrine and paracrine signalling. 2'3'cGAMP subsequently binds to and activates STING in ER. Activated STING undergoes conformational change, enhancing its binding to TBK1 and inducing its oligomerisation. Subsequently, TBK1 is activated via trans-autophosphorylation, followed by STING and IRF3 phosphorylation. Simultaneously, STING signalosome is translocated to the Golgi through ER-Golgi Intermediate Compartment (ERGIC) and recruits IKK complex, ultimately resulting in the induction of proinflammatory cytokines and type I/III IFN production. Created in BioRender.

On the other hand, mechanistic regulation of the STING signalosome consists of multiple layers and is more sophisticated than solely its downstream effector proteins. Initially, after the ligand binding, STING oligomerisation is further reinforced by disulphide bridges at the position of Cys148, which is essential for STING exit from ER and downstream IFN induction despite unknown exit signal²⁰⁸. However, a recent study suggested that LUBAC decorates ER-resident STING with linear-Ub

at position K338 following its oligomerisation, which allows the strong association with Sec24b subunit of COPII coat complex, mediating subsequent STING translocation to the Golgi via ER-Golgi Intermediate Compartment (ERGIC). In the deficiency of HOIP or the presence of linear-Ub defective mutant of HOIP, downstream signalling is substantially diminished, albeit another study also indicated Sec24c dependent-STING translocation, which suggests the possibility of LUBAC-independent signal for STING translocation as well^{209, 210}. Also, OTULIN, the only so far known linear-Ub specific DUB, has been proposed as counter-acting module in later stage to avert aberrant cGAS-STING signalling by removing linear ubiquitin chains on STING²⁰⁹. Despite the similar consequences, another study asserted that LUBAC engages with STING signalosome in Golgi rather than ER, positively modulating NF-κB signalling while IRF3 pathway is unaltered and no trafficking role of LUBAC is reported²¹¹. After exiting the ER, STING oligomers are able to associate with IRF3 and initiate signal transduction in ERGIC²¹². Also, it has been manifested that the palmitoylation of STING at position C88 and C91 in Golgi is necessary for robust NF-κB and IRF3-induced cytokine production with no effect in STING trafficking²¹³. In addition, TRIM32 was proposed as an E3 ubiquitin ligase that promotes TBK1-STING association by decorating STING with K63-Ub²¹⁴. Intriguingly, a pivotal study suggested that Autocrine motility factor receptor (AMFR) and insulin-induced gene 1 (INSIG1), an E3 ubiquitin ligase complex, is responsible for K27-Ub of STING, which supports its interaction with TBK1. In deficiency of either AMFR or INSIG1, IRF3 activation and IFN induction was substantially impaired²¹⁵. Furthermore, another suggestion was made for MUL1, which builds K63-linked ubiquitin chains on K224 of STING and increases IRF3 activation and downstream IFN production, indicating the necessity of STING ubiquitination for STING-TBK1-IRF3 association and signaling axis²¹⁶. Besides it has been reported that RNF26 promotes K11-Ub of STING at K150, which blocks RNF5-mediated K48-Ub of same lysine residue, thereby interfering the proteasomal degradation of STING signalosome in early stage of the activation, suggesting a scaffolding role of K11-Ub in immune signalling²¹⁷. As an additional layer of the mechanism, CYLD has been proposed as a responsible DUB counteracting RNF5-mediated K48-Ub of STING and interfering its degradation²¹⁸. Nonetheless, classical mechanism for the termination of cGAS-STING signalling occurs via p62-dependent autophagic trafficking of the STING signalosome to the lysosome and its subsequent degradation rather than being degraded by proteasome in spite of insufficient data for the description of this route²¹⁹. In consideration of those, a deeper understanding of the cGAS-STING pathway and its regulatory mechanisms, particularly those governing TBK1 activation, remains necessary. Beyond its PRR-associated function, independently of its CTT and binding ability to TBK1, STING is also mediator of non-canonical autophagy, highlighted particularly in *Mycobacterium tuberculosis* (*M.tb*) clearance²⁰⁴. Furthermore, STING has been identified as a proton channel that facilitates proton efflux from intracellular organelles, particularly the Golgi apparatus, although the physiological significance and mechanistic basis of this activity remain incompletely understood²²⁰. Nevertheless, over the years, cGAS-STING pathway has not only associated with chronic inflammation and autoimmune disease, such as Aicardi-Goutières syndrome (AGS) or STING-

associated vasculopathy with onset in infancy (SAVI), but also emerged as an essential mediator of immune response and a therapeutic tool, boosting anti-viral particularly against dsDNA viruses and anti-tumour immunity in certain cancer types²²¹⁻²²⁴. Consequently, defining the physiological roles mediated by cGAS–STING signalling is critical and subjected to immense investigation.

1.4 IFN Signalling

IFNs are pivotal signalling proteins essential to both physiological homeostasis and pathological states. Initially identified as a "virus inhibitory factor" in the 1950s, they were formally discovered by Isaacs and Lindenmann²²⁵⁻²²⁷. While IFNs primarily exert protective functions against viral, bacterial, and fungal infections by modulating robust immune responses, sustained or uncontrolled IFN induction can precipitate autoimmune diseases, inflammatory pathologies, and tumorigenesis. Depending on the specific class, IFN expression is induced via inflammatory cytokine into three distinct classes: type I IFNs (IFN-Is), type II IFNs (IFN-IIIs), and type III IFNs (IFN-IIIs). Although IFN-Is and IFN-IIIs exhibit similarities in signalling and functional outcomes, all IFN classes are structurally distinct and specialised for specific cellular compartments, serving diverse biological purposes despite their integrated roles within the immunological landscape²²⁸.

1.4.1 IFN-I

Type I IFNs consist of 13 IFN- α (14 in mice), IFN- β , IFN- ϵ , IFN- κ , and IFN- ω . Even though all are clustered in chromosome 9 and upon their secretion, they initiate same IFN signalling, they exhibit distinct expression profiles, sequence similarities, and receptor-binding potencies^{228, 229}. For example, IFN- ϵ expression is constitutively driven by E74-like factor 3 (ELF3) transcription factor in male and female reproductive tracts and it possesses approximately 100 fold lower affinity for IFNAR1/2 and weakly induce classical anti-microbial immunity than IFN- α/β ²³⁰⁻²³² whereas IFN- κ expression is mainly regulated by p63 and Activating Protein-2 (AP-2) transcription factors in keratinocytes and epithelial cells in the skin and shows modest antiviral potency and receptor binding affinity that remains lower than IFN- α/β ^{230, 233, 234}. Furthermore, IFN- ω expression is primarily induced in immune and hematopoietic tissue in a IRF3/7 and NF- κ B dependent manner. It is strongly binds to the receptor and triggers a robust immune response comparable to IFN- α ^{229, 230}. On the other hand, IFN- α is produced mainly in plasmacytoid dendritic cells (pDCs) and myeloid compartment in an IRF7/IRF3 dependent manner²³⁵⁻²³⁷, albeit IRF7 is a short-lived protein and its expression largely relies on downstream IFN signalling through Interferon-Stimulated Gene Factor 3 (ISGF3)²³⁸. As a result of positive feedback loop of IFN response, IFN- α expression is enhanced and it further boosts inflammatory responses by strongly binding to IFNAR1/2 receptors²³⁹ and inducing ISGs expression. Furthermore, IFN- β has the highest affinity to IFNAR1/2 receptors among all IFN-Is and it is expressed by almost all nucleated cells upon PRR activation^{228, 237, 240}. Unlike others, the expression of IFN- β is regulated by a transcription factor complex, termed enhanceosome, which contains IRF3, IRF7, NF- κ B and AP-1²⁴¹. Importantly, IRF1 and IRF5 have also been reported to contribute IFN- β production in human monocytes as a result of

positive feedback loop of IFN response, but underlying mechanism and differential requirements of several transcription factors are still elusive²⁴². It is also asserted that IRF5 is one of the main drivers of IFN- β expression in murine myeloid dendritic cells (mDCs) following West Nile virus (WNV) infection²⁴³.

PRRs, including TLR3/4/7/8/9, RIG-I and MDA-5, and cGAS, are the primary receptors triggering the expression of IFN-Is and IFN-IIIs upon recognition of PAMPs and DAMPs. Nevertheless, each receptor is specialised to be activated by certain stimuli in specific subcellular location. TLR3/4/7/8/9 can potentially induce IFN-I/III production through IRFs which can bind unique p-LxIS motif in respective receptor-associated signalling complexes in endosomes for TLR4 and endolysosome for TLR3/7/8/9¹⁴⁵. Even though RIG-I and MDA-5 reside in cytosol and initiate IFN-I/III induction through sensing dsRNAs from endogenous and microbial source, cGAS recognises endogenous or microbial cytosolic dsDNA and synthesise secondary messenger 2'3' cGAMP, which then engages p-LxIS motif bearing scaffold protein STING in ER, followed by induction of IFN production. Even though all those signalings are mainly responsible for IFN-I/III production, growing evidences and several reports indicate that TLR2 and TLR5 can induce IFN-I/III production in a context dependent manner^{244, 245}. Moreover, NOD1/2 is potent to trigger IFN-I/III production upon bacterial infections^{246, 247}. Also, their expression is driven by CLRs, particularly Dectin-1 and Dectin-2, in human and mouse^{248, 249}. In addition to those, involvement of many other receptors, such as DNA-dependent protein kinase catalytic subunit (DNA-PKcs), protein kinase R (PKR), oligoadenylate synthetase 1 (OAS1)/RNASEL, and Z-DNA binding protein 1 (ZBP1) were reported to contribute to IFN production, albeit their association coincides with cell death and it needs to be determined whether they directly act on the induction of IFN production or lead it through cell death-induced DAMP release²⁵⁰⁻²⁵³.

All IFN-Is promote fast, robust, but short-lived, anti-viral state in both infected cells and bystander cells. Once they engage same Interferon Alpha and Beta Receptor Subunit 1/2 heterodimer (IFNAR1/2) and activate the Tyrosine Kinase 2 (TYK2) and Janus Kinase 1 (JAK1), thereby triggering phosphorylation and activation of Signal Transducer and Activator of Transcription 1 (STAT1) and STAT2, respectively. Both activated STAT1 and STAT2 form a complex with IRF9 to assemble ISGF3, which binds IFN-stimulated response elements (ISRE) elements and initially function as a scaffold protein that recruits histone acetyl transferases like CREB-binding protein/p300 to mediate chromatin opening. This is followed by ISGF3-mediated induction of hundreds of IFN stimulated genes (ISGs) expression^{228, 237, 254} as well as downregulation of certain genes that counteract IFN production and response as part of a positive feedback loop²⁵⁵. For a robust ISG expression, TYK2, associated with IFNAR1 is particularly required²⁵⁶. Nevertheless, timing and robustness of the anti-viral response are critical and the expression of ISG is boosted in early time of the infection, but it needs to be terminated in later stage to prevent an over activation of the immune system and ultimately tissue damage. For instance, it was reported that IFN-I-induced IRF1 drives a certain subset of pro-inflammatory ISGs for early anti-viral immune

response²⁵⁷. On the other hand, ubiquitin-specific peptidase 18 (USP18), as one of the ISGs, blocks association of JAK1 with IFNAR2 and mitigates receptor assembly IFN signalling²⁵⁸. Also, ISG15 can stabilise IRF3 in early time of the infection, enhancing IFN-I expression, thereof downstream signalling, but later it negatively regulates IFN-I signalling through stabilisation of USP18^{259, 260}. Furthermore, the suppressor of cytokine signalling (SOCS) 1, another ISG, is a potent inhibitor of TYK2, which eventually restricts downstream IFN-I signalling^{261, 262}. Receptor internalisation serves as an additional regulatory mechanism, limiting the availability of IFNAR for subsequent ligand binding²⁶³. Overall, IFN-I signalling is orchestrated by various feedback loops and the clarification of those underlying mechanisms is essential in order to modulate IFN response and limit IFN-related pathologies.

IFN-Is and its response have crucial roles in homeostasis, immune cell development and immune reactions against viruses and bacteria, albeit they could be both beneficial and detrimental. For example, high IFN-I signalling is protective in children against severe airways infections by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but in adults, it culminates disruption in antiviral IFN-I response^{264, 265}. Also, following acute SARS-CoV-2 infection, some patients showed prolonged and persistent symptoms, which is called coronavirus disease 2019 (COVID-19), that is characterised by plethora of all types of IFN. To illustrate, reduced cognitive skills and serotonin levels are described in those patients, which is strongly corresponded with aberrant TLR3 and IFNAR signalling²⁶⁶. In addition, it was previously shown that IFN-I guards the cells against Influenza A virus (IAV) in early stage of infections and in the depletion of IFN-I, antiviral defence switches to caspase dependent apoptotic or necroptotic mechanism which might be more detrimental for the host²⁶⁴. Besides, IFN-Is primes macrophages into proinflammatory M1 stage upon bacterial infection and increases T cell-mediated adaptive immune response²⁶⁷; nonetheless, their exact mechanism of action highly depends on the pathogen type.

On the contrary, constitutive and high IFN-I production is strongly associated with deleterious effects infections and pathologies, termed as interferonopathies, causing high morbidity and mortality, such as AGS or SAVI. Clinical application of IFNAR1-specific antibody, Anifrolumab, demonstrated that IFN-I response is one of the central drivers in those diseases^{268, 269}. Moreover, *Escherichia coli* or LPS-induced septic shock, is characterized by high IFN-I signature, associated aberrant immune response and high lethality, but it was demonstrated that IFN- β -deficient mice are more resistant to high-dose LPS, indicating that IFN-I is not always protective and can be detrimental during strong PRR stimulation²⁷⁰. Another detrimental role of IFN-Is is *M.tb* which bacteria-induced high IFN-I signature correlates with more susceptibility to the infection in human and mice. Mechanistically, IFN-I suppresses T helper 1 (Th1) cell response and limit ability of the macrophages to control bacterial clearance²⁷¹. In mice, depletion of IFNAR1 in pDCs alleviate the disease²⁷², but also people bearing IFNAR1 variant that binds IFN β with less affinity showed diminished susceptibility to the *M.tb* infection²⁷³. Correspondingly, in *Salmonella* infection, IFN-Is favour bacterial replication through supporting

necroptosis in macrophages and induce late endosome/lysosome acidification in intestinal epithelial cells (IECs)^{274, 275}.

IFN-Is is also crucial for adaptive immunity, particularly during viral infections. IFN-Is enhance cytotoxic activity of natural killer (NK) cells to the viruses²⁷⁶. Moreover, they can act on dendritic cells (DCs) by enhancing the expression of major histocompatibility complex (MHC)I/II, CD80 and CD86 co-stimulatory factors for T cell activation^{277, 278}. They play a costimulatory role during cross-presentation of the antigens to T cells by DCs and without robust IFN-I signalling, differentiation of naïve T cells to cytotoxic T cells and their expansion are disrupted²⁷⁹. Nevertheless, some studies were asserted that long-lasting IFN-I exposure of T cell before antigen presentation can limit T cell clonal expansion²⁸⁰. In addition, chronic IFN-I signalling promotes expression of programmed cell death ligand 1 (PDL-1), which results in cytotoxic T and NK cell exhaustion across many conditions²⁶⁷. In B cells, IFN-Is promote antibody class switching and contribute to the designation of the quality and magnitude of antibody response^{281, 282}. Thus, the consequences of acute and chronic IFN-I signalling corresponds with opposite outcomes and further investigation is required to delineate beneficial and pathological effect of IFN-Is.

1.4.2 IFN-II

To date, IFN- γ is the only member in the class of IFN-II. In contrast to IFN-I, IFN- γ is primarily produced in immune compartment, especially by innate lymphoid cells (ILCs), natural killer (NK), NKT and T cells²⁸³. IFN- γ is one of the most characteristic cytokines of T helper (Th)1 CD4⁺ T and its expression is governed by transcription factor T-bet mainly²⁸⁴. However, it can be induced in response to IL-12, IL-2, IL-15, and IL-18 of triggered NK and memory T cells^{228, 285, 286}. In addition, the cells in myeloid lineage, such as DCs and macrophages are major producer of those cytokines upon pathogen engagement²⁸³. In addition to these, because NK cells have high level of STAT4, IFNAR1-2 initially signal through STAT4 upon IFN-I binding, which leads to IFN-I- induced IFN- γ transcription in early time of the infections, yet STAT1 level increased in later stages because of the positive feedback loop and the signalling switches to canonical IFN-I pathways and IFN-I- induced IFN- γ transcription is shut down²⁸⁷. Besides, IFN-Is indirectly contribute to IFN- γ expression through induction of IL-15 production²⁸⁸.

Similarly to IFNAR, IFN gamma receptor 1&2 (IFNGR1&2) are expressed in almost all cells. Upon the engagement of IFN- γ to IFNGR1 and IFNGR2, JAK1 and JAK2 are auto- and trans- phosphorylation are induced, giving rise to STAT1 phosphorylation and homodimerisation. In turn, STAT1 homodimer translocates to the nucleus, interacting γ -activated sites (GASs) and triggering the expression of ISGs^{283, 289}. In spite of some overlapping IFN-I and IFN-II-induced ISGs, such as IRF1, they create markedly distinct expression profile and response²⁹⁰.

Mirroring the dual nature of IFN-Is, IFN- γ can be both protective and deleterious for the host. For instance, IFN- γ signalling enhances antigen presentation by increasing the efficiency, quantity and diversity of viral peptides loading onto MHC I during T cell priming²⁹¹. Along with that, it augments the expression of MHC II in DCs²⁹². Furthermore, it primes macrophages for M1 polarisation and promotes their proinflammatory cytokine productions like TNF α and IL1 β ²⁹³. Also, during Herpes Simplex Virus (HSV-2) infection, similarly to IFN-Is, IFN- γ suppresses the activation of innate lymphoid cell 2 (ILC2) and subsequent production like IL-13 and IL-5 which their high level is linked to immunopathology and fibrosis²⁹⁴. Nevertheless, the physiological consequence of IFN- γ on ILC2 is highly dependent on the timing. In early viral infection, IFN- γ -mediated suppression of ILC2 blocks and delay tissue repair, but in later stages, it prevents tissue damage and fibrosis²⁹⁵. In *M.tb* infection, deficiency of the elements in IFN- γ pathways increases the vulnerability of the host in both humans and mice²⁹⁶.

Despite the indispensable function of IFN- γ in immune cell activation, expansion and homeostasis, excessive IFN- γ is linked to autoimmune diseases like Autoimmune polyendocrine syndrome type 1 (APS-1), and blocking either IFN- γ production or its downstream signalling in mouse alleviated disease symptoms, emphasising its involvement in tissue damage²⁹⁷. Besides, during *Salmonella Typhimurium* infection, T and NK cells-derived IFN- γ triggers inflammation and tissue damage along with antibiotic therapy via inducing TNF, and pro-IL-1 β expression, yet IFN- γ is still crucial for macrophage defence to prevent systemic spread of *Salmonella Typhimurium*^{298, 299}.

In conclusion, IFN- γ bears an indispensable, but functionally different than IFN-Is, role to mediate anti-viral and bacterial immunity.

1.4.3 IFN-III

IFN-IIIs are comprised of IFN- λ 1-3 (also termed IL-29, IL-28A, and IL-28B) and IFN- λ 4 (of which only IFN- λ 2 and IFN- λ 3 exist in mice). IFN- λ 1-3 share high homology whilst IFN- λ 4 shares only 41% sequence similarity with the other IFN- λ family members³⁰⁰. In spite of the dependency of their expression on PRR-mediated activation of IRF3, IRF7 and NF- κ B, they strongly associate with slow and delayed production kinetics following infections in contrast to IFN-I^{263, 301}.

The underlying mechanism of IFN-III signalling shares core elements with IFN-I pathway and mostly exert its function via a similar cascade. Upon binding of IFN- λ to its heterodimeric IFN lambda receptor (IFNLR) and IL-10 receptor subunit beta (IL10RB) signal through TYK2 associated with IFNLR, and JAK1. The latter induces phosphorylation of STAT1/2 which subsequently assemble with IRF9 to form ISGF3 complex, and ultimately driving ISG expression via binding ISRE elements across the genome³⁰². Nonetheless, it was reported that the variance in ISG expression profiles between IFN-I and IFN-III, is quantitative rather than qualitative, characterised by a delayed and lower magnitude of IFN-III-induced ISG expression, particularly in hepatocytes and hepatocyte-derived cells³⁰³.

Even though almost all nucleated cells are responsive to IFN-Is, only a small portion of cells, including certain subsets of epithelial cells, neutrophils, B cells, and DCs initiate IFN-III signalling because of the restricted expression of IFNLR receptors²²⁸.

Contrary to IFN-I signalling, previous studies have asserted that TYK2 deficient cells retain the capacity to produce ISGs upon IFN-III treatment, yet JAK2-depleted or inhibited cells failed to respond to IFN-III and produce ISGs despite the fact that their IFN-I signalling remained unaffected^{304, 305}. Nonetheless, direct JAK2 association with IFNLR has not yet been shown; thus, further mechanistic insight and investigation are needed.

Notably, IFN-III signalling is more persistent compared to IFN-Is because USP18 does not lead to disruption of IFN-III signalling as it preferentially interacts with IFNAR2 and rather than IFNLR²⁵⁸. Nevertheless, similarly to IFN-I signalling, the overexpression of SOCS1 constraints ISG production in hepatocytes as a consequence of IFN-III treatment. *In vivo*, SOCS1 deficient mice showed elevated baseline ISG expression in liver alongside milder effect in lung and gut after treated with IFN-IIIs, which demonstrates the involvement of SOCS1 in IFN-III signalling in spite of suggesting its organ-specific regulatory mechanism³⁰⁶. In addition, IL10RB receptor is able to engage with IL-10, IL-22 and IL-26, which may give rise to a crosstalk with IFN-III signalling in a synergistic, as an example of IL-22³⁰⁷, or antagonistic manner.

IFN-IIIs especially act on neutrophils to limit tissue damage by reducing their recruitment to the infection site, reactive oxygen species (ROS) generation and extracellular trap formation while maintaining a modest level of ISG expression relative to IFN-I during cutaneous HSV-1 infection^{308, 309}. Despite the functional similarities between IFN-I and III, IFN-I cannot recapitulate IFN-III physiological consequences mediated by IFN-III, which remain strictly dependent on the target tissue, timing, and local inflammatory environment^{302, 308}, albeit they display certain redundancy in certain cases. For instance, IFN-IIIs provide still partial protection in *Ifnar1* deficient mice against Influenza A virus, whereas *Ifnar1* and *Ifnlr1* deficient mice entirely succumb to the infection³¹⁰. Another specialised function of IFN-IIIs is to drive the signalling in IECs against enteropathogens because they are relatively hyposensitive to IFN-Is and favour local inflammation through IFN-IIIs, over systemic IFN-I responses that promotes longitudinal epithelial cytotoxicity³¹¹. Even in mice lacking adaptive immunity via *Rag1* deficiency, IFN-III treatment protected IECs from norovirus infection³¹². In humans, it was manifested that IFN-III treatment can guard IECs against SARS-COV2 *in vitro*³¹³. Besides, IFN-IIIs particularly induce the upregulation of tight junction proteins in IECs and improve barrier function, thereof blocking transmigration of *Salmonella enterica*²⁴⁵.

In summary, IFN-Is and IFN-IIIs share common features and regulatory function under many circumstances, yet differential expression profile of both IFNs and their respective receptors, combined with key regulatory differences in their signalling, result in a compartmentalised and unique physiological role of IFN-IIIs. Nevertheless, further investigation into the distinct mechanisms

governing IFN-III function remains essential to provide a deeper understanding of these localised immune responses.

1.5 Cell Death

Cell death is an essential process that allows organisms to remove cells that are no longer needed, damaged, or potentially harmful. In the context of immunity and disease, it plays an important role in shaping inflammation, tissue integrity, and host defence. Different cell death modalities, such as apoptosis, necroptosis and pyroptosis, perform unique roles, depending on the type and intensity of stress, and their balance can strongly influence whether a response is protective or pathological.

1.5.1 Apoptosis

Apoptosis represents a distinct form of programmed cell death that is vital for both embryonic development and cellular homeostasis. Upon initiation, apoptotic cells undergo a systematic cascade characterised by chromosome condensation, DNA fragmentation, and the cleavage of structural proteins, culminating in morphological alterations and cellular disintegration. This process is primarily governed by caspase family. Apoptosis proceeds through two principal, interconnected pathways: the extrinsic pathway, which is initiated by cell-surface DRs, and the intrinsic pathway, which is mediated by mitochondria in response to cellular stress or damage as illustrated in Figure 1.10.

While specific immune receptors, such as TLR3/4, can induce apoptotic signalling via mechanisms analogous to canonical DRs, the extrinsic pathway is predominantly triggered by three major receptor-ligand systems belonging to the death domain (DD)-containing TNFRSF-TNFSF, such as TNF-TNFR1, Fas-FasL, and TRAIL-TRAIL-R1/2. Unlike the TNF-TNFR1 system, which propagates through a previously described cytosolic complex II, the Fas-FasL and TRAIL-TRAIL-R1/2 pathways induce cell death via a distinct mechanism. Upon ligand binding, Fas and TRAIL-R1/2 directly recruit procaspase 8 to the membrane-bound receptor-ligand complex via FADD, notably bypassing TRADD engagement. The spatial juxtaposition of procaspase 8 molecules facilitates a multi-step auto-processing sequence driven by their intrinsic self-cleavage activity. Initially, procaspase 8 homodimers undergo primary processing to generate p43 and p10 fragments. This is followed by further cleavage events that produce p30, p26, p18, and p10 subunits. The process culminates in the assembly of an active cytosolic heterotetramer composed of two p18 and two p10 fragments, collectively referred to as active caspase 8. Executioner caspases 3/6/7 are activated through their cleavage by caspase 8. These effector caspases dismantle critical cellular substrates—including cytoskeletal elements, pro-survival factors, and inhibitors of endonucleases—thereby driving cellular disintegration. Furthermore, caspase 3 can cleave and activate caspases 6 and 7, establishing a feed-forward loop⁸³.

Nonetheless, extrinsic apoptotic signalling is tightly regulated to prevent unintended cell death. High levels of c-FLIP can halt apoptosis initiation by interfering with caspase 8 activation; under these

conditions, the caspase may undergo initial processing but fails to achieve full catalytic maturation. However, growing evidence highlights a primordial role for c-FLIP in scaffolding the caspase 8 "filament" within the DISC, and its precise regulatory dynamics remain an active area of investigation³¹⁴. Additionally, the caspase 8 homolog, caspase 10, functions as a negative regulator of caspase 8-mediated cell death by disrupting its association with the DISC³¹⁵. When death receptor-mediated signalling is insufficient to execute apoptosis independently, active caspase 8 can engage in cross-talk with the intrinsic pathway. This is achieved by the proteolytic cleavage of B-cell lymphoma 2 (Bcl-2) homology (BH) 3-interacting domain death agonist (BID) into truncated BID (tBID), which translocates to the outer mitochondrial membrane (OMM) to amplify the apoptotic signal³¹⁶.

The intrinsic pathway centers on mitochondrial outer membrane permeabilisation (MOMP) and the subsequent release of intermembrane space proteins into the cytosol. MOMP is strictly regulated by members of the Bcl-2 family, which share up to four BH1 to BH4 domains. These domains enable homotypic interactions between family members to either induce or block apoptosis, allowing them to be categorised into three functionally distinct classes based on their specific roles and shared BH domains: one anti-apoptotic class and two pro-apoptotic classes. Anti-apoptotic proteins, including Bcl-2, Bcl-xL, and myeloid cell leukaemia 1 (Mcl-1), possess three or four BH domains. Conversely, the first pro-apoptotic class, which includes Bcl-2 antagonist of cell death (BAD) and Bcl-2-associated X protein (BAX), contains two or three BH domains, while the second pro-apoptotic class consists of BH3-only proteins, such as BID^{317, 318}.

During intrinsic apoptosis, the pro-apoptotic multi-domain proteins Bcl-2-antagonist/killer (BAK) and BAX are indispensable for pore formation on the OMM. Under homeostatic conditions, anti-apoptotic Bcl-2 proteins maintain survival either by sequestering BAK and BAD or by inhibiting apoptosis-activating BH3-only proteins. Upon receiving apoptotic stimuli, BH3-only proteins like tBID repress these anti-apoptotic Bcl-2 family members, relieving the inhibition on BAK and BAX to drive their activation and subsequent MOMP^{319, 320}. Following OMM pore formation, cytochrome C is released into the cytosol, where it induces the oligomerisation of apoptotic protease activating factor 1 (APAF-1) and the clustering of procaspase 9 to assemble the "apoptosome." Self-cleavage and activation of procaspase 9 then allow it to process and activate downstream effector caspases to enforce cell death³²¹. Concurrently, second mitochondria-derived activator of caspase/direct IAP-binding protein with low pI (SMAC/DIABLO) is released into the cytosol. SMAC/DIABLO binds to and induces the auto-ubiquitination and proteasomal degradation of X-linked inhibitor of apoptosis (XIAP) cIAP1/2. This neutralisation is crucial, as XIAP otherwise directly inhibits active caspase 3 by targeting it for proteasomal clearance^{322, 323}.




Figure 1.10: A comprehensive overview of the extrinsic and intrinsic apoptotic pathways. Key components of extrinsic pathway include Tumour Necrosis Factor (TNF) Receptor 1 (TNFR1), TNF-Related Apoptosis-Inducing Ligand Receptor 1/2 (TRAIL-R1/2), and the adaptor proteins TNFR1-associated death domain (TRADD) and Fas-associated DD (FADD). The signalling network further involves TNF receptor-associated factor 2 (TRAF2), cellular inhibitors of apoptosis proteins (cIAPs), receptor-interacting protein kinase (RIPK), and X-linked inhibitor of apoptosis (XIAP). Mitochondrial involvement is highlighted by the release of second mitochondria-derived activator of caspase/direct IAP-binding protein with low pI (SMAC/DIABLO) and the cleavage of BH3-interacting domain death agonist (BID) into truncated BID (tBID). Cytosolic assembly of the apoptosome involves apoptotic protease activating factor 1 (APAF-1), while the pathway is further modulated by ubiquitin (Ub) modifications. Adapted from Biorender template.

Beyond these canonical intrinsic and extrinsic pathways, cytotoxic T lymphocytes and natural killer (NK) cells can independently stimulate apoptosis in target cells via the perforin-granzyme system. Upon exocytosis, perforin forms pores in the plasma membrane of the target cell, facilitating the entry of granzymes which directly cleave and activate downstream executioner caspases to trigger apoptosis^{317, 324}. Ultimately, while apoptosis does not typically elicit a robust, pro-inflammatory phenotype, it still modulates the immune system through the immunologically controlled engulfment of apoptotic bodies. For a long time, apoptosis was considered as an immunologically silent modality of cell death; however, accumulating evidence increasingly demonstrates that it can exert the opposite effect through secondary necrosis and by actively modulating immune responses.

1.5.2 Necroptosis

Although necrosis was long considered an accidental form of cell death, the discovery that it can be regulated emerged in 2005. This regulated necrosis displays morphological and biochemical characteristics of both necrosis and apoptosis and was subsequently termed necroptosis³²⁵. Morphologically characterised by cell swelling and plasma membrane disruption, necroptosis serves as an alternative cell death pathway when apoptosis is inhibited by pharmacological agents or pathogens. The execution of necroptosis triggers the release of elevated levels of inflammatory cytokines and DAMPs, consequently enhancing immune cell infiltration at the inflammatory site³²⁶.

Necroptosis can be induced via DRs and PRRs. Within the context of DR signalling, DISC is initially assembled to drive the apoptotic pathway. However, if the apoptotic signal cannot proceed due to the inhibition or genetic elimination of caspase 8, RIPK1 interacts with RIPK3 via their respective RHIM domains. This interaction promotes, either directly or indirectly, the phosphorylation and activation of RIPK3. Activated RIPK3 then phosphorylates MLKL, prompting its oligomerisation and subsequent translocation to the plasma membrane^{327, 328}. These MLKL oligomers form pores in the plasma membrane that facilitate the influx of Ca^{2+} and Na^{+} ions, thereby disrupting cellular osmotic balance and culminating in cell swelling and membrane rupture. This sequence of events constitutes the canonical necroptosis pathway^{329, 330}. However, whether ion channels actively contribute to necroptotic progression remains elusive and requires deeper investigation.

While PRRs, such as TLR3, can induce necroptosis in a highly similar manner, the signalling differs in certain ways, indicating that multiple upstream pathways can trigger this process. In the non-canonical necroptosis pathway, other RHIM domain containing proteins can be involved like TRIF in the TLR3/4 pathway, as well as IFN-induced ZBP1. Notably, ZBP1 is an ISG-encoded protein, serving as a critical link between pathogen sensing, interferon induction, and necroptotic cell death³³¹. These components can associate with and activate RIPK3 to initiate downstream necroptotic signalling^{89, 332}; however, whether RIPK1 plays a context or cell type-dependent role in these specific pathways remains unclear.

The regulation of the necroptosis pathway involves several E3 ubiquitin ligases that either stabilise DR signalling complexes, such as cIAP1/2, or control the molecular turnover of key necroptotic modules. For instance, tripartite motif-containing protein 25 (TRIM25) can induce the proteasomal degradation of RIPK3 via K48-linked polyubiquitination³³³. Additionally, certain E3 ubiquitin ligases can ubiquitinate MLKL oligomers to target them for proteasomal or lysosomal degradation, thereby preventing necroptosis³³⁴. Furthermore, the endosomal sorting complexes required for transport (ESCRT) machinery can counteract MLKL pores by repairing the plasma membrane, which results in either the complete blockade or the delay of necroptosis³³⁵. Concurrently, heterodimers formed by c-

FLIP large isoform and procaspase 8 within the DISC complex can cleave both RIPK1 and RIPK3, thereby inhibiting the induction of necroptosis⁹⁰.

1.5.3 Pyroptosis

PRRs, including TLRs and NLRs, also contribute to another highly inflammatory modality of regulated cell death termed pyroptosis, which is executed by five primary proteins: gasdermin A, B, C, D, and E. Among these, gasdermin D (GSDMD) and E (GSDME) represent the most thoroughly characterized members of the group. To achieve activation, these gasdermins must undergo proteolytic cleavage by specific caspases. The classical framework of inflammasome formation and pyroptosis requires two distinct phases. The first phase involves the sensing of infection, notably via PRRs, leading to the removal of inhibitory PTMs from several pyroptosis-related components and the induction of gene-activating pathways that promote the expression of different proteins implicated in pyroptosis, such as NLR family pyrin domain containing 3 (NLRP3), alongside pro-inflammatory cytokines like pro-IL-1 β and IL-18^{336, 337}. Additionally, caspase-11 (an analogue of caspase-4 and caspase-5 in humans) is upregulated following interferon signalling, allowing for the subsequent activation of GSDMD, independently from canonical pathway in mice³³⁸. The second phase comprises the induction of pyroptosis mediated by the intracellular sensing of the pathogenic molecules or danger signals by various NLRs or AIM2, ultimately leading to the assembly of the canonical pyroptosis-initiating complex, the inflammasome. In this process, apoptosis-associated speck-like protein containing a CARD (ASC) and caspase-1 are recruited to the activated receptor via homotypic PYD interactions. Subsequently, ASC binds procaspase-1 through homotypic CARD interactions, promoting the autocatalytic processing and activation of caspase-1³³⁹. Activated caspase-1 then cleaves GSDMD, relieving its autoinhibitory state and enabling its oligomerisation and pore formation within the plasma membrane. Simultaneously, caspase-1 processes pro-IL-1 β and pro-IL-18 into their mature forms, which are subsequently released through GSDMD pores to amplify inflammatory responses³³⁸. However, GSDMD pores alone are insufficient to induce complete lytic cell death. Instead, Nerve Injury-Induced Protein 1 (NINJ1) oligomerises to generate larger membrane disruptions that ultimately mediate plasma membrane rupture. Although it is proposed that osmotic imbalance caused by GSDMD pores triggers NINJ1 activation, the underlying mechanism has not yet been fully elucidated³⁴⁰. Similarly in necroptosis, the ESCRT machinery can be involved in plasma membrane repair during the early stages of GSDMD-mediated pore formation, thereby counteracting the progression of pyroptosis³⁴¹. Importantly, researchers have demonstrated that other caspases, previously associated exclusively with apoptosis, are also capable of cleaving several GSDMs. For instance, caspase-8 can cleave GSDMD as caspase-1, whereas caspase-3 cleaves GSDME to induce pyroptosis or as previously named secondary necrosis of apoptotic bodies^{342, 343}. Furthermore, lymphocyte-derived granzymes have been directly linked to the cleavage of gasdermin B and E^{344, 345}. Accumulating evidence suggests that extensive biochemical cross-talk exists between these different cell death modalities. The non-canonical

inflammasome pathway is activated by cytosolic LPS, which directly binds to and activates caspase-11 (or caspase-4/5 in humans), thereby inducing downstream cleavage of GSDMD. Although caspase-4/5, but not caspase-11, are capable of cleaving and activating IL-18, their processing of pro-IL-1 β appears to be inhibitory rather than activatory³⁴⁶. During LPS-induced sepsis or septic shock, genetic knockout of either caspase-1 or caspase-11 prevents lethality, proving a potential cross-talk between the canonical and non-canonical inflammasomes and, most importantly, highlighting the crucial role of pyroptosis in counteracting host infection^{347, 348}. Despite significant advances in understanding pyroptosis, further research is still required to elucidate the molecular mechanisms underlying its activation, regulation, and functional diversity. In particular, the specific roles of the different pyroptotic modules, including various GSDM family members, as well as the physiological significance of pyroptosis, remain incompletely understood.

PTMs, particularly ubiquitination, also tightly regulate this cell death modality. Indeed, several ubiquitin E3 ligases control the activation or expression of crucial pyroptotic components. For example, PARKIN promotes the autophagic degradation of NLRP3³⁴⁹, whereas the LUBAC and TRAF3 ubiquitinates ASC to induce its activation^{350, 351}. As an additional layer of regulation, despite the fact that underlying mechanism remains unclear, type I IFN signalling has emerged as a negative modulator of NLRP3-induced pyroptosis and IL-1 β release³⁵². Ultimately, immune receptor-mediated signalling pathways possess the dual capacity to trigger robust inflammatory responses via the activation of gene-activating pathways or the induction of cell death, both of which are tightly orchestrated by ubiquitination and coordinated crosstalk between distinct immune signalling network.

1.6 ANKIB1

ANKIB1 is a 122 kDa protein characterised as a putative member of the RBR E3 ligase family. Although its primary sequence strongly suggests E3 ligase activity, empirical evidence confirming its catalytic function and regulation remains limited. Structurally, the protein exhibits a complex modular architecture that dictates its potential interactome and regulatory mechanisms. However, the current characterisation of these domains relies predominantly on sequence similarity, structural homology, and amino acid residue conservation; consequently, the exact boundaries of these functional domains have yet to be fully elucidated and experimentally proven. As illustrated in Figure 1.11, at the N-terminus, ANKIB1 features two extensive Ankyrin repeat domains, which are motifs classically associated with mediating high-affinity protein-protein interactions; this structural arrangement suggests that ANKIB1 serves as a versatile scaffolding platform in addition to its potential enzymatic roles³⁵³. Following these repeats, bioinformatic analysis predicts the presence of a Ubiquitin-Associated (UBA)-like domain, which typically characterises binding to mono-ubiquitin and polyubiquitin chains through the hydrophobic patch centred around isoleucine 44 (Ile44) of the ubiquitin molecule³⁵⁴. Following this region is the RBR domain, which typically facilitates the ubiquitination of target proteins. As described in Figure 1.12, the RING1 domain of ANKIB1 possesses all the conserved cysteine and histidine

residues required for Zn^{2+} ion coordination similarly to canonical RING-type E3 ligases. Additionally, previous reports have demonstrated the essentiality of specific hydrophobic and proline residues in the canonical RING-type E3 ligase, cIAP2, for E2-binding and subsequent ubiquitin transfer to the substrate^{355, 356}. Another characteristic of RING family E3s is to bear basic (Lys/Arg) linchpin residues after the last conserved cysteine, enabling the closed conformation of E2-Ub complex that is essential for E2-dependent linkage specificity⁴⁶. As illustrated in Figure 1.12, ANKIB1 also carries these specific residues and features a unique RING1 domain that shares the highest similarity within the RBR E3 category to canonical RING-type E3 ligases, except the linchpin residue. It suggests that potential, but mechanistically distinct, catalytic activity for ANKIB1-RING1 domain unlike other RBR E3s. Nevertheless, comparison of the RING2 domain across various RBR E3 ubiquitin ligases reveals that ANKIB1 retains all conserved cysteine and histidine residues required for its catalytic activity. Furthermore, it possesses the characteristic negatively charged residue situated between the fifth and sixth cysteine residues, which is essential to exert its RING2-dependent catalytic function as shown in Figure 1.13³⁵⁷. Distal to the RBR domain, in silico structural predictions via AlphaFold 3, supported the presence of an Ariadne domain. This domain consists of four alpha-helices that function as an auto-inhibitory module by sterically masking the RING2 ubiquitin-binding site³⁵⁸. Consequently, activation of ANKIB1 likely requires a conformational change, triggered by PTMs or heterotypic protein interactions, to displace this domain and enable ligase activity.



Figure 1.11: Domain architecture of ANKIB1, (generated by BioRender), **and its conservation scores of its residues** (analysed by ConSurf and adapted by ChatGPT 5.5).




Figure 1.12: Alignment of the RING domain sequences across different RBR and RING type E3 ligases. The sequence alignment illustrates the structural conservation within the RING1 domains across various RBR-containing E3 ligases compared to two classical RING domains from canonical RING E3 ligases. The critical zinc-coordinating residues are highlighted, with conserved cysteines underlined in green and the conserved histidine underlined in blue. Essential functional residues involved in E2-binding and ubiquitin transfer are also denoted: conserved hydrophobic amino acid positions are indicated by a blue triangle, while the conserved proline is marked with an asterisk. Conversely, structural deviations are noted where substituted hydrophobic amino acids are highlighted in bold red, additional amino acids deviating from the original motif are underlined in black, and any missing conserved histidine residues are identified by a black dot. The basic linchpin sequence is indicated as yellow.

Located near the C-terminus, a Ubiquitin-Interacting Motif (UIM) suggests that ANKIB1 specifically associates with ubiquitinated substrates, with research indicating a preferential binding affinity for polyubiquitin chains central to immune signalling cascades, such as those governed by TNF and TLR3^{154, 359}. Evolutionary analysis using the ConSurf platform reveals high sequence conservation across more than 150 species for all major functional domains, including the ankyrin repeats, RBR, and Ariadne domains (Figure 1.10). While the C-terminal region is generally less conserved, the UIM and a secondary sequence (between aa969-991) with unknown function remain highly conserved across species, highlighting their potential biological importance. Furthermore, amino acid sequence analysis, using ExPASy platform, suggested that ANKIB1 is N-myristoylated on its glycine residue immediately following the initiating methionine. This PTM is typically responsible for membrane localisation, such as the plasma membrane, ER, or mitochondria³⁶⁰. Given that many immune signalling complexes

assemble at membranous compartments, this subcellular localisation may support the hypothesis that ANKIB1 participates in membrane-associated immune transduction.




Figure 1.13: Alignment of the RING2 domain sequences across different RBR E3 ligases. The cysteine and histidine residues involved in Zn^{2+} ion coordination are highlighted as blue. The triad residues, which are essential for the ligase activity, are indicated by black triangles, while the catalytic cysteine residue is underlined in red. Adapted from³⁵⁷.

Until recently, the physiological role and molecular function of ANKIB1 remained unclear, though several studies indirectly highlighted its conceptual importance. Transcriptomic data demonstrated a significant upregulation of ANKIB1 expression following bacterial challenge, suggesting a regulatory role in the immune response and a potential link to PRR pathways³⁶¹. Beyond immunity, ANKIB1 has emerged as a potential biomarker for Alzheimer's disease, with its elevation in transcript levels observed in patient cohorts compared to healthy controls³⁶². Additionally, non-coding RNAs derived from the ANKIB1 locus have been implicated in oncogenic progression³⁶³.

Notably, it has recently been proposed that ANKIB1 acts as a negative regulator of the RIG-I/MAVS signalling pathway by catalysing K48-Ub on MAVS, which marks it for proteasomal degradation, thereby blocking the production of pro-inflammatory cytokines and IFN-I upon RNA virus infection or ligand stimulation. However, despite these promising indications of a functional role for ANKIB1 in the immune response, the proposed mechanism relied primarily on overexpression experiments performed in the absence of stimuli. Furthermore, these studies lacked functional validation assays for direct ubiquitination, and the possibilities of functional redundancy or indirect regulation by ANKIB1 were not excluded¹⁹⁹. Consequently, the precise molecular mechanism of ANKIB1 remain elusive. In addition, a biochemical study suggested that a truncated form of ANKIB1 (aa 1–778) purified from insect cells is unable to catalyse ubiquitination in coordination with UBE2L3. This finding highlights

that ANKIB1 is in autoinhibited state mediated by its Ariadne domain, and suggests that the insect cell expression system may lack the specific cellular elements or PTMs required to relieve this inhibition³⁶⁴. Another study was asserted that ANKIB1 can generate K48-linked polyubiquitination chains and that its enzymatic activity is enhanced by its palmitoylation. Nevertheless, these findings remain inconclusive due to the absence of a functional ubiquitination assay to definitively detect the presence of ANKIB1-dependent K48-Ub, as well as a lack of direct evidence confirming that palmitoylation can increase the catalytic activity of ANKIB1. Furthermore, the molecular and functional characterisations in these studies were heavily based on overexpression systems; consequently, whether these mechanisms occur under physiological conditions and the ultimate validation of these data require further clarification³⁶⁵.

1.7 Aim of the study

The immune system is a critical component for defending the host against pathogens and maintaining tissue homeostasis, with its dysregulation being strongly associated with various pathologies, diseases, and high mortality. Consequently, immune responses are tightly regulated both intrinsically within immune cells—via the differential expression of effector proteins and their PTMs—and extrinsically through crosstalk between immune and non-immune cells mediated by messenger molecules such as cytokines. Upon engagement, specific cytokines and their associated receptors, such as TNF-TNFR1, initiate intracellular signal transduction pathways that ultimately shape cellular transcriptional profiles, cell fate, and overall biological activity. Similarly, the sensing of pathogenic molecules via PRRs, such as dsRNA recognition by TLR3, results in the activation and regulation of immune cells in a comparable manner. Ubiquitination has emerged as a decisive modulatory modification within these pathways, essential both for inducing a robust immune response against pathogens and for preventing the aberrant immune activation that leads to chronic inflammatory disorders and tissue damage.

Numerous E3 ubiquitin ligases are implicated in both the TNF and TLR3 pathways; however, they do not necessarily fulfil identical functions, and their ubiquitin ligase activities are not equally required. A major divergence lies in the specific role of linear ubiquitin chains during the activation of the non-canonical IKKs, i.e., TBK1 and IKK ϵ . In the TNF signalling pathway, it has been demonstrated that the presence of linear ubiquitin chains on RIPK1 is crucial for the recruitment and activation of TBK1 and IKK ϵ ⁷⁹. Specifically, these linear chains promote the recruitment of NEMO to the signalling complex, which subsequently facilitates the recruitment of the critical adaptor protein, TANK, along with its associated kinases, TBK1 and IKK ϵ . However, in late TNF-induced complex I signalling, association of TBK1 alone is instead maintained with A20 and the adaptor protein, NAP1⁸². In contrast to other cascades like TLR3 signalling, the recruitment of these non-canonical IKKs in the TNF pathway is not mediated by TRAF3 and does not induce IFN-I production¹²³. Instead, they generate inhibitory

phosphorylation on RIPK1 to prevent its autophosphorylation and activation, thereby inhibiting TNF-induced cell death and retain the robust gene activating pathways.

Intriguingly, despite a similarly conserved role for the LUBAC in regulating the MAPK/ NF- κ B pathways and inhibiting cell death during TLR3 signalling, pioneering work from Walczak lab has demonstrated that the absence of HOIP barely impacts the recruitment of TBK1 to the TLR3-SC and its subsequent activation¹²³. Furthermore, several studies proposed the requirement of different TBK1 adaptor proteins, including TANK, NAP1, SINTBAD and OPTN, in the TLR3 pathway¹⁴⁸⁻¹⁵¹. Yet, which specific adaptor (or adaptors) is essential for TLR3-induced IFN induction has remained unresolved. Given the crucial role of TBK1 in driving IFN production, this study aimed to decipher the underlying molecular requirements governing TBK1 recruitment and activation within the TLR3 pathway. Specifically, it sought to determine whether an alternative E3 ubiquitin ligase, possibly a second linear ubiquitin generating ligase, may operates in this process, potentially collaborating with TRAF3 and specific adaptor protein(s), which could clarify the mechanistic discrepancy between the TNFR1 and TLR3 signalling pathways with regard to their differential reliance on HOIP and its linear-ubiquitin-forming activity for TBK1 recruitment.

2 Materials and Methods

The entire “Materials and Methods” section was established based on a recent publication under <https://doi.org/10.1038/s41556-026-01886-z>. To ensure a comprehensive description of the methodology, several procedures were further elaborated and the formal disclosure regarding the utilization of artificial intelligence in this dissertation was included.

2.1 Generation of ANKIB1 Expression Constructs

The coding sequence of ANKIB1 was amplified using Phusion High-Fidelity PCR Master Mix (New England Biolabs) and cloned to pBABE-Puro plasmid using XhoI and AgeI (New England Biolabs). Deletions and point mutations were introduced to into the plasmid using Q5® Site-Directed Mutagenesis Kit (New England Biolabs) according to manufacturer’s instructions and following primers: ANKIB1_RING2_mut_Fw: CACATGCAGAGTGCTAAGAGCAAGTATGACTTTAGCTGGATTAGCCTTGAAGAGTGGAACAAAACATAG; ANKIB1_RING2mut_Rv: ATTGCTGCCTTCATCTTCTGTATTGGAGACTTACTGTTGGCACTAGGCTTGGAGTTAGTTAATAAC; ANKIB1_ΔRING2_Fw: CTTGAAGAGTGGAACAAAACATAG; ANKIB1_ΔRING2_Rv: AGGCTTGGAGTTAGTTAATAAC; ANKIB1_ΔRBR_Fw: CTTGAAGAGTGGAACAAAAC; ANKIB1_ΔRBR_Rv: CAAACTGGTGTCTAAATCC; ANKIB1_RING1mut_Fw: TTTGAAGACCCTGTGGATATGCCCGCTGCTGACTTTTGTAGAGGATGTTG; ANKIB1_RING1mut_Rv: TACAGAGATACTGCACATAGCAGCGTCAGCCAACTGGTGTCTAAATCC; ANKIB1_ΔUIM_Fw: CTCGATGAAGAACTAGAG; ANKIB1_ΔUIM_Rv: ATCCAAGGAACTCAGAGC

2.2 Recombinant proteins, cells and cell lines

E1, E2s, USP2 and ubiquitin were purchased from R&D. moTAP-TNF was produced and purified as described in⁹⁸. Poly (I:C) HMW was purchased from Invivogen. LPS was purchased from Enzo Life Sciences. ADU-S100 was purchased from MedchemExpress and 2'3' cGAMP was purchased from Selleck Chemicals.

WT HeLa (ATCC CCL-2), HT-29 (ATCC HTB-38), and A549 (ATCC CCL-185) cell lines used herein were purchased from the ATCC. ANKIB1 and TLR3 were depleted by using the plasmid px458 and performing single cell sorting upon transfection. gANKIB1_Fw: CACCGGCGTGCCAAGCGAGGATGA; gANKIB1_Rv: AAATCATCCTCGCTTGGCACGCC; gTLR3_Fw: CACCCAGCTAACTAGCTTGGATGT; gTLR3_Rv: AAACACATCCAAGCTAGTTAGCTG. TANK/NAP1/SINTBAD/OPTN were generated using the gRNA published in⁷⁹. In order to generate viral particles and stably re-express moTAP-ANKIB1 or moTAP-TLR3 in cells, 5 million Platinum Amphi cells were seeded per 10 cm dishes in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% Fetal Bovine Serum (FBS). Platinum Amphi cells constitutively express gag-pol and the envelope protein for amphotropic viruses. The next day, 5 µg retroviral pBABE vector including the construct of interest were mixed with 20 µl at 1mg/ml polyethyleneimine (PEI) (Sigma-

Aldrich 764965) in Opti-MEM and they were incubated at room temperature for 20 minutes. Then, cells in each dish were transfected dropwise. The next day, the medium was removed and replaced with 5 mL of fresh medium. 48 hours later, supernatants were collected and filtered with a 0.45 µm filter. Then, the supernatant comprising viral particles was mixed with fresh RPMI supplemented by 5% FBS and 1% penicillin-streptomycin. Additionally, 8 µg/ml polybrene (Sigma-Aldrich TR-1003) was added to increase the efficiency of the transduction. Plates were subjected to spin-infection at 2500rpm for 45 minutes at 30°C. After two days, cells were either selected via GFP-positive cell sorting by Fluorescence-activated cell sorting (FACS) or via puromycin (Invivogen ant-pr-1) selection.

2.3 SDS-PAGE and Western blotting

Proteins were separated using 4 – 15% Mini- or Midi-PROTEAN®-TGXTM-gels (BioRad) with Tris/glycine/SDS running buffer. Proteins were transferred on Mini- or Midi- 0.2 µm nitrocellulose membranes (BioRad transfer packs) using the Trans-Blot® Turbo™ Transfer System from BioRad. The membranes were blocked with 2.5% non-fat dried milk 0.025% Tween-20 in PBS (137 mM NaCl 8.1 mM Na₂HPO₄ 2.7 mM KCl 1.5 mM KH₂PO₄ pH 7.4). Proteins were subsequently analysed by western blotting with following antibodies: anti-ARIH1 (Novus Biology, NBP1-55039, Rabbit, 1/1000) anti-ARIH2, monoclonal (EPR7670) (Abcam, ab133744, Rabbit, 1/1000) anti-β-Actin (ACTB), monoclonal (AC-15) (Sigma, A5441, Mouse, 1/10000) anti-ANKIB1 (Atlas Antibody, HPA021780, Rabbit, 1/750) anti- cullin 9 (ThermoFisher, A300-098A-T, Rabbit, 1/1000) anti-GAPDH (Sigma, G9545, Rabbit, 1/10000) anti-IRF3, monoclonal (D83B9) (Cell Signalling, 4302, Rabbit, 1/1000) anti-IκBα (Cell Signalling, 9242, Rabbit, 1/1000) anti-HOIP (Ubiquigent, 68-0013-100, Sheep, 1/500) anti-NEMO (IKKγ) (Atlas Antibodies, HPA000426, Rabbit, 1/1000) anti-RIPK1, monoclonal (D94C12 XP®) (Cell Signalling, 3493, Rabbit, 1/1000) anti-OPTN (Proteintech, 10837-1-AP, Rabbit, 1/5000) anti-Phospho-IκBα (Ser32/36), monoclonal (5A5) (Cell Signalling, 9246, Mouse IgG1, 1/750) anti-IRF3 (phospho S386), monoclonal (EPR2346) (Abcam, ab76493, Rabbit, 1/1000) mouse anti-phospho-IRF3 (396), monoclonal (E.875.8) (Thermo Scientific, MA5-14947, Rabbit, 1/500) anti-phospho-SAPK/JNK (Thr183/ Tyr185), monoclonal (G9) (Cell Signalling, 9255, Mouse IgG1, 1/1000) anti-phospho-p38 MAPK (Thr180/Tyr182), monoclonal (3D7) (Cell Signalling, 9215, Rabbit, 1/1000) anti-phospho-NF-κB p65 (Ser536), monoclonal (93H1) (Cell Signalling, 3033, Rabbit, 1/1000) anti-phospho-TBK1/NAK (Ser172), monoclonal (D52C2 XP®) (Cell Signalling, 5483, Rabbit, 1/1000) anti-RNF14, monoclonal (EPR9041) (Abcam, ab134927, Rabbit, 1/1000) anti-RNF216 (Abcam, ab226215, Mouse IgG1, 1/1000) anti-TBK1 (Cell Signalling, 3013, Rabbit, 1/1000) anti-TLR3, monoclonal (D10F10) (Cell Signalling, 6961, Rabbit, 1/1000) anti-TNFR1, monoclonal (H-5) (Santa Cruz, 8436, Mouse IgG2b, 1/1000) anti-TRIF (Cell Signalling, 4596, Rabbit, 1/200) mouse anti-phospho-STING (Ser365), monoclonal (D8F4W) (Cell Signalling, 72971, Rabbit, 1/500) human anti-phospho-STING (S366), monoclonal (D7C3S) (Cell Signalling, 19781, Rabbit, 1/500) anti- STING, monoclonal (D2P2F) (Cell Signalling, 13647, Rabbit, 1/500) anti-TRAF3, monoclonal (D1N5B) (Cell Signalling, 61095, Rabbit, 1/500) anti-phospho-STAT1 (Y701), monoclonal (58D6) (Cell Signalling, 9167, Rabbit, 1/1000) anti-ubiquitin

(Sigma-Aldrich, U5379, Rabbit, 1/1000) anti-Actin, monoclonal (mAbcam 8226) (Abcam, ab8226, Mouse IgG1, 1/10000) anti-VACV antibody (Abcam, ab19970, Rabbit, 1/1000), anti-Mouse IgG1-HRP (Southern Biotech, 1070-05, Goat, 1:10000) anti-Mouse IgG2b-HRP (Southern Biotech, 1091-05, Goat, 1:10000) anti-Rabbit IgG-HRP (Southern Biotech, 4050-05, Goat, 1:10000) anti-Sheep IgG-HRP (Southern Biotech, 6150-05, Rabbit, 1:10000) anti-Human IgG-HRP (Thermo Scientific, 31482, Goat, 1:10000) anti-Rabbit IgG 680 nm (Licor, 926-68071, Goat, 1:10000) anti-Mouse IgG 800 nm (Licor, 926-32210, Goat, 1:10000). The protein signals were monitored using either LLC WESTERN LIGHTNING PLUS ECL (Revvity Health Sciences) for chemiluminescent signal or a Li-Cor Odyssey CLx for fluorescent signal.

2.4 Cell Activation and Immunoprecipitation

5 million HeLa or 7 million HT-29 cells were seeded in 15 cm dishes in RPMI. The following day, cells were treated with 10 µg/ml poly(I:C) for 0, 30 minutes, and 1 hour. The medium was removed and cells were washed with ice-cold PBS. Subsequently, they were lysed in 1 mL lysis buffer including (30 mM Tris-Cl pH 7.5, 120 mM NaCl, 1,7 mM DDM, 2 mM KCl, 2 mM EDTA, 10% Glycerol) phosSTOP (Roche), EDTA free protease inhibitor cocktail (Roche) and tumbled at 4 °C for 20 minutes before centrifugation at 13,600 RPM at 4 °C for 30 minutes. Then, Pierce™ BCA Protein Assay (Thermo Scientific™ 23225) was performed as the manufacturer's instructions. After calibrating samples to each other, 50 µl from each sample were kept as whole cell lysate and boiled with 4x Laemmli buffer and 25 mM DTT at 95 °C for 5 minutes. The rest of the cell lysates were incubated with 15 µl of M2 anti-Flag magnetic beads (Sigma Aldrich) per conditions overnight after pre-washed the beads three times with the lysis buffer. The following day, beads were washed with lysis buffer 5 times with 1mL of lysis buffer and boiled with 2x Laemmli buffer involving 50 mM DTT at 95 °C for 5 minutes. Samples were analysed by previously described western blotting.

2.5 Production of Tandem Ubiquitin Binding Entity (TUBE) and Deubiquitinases

The coding sequence of AMSH was cloned into the pGEX6-P2 vector. pOPINK-Cezanne (OTU, aa 53-446) was a gift from David Komander (Addgene plasmid # 61581; <http://n2t.net/addgene:61581>; RRID: Addgene_61581). Glutathione S-transferase (GST)- tagged TUBE was previously³⁶⁶. Expression vectors were transformed into BL21 (DE3) bacteria. Protein expression was induced by 1 mM Isopropyl-β-D-thio-galactoside (IPTG) and incubated overnight at 30 °C. Following day, proteins were extracted using bacteria lysis buffer (50 mM Tris, pH 7.4, 0.5 % Triton X-100, 200 mM NaCl, 100 mM KCl, 10% glycerol, 40 mM imidazole, 200 µg/ml lysozyme, 70 µM AEBSF, 5 µM mM E-64, 1.2 µg/ml aprotinin, 1 µM pepstatin A, 5 U/ml benzonase, 2 mM β-mercaptoethanol), sonicated, cleared by centrifugation at 13,300 rpm, 30 min, 4°C. The respective proteins were purified using glutathione sepharose beads (Cytiva GE17-0756-01). After purification, the GST tag was removed from AMSH and Cezanne using human rhinovirus (HRV) 3C protease (Cytiva 27084301) according to the manufacturer's instructions. Protein concentration was measured with a Nanophotometer (Implen).

2.6 *In vitro* Ubiquitin Assay

moTAP ANKIB1 WT was purified by modified tandem affinity purification. After protein purification, the efficiency of the purification and the amount of ANKIB1 enriched were assessed by Coomassie brilliant blue G-250. Then, the different versions of ANKIB1 were incubated for 1 hour at 37 °C in a 30 µL reaction mixture containing 200 nM UBA1, 1 µM UBE2L3 or 1 µM UBE2D3 or 1 µM UBE2L6, 100 µg/mL ubiquitin, 2 mM DTT, 30 mM Tris-HCl, pH 7.5, 5 mM MgCl₂ and 1x Energy Regenerating Solution (Enzo Life Sciences). For negative controls, ubiquitin buffer was added instead of the E1 and E2. Afterwards, the samples were subjected to analysis by western blot. For subsequent deubiquitinase assay, ANKIB1 was removed with M2-FLAG beads and either USP2 or Cezanne were added at a concentration of 1 µM and 0,5 µM respectively and samples were incubated at 30 °C for 1h. The reaction was terminated by adding reducing sample buffer and boiling at 95°C for 5 min.

2.7 K11-Ub Specific Antibody Production

The amino acid sequence of the K11-ubiquitin linkage-specific 2A3/2E6 antibody was previously described²⁰, and the coding sequence was synthesised by Thermo Scientific and cloned into the pVITRO plasmid using AgeI, BsrGI, BspEI, and BamHI restriction enzymes (New England Biolabs). The antibody was transiently expressed in Expi293F cells and purified using a Protein G column (Cytiva).

2.8 Tandem Ubiquitin Binding Entity Pulldown (TUBE PD) and *In vitro* Deubiquitination Assay

6 million HeLa WT, ANKIB1 deficient, and stably expressing RING1 mutant ANKIB1 cells were seeded in 15 cm dishes in 5% FBS RPMI media. The following day, cells were treated with either 15 µg/ml poly(I:C) for 1 hour or 10 µg/ml 2'3'-cGAMP for 2 and 4 hours. The medium was removed, and the cells were washed with ice-cold PBS. Subsequently, cells were lysed in denaturing SDS containing TUBE PD-lysis buffer (30 mM Tris-HCl, pH 7.5, 120 mM NaCl, 2 mM EDTA, 2 mM KCl, 1 mM CaCl₂, 1 mM MgCl₂, 0.5% Triton-X 100 1%SDS, 10% Glycerol, phosSTOP (Roche), EDTA free protease inhibitor cocktail (Roche) and 45 µM PR619 DUB inhibitor (Selleckchem) and were sonicated for 30 s. Samples were tumbled at 4 °C for 30 minutes and cleared by centrifugation at 13,600 RPM for 30 minutes. Samples were then diluted with TUBE PD-lysis buffer without SDS to decrease SDS concentration to 0.1%. The samples were calibrated after performing Pierce™ BCA Protein Assay according to the manufacturer's instructions. 50 µl from each sample was kept as whole cell lysate and boiled with 4x Laemmli buffer and 25 mM DTT at 95 °C for 5 minutes. The rest of the samples were incubated with Glutathione sepharose-beads (6.5 µl per sample) freshly pre-coupled with GST-TUBE (20 µg per sample) overnight at 4°C. Following day, beads were washed three times with TUBE PD-lysis buffer without SDS, protease-, phosphatase-, DUB inhibitors and proteins were either eluted from beads by boiling them in 2x Laemmli buffer containing 50 mM DTT and analysed by immunoblotting or subjected to *in vitro* deubiquitination assay after washing beads twice with DUB reaction buffer (50 mM Tris-HCl pH 7.5, 100 mM NaCl). In short, the beads were incubated with 600 µg/mL K48-tetraubiquitin chains (Adipogen) in DUB Reaction buffer with 1 mM DTT at 37 °C for 30 minutes.

Meanwhile, AMSH, Cezanne, and USP2 (R&D Systems) DUBs were diluted to 2x the indicated concentrations in DUB dilution buffer (25 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM DTT) and incubated at room temperature for 10 minutes. Then, the respective DUBs were mixed with the beads and incubated at 37 °C for 1 hour. The reactions were terminated by boiling the samples in Laemmli sample buffer with 25 mM DTT at 95 °C for 5 minutes before analysis by immunoblotting.

2.9 K11-Ub IP

6 million HeLa WT and ANKIB1-deficient cells were seeded in 15 cm dishes in 5% FBS RPMI media. The following day, cells were treated with either 15 µg/ml poly(I:C) for 0, 30 minutes or 1h. The medium was removed, and the cells were washed with 5 mL ice-cold PBS. Subsequently, cells were lysed in denaturing SDS containing K11 IP-lysis buffer (30 mM Tris-HCl, pH 7.5, 120 mM NaCl, 2 mM EDTA, 2 mM KCl, 1% Triton-X 100 1%SDS, 10% Glycerol, phosSTOP, EDTA free protease inhibitor cocktail and 45 µM PR619 DUB inhibitor) and processed till the calibration step as described in TUBE PD. 50 µl from each calibrated sample was kept as whole cell lysate and boiled with 4x Laemmli buffer and 25 mM DTT at 95 °C for 5 minutes. The rest of the samples were incubated with protein G-beads (15 µl per sample) freshly pre-coupled with K11 antibody (20 µg per sample) overnight at 4°C. Following day, beads were washed three times with K11 IP-lysis buffer without SDS, and inhibitors. Then, proteins were eluted from beads by boiling them in 2x Laemmli buffer containing 50 mM DTT and analyzed by immunoblotting.

2.10 Mice

C57BL/6N *Ankib1*^{-/-} tm1a mice have been developed by EUCOMM (European Conditional Mouse Mutagenesis Program) using the Knockout-First-Reporter Tagged Insertion allele technology. Mice used in this study were maintained and bred in the animal facility of the CECAD Research Centre, University of Cologne. University of Cologne, in individually ventilated cages (Tecniplast, Greenline GM500) at 22 °C (±2 °C) and a relative humidity of 55% (±5%) under a 12-h light/12-h dark cycle on sterilized bedding with access to a sterilized commercial pelleted diet and acidified water ad libitum. The microbiological status of the mice was examined as recommended by the Federation of European Laboratory Animal Science Associations (FELASA), and the mice were free of all listed pathogens. All animal procedures were conducted in accordance with European, national and institutional guidelines and approved by local government authorities (LAVE NRW; permission Az. 81-02.04.2020.A022). Study protocols and animal experiments performed in Zaragoza were approved by the Animal Experimentation Ethics Committee of the University of Zaragoza (numbers: PI 18/2, PI 18/23, PI 62/22, PI 24/25) and in accordance with institutional, national and European ethical animal regulations (Protection of Animals Act).

2.11 Isolation of Bone Marrow Derived Macrophages (BMDMs) and splenocytes

Femur tibias from 6- to 12-weeks-old mice were isolated and opened on each side using scissors. Bone marrow was flushed out using a 25-gauge needle and syringe with PBS. Red blood cells were lysed using a red blood cell lysis buffer. Cells were washed with 50 mL of PBS, cells were counted and resuspended in BMDM medium (IMEM with 10% decompemented FBS, 1 % penicillin/streptomycin and 20 ng/mL of M-CSF). Cells were plated in non-coated 10cm dishes with a concentration of 2×10^6 cells/mL for seven days. Cells were then detached with 10 mM EDTA for 10 minutes and plated in a 12-well plate for experiment. Splenocytes were isolated from 8 to 12-week-old mice. Spleen were mashed on a 75 μ m filter and red blood cells were remove as for BMDMs. Cells were counted and plated 2.5×10^6 cells/mL in RPMI containing 1% L-glutamine, 1% penicillin/streptomycin with 10% decompemented FBS.

2.12 RNA Isolation and RT-qPCR

From the cDNA generated, quantitative real-time PCR was performed using Itaq Universal SYBR (Bio-RAD) following the manufacturer's recommendations. The master mix was prepared as detailed in Table. Each sample was loaded three times in a 96-wells plate and run on a Bio-Rad CFX Opus 96. The initial polymerase activation step lasted 30 sec at 95°C, followed by 40 amplification cycles of 5 seconds at 95°C and 30 seconds at 64°C. GAPDH was used as reference gene and the relative expression of the gene transcripts was analysed using $2^{-\Delta Ct}$. Primers used: GAPDH_fw: ACCCAGAAGACTGTGGATGG; GAPDH_rv: TTCTAGACGGCAGGTCAGGT; IFNB1_fw: ACATCCCTGAGGAGATTAAGCA; IFNB1_rv: GCCAGGAGGTTCTCAACAATAG; IFNL3_fw: CTGAAGGACTGCAAGTGCCG; IFNL3_rv: GGCTGGTCCAAGACATCCC

For RT-qPCR after *in vitro* infection with either MVA or SeV, samples were harvested with 250 μ l lysis buffer (4 M guanidine thiocyanate, 25 mM Tris-HCl pH7, 143 mM 2-mercaptoethanol) followed by an addition of 250 μ l 70% ethanol. Total RNA was extracted using a silica column (Epoch Life Science) and washed once with wash buffer 1 (1 M guanidine thiocyanate, 25 mM Tris-HCl pH 7, 10% ethanol) and twice with wash buffer 2 (25 mM Tris-HCl pH 7, 70% ethanol). Total RNA was eluted using nuclease-free water. 500ng of RNA was used to produce cDNA using SuperScript III reverse transcriptase (Thermo Scientific) following the manufacturer's protocol. Samples were diluted used as input in a 20 μ l reaction using the KAPA SYBR Fast System (Roche) following the manufacturer's protocol.

2.13 RNA sequencing

Total RNA from HeLa cells with/without 10 μ g/mL poly(I:C) treatment were extracted using the RNeasy Mini Kit (QIAGEN) according to manufacturer's instructions. Total RNA sequencing (RNA-seq) was performed by CeGaT GmbH (Tübingen, Germany). In brief, 10 ng RNA of each sample were used for library preparation with the SMART-Seq stranded total RNA kit (Takara). Libraries were sequenced on

a NovaSeq 6000 machine (Illumina) with 2×100 bp. The sequencing reads were demultiplexed with Illumina bcl2fastq (2.20) and adaptors were trimmed with Skewer (version 0.2.2). Quality trimming of the reads has not been performed. The raw counts derived from the mapping contain the number of reads that map to each gene ID. Based on these numbers the normalized counts were calculated. Normalized counts have been calculated with DESeq2 in R.

Total RNA from the spleen of 10mg/kg poly (I:C) injected mice (3 or 6 hours) were extracted using the RNeasy Mini Kit (QIAGEN) according to manufacturer's instructions. mRNA Sequencing for mouse spleen samples was performed by Cologne Center for Genomics (CCG). Briefly, 3' mRNA libraries were generated from 200ng (spleen samples) total RNA using the QuantSeq 3' mRNA-Seq FWD V2 Library Prep Kit (Lexogen) according to the manufacturer's protocol and using 17 cycles for library amplification. After validation (TapeStation, Agilent Technologies) and quantification (Qubit, Thermo Fischer Scientific) individual libraries were pooled. The library pools were quantified using the Colibri Library Quantification Kit (Thermo Fischer Scientific) and the QuantStudio 5 Real-Time PCR System (Thermo Fischer Scientific). Libraries were subsequently sequenced on an Illumina NovaSeq 6000 instrument using a 1x100 bp sequencing protocol and aiming for 10-12 million reads per sample.

2.14 ELISA

Supernatants were collected upon respective treatment. Before freezing at -80°C , samples were spin down for 10 minutes at 1.500 rpm and supernatant were transferred. IFN β ELISA were conducted following the manufacturer's protocol (R&D).

2.15 HSV-1 Infection and Disease Monitoring

Age-matched (12-16 weeks old) male WT littermate control (n=8) and *Ankib1*^{-/-} (n=5) mice were anaesthetised in a mouse anaesthesia induction chamber with 2-3% isoflurane. Mice were infected intranasally with 1×10^6 PFU of HSV-1 SC16 strain, using a total volume of 40 μL . Mice were weighed daily, and a clinical score was applied when mice showed signs of disease. The clinical score evaluated mouse appearance, level of consciousness, activity, response to stimuli, eye appearance, and frequency and quality of respiration, standardised to a five-point scale ranging from 0 to 4. The humanitarian endpoint was reached with a 25% weight loss, or a score equal to or higher than 15, or if any respiratory characteristics increased by more than 3^{367} . Mice were euthanised following human endpoint standards.

2.16 Secondary HLH and *E. coli* sepsis model

The model of secondary HLH was performed using age matched (8 weeks old) female and male WT littermate control (n=8) and *Ankib1*^{-/-} (n=9) mice as described³⁶⁸. For the sepsis model, a strain of *E. coli* isolated from the blood of a wild-type (WT) mouse with CLP-induced sepsis was used³⁶⁹. Sepsis was induced by inoculating 2×10^8 CFU in 200 μL of PBS to 8 weeks old female and male WT littermate control (n=9) and *Ankib1*^{-/-} (n=8) mice via intraperitoneal injection. The mice were weighed and observed daily, with sepsis scoring performed regularly, and survival monitored over 5 days. A humane

endpoint was applied when the murine sepsis score exceeded 14 or when body weight loss was greater than 25%.

2.17 IAV Infection

Age matched (12-16 weeks old) WT littermate control (n=7) and *Ankib1*^{-/-} (n=7) female and male mice were infected with a mouse-adapted pandemic influenza strain H1N1 A/PR/8/3424 virus. The mice were anesthetized in a chamber with 2-3% isoflurane and intranasally infected with 2×10³ PFU of IAV in 40 µL. The mice were weighed and observed daily, with sepsis scoring performed, and survival monitored as described³⁶⁷.

2.18 *In vitro* Infection Assays

Monolayers of HeLa or A549 cells in 6-well plates were washed once with PBS and infected with the indicated viruses at a MOI of 5 (MVA, HSV-1 and IAV) or 1 (SeV) in diluted serum-free media for 2 h at 37 °C. Inoculum was then removed and replaced with complete DMEM. Cell lysates were harvested on ice at indicated time points with RIPA buffer (50mM Tris-HCl pH8, 150mM NaCl, 1% NP40, 0.1%SDS, 0.5% Na Deoxycholate) supplemented with cOmplete Mini EDTA-free protease inhibitors (Roche) and PhosSTOP phosphatase inhibitor cocktail (Roche) for western blot analysis.

2.19 nCounter RNA Analysis

At day 3 post-infection with HSV-1, brainstems of mice were isolated and subjected to RNA extraction using the RNeasy Mini Kit (QIAGEN) according to manufacturer's instructions. Total RNA was quantified using a spectrophotometer. For each reaction, 300 ng of purified total RNA was hybridized with nCounter Reporter and Capture probe sets (nCounter XT PGX MmV1 Cancer Immune) according to the manufacturer's protocol. Hybridization was performed in a total volume of 15 µL at 65°C for 18 hours. Following hybridization, samples were loaded on the nCounter cartridge using the nCounter Prep Station, and data was collected with the nCounter Digital Analyzer. Raw counts were normalized using the housekeeping genes included in the nCounter XT Codeset and the nSolver software's Basic Analysis tool. Normalized counts were exported for downstream analysis. Heatmaps were generated using the pheatmap function from the pheatmap R package (version compatible with R 4.5.1).

Pathway analysis was performed with an overrepresentation test (Fisher's exact test) using PANTHER v19.0 and the GO Ontology database (DOI: 10.5281/zenodo.15066566, released on 2025-03-16). In brief, downregulated genes with a moderate to high effect (log2FC<-0.5) were used as a gene list, and the entire gene panel measured by the nCounter assay was used as the background. Gene symbols were used as identifiers.

2.20 Cytokine/Chemokine Quantification

Lung samples were obtained from a weighed portion of murine lung, homogenized in 500 µl DMEM with a GentleMACS Dissociator (Miltenyi), and clarified by centrifugation (1500 rpm × 5 min). Prior to

analysis, 0.5% Triton X100 was added to the homogenates for virus inactivation. Protease inhibitor (Complete, Roche) was added to prevent degradation.

The multiplex ELISA was performed via a custom Luminex Discovery Assay (R&D Biotechne) according to the manufacturer's instructions. Samples were centrifuged at $10000 \times g$ for 5 min and diluted at 1:2 ratio in Calibrator Diluent (R&D Biotechne) prior to analysis. Samples were measured with Luminex 200 xMAP system (Luminex) and xPONENT software was used for data collection and analysis.

2.21 Ubiquitin Linkage Type Identification

Upon *in vitro* ubiquitin assay, samples were prepared for mass spectrometry (MS) analysis after in gel digestion overnight with trypsin. All samples were analyzed by the CECAD Proteomics Facility on aQ Exactive Plus Orbitrap mass spectrometer that was coupled to an EASY nLC (both Thermo Scientific). Peptides were loaded with solvent A (0.1% formic acid in water) onto an in-house packed analytical column (50 cm, 75 μ m inner diameter, filled with 2.7 μ m Poroshell EC120 C18, Agilent). Peptides were chromatographically separated at a constant flow rate of 250 nL/min using the following gradient: 3-5% solvent B (0.1% formic acid in 80 % acetonitrile) within 1.0 min, 5-30% solvent B within 121.0 min, 30-40% solvent B within 19.0 min, 40-95% solvent B within 1.0 min, followed by washing and column equilibration. The mass spectrometer was operated in data-dependent acquisition mode. The MS1 survey scan was acquired from 300-1750 m/z at a resolution of 70,000. The top 10 most abundant peptides were isolated within a 1.8 Th window and subjected to HCD fragmentation at a normalized collision energy of 27%. The AGC target was set to 5e5 charges, allowing a maximum injection time of 110 ms. Product ions were detected in the Orbitrap at a resolution of 35,000. Precursors were dynamically excluded for 10.0 s.

All mass spectrometric raw data were processed with Maxquant (version 2.0.3.0)³⁷⁰ using default parameters against the Uniprot canonical Human database (UP5640, downloaded 26.08.2020) with the match-between-runs option enabled between replicates. Follow-up analysis was done in Perseus 1.6.15³⁷¹. Protein groups were filtered for potential contaminants and insecure identifications.

Log2 intensities values of the different linkage types found in the samples were used to identify their respective abundance.

2.22 Statistics, Reproducibility and Softwares

All data collection and analysis for *in vivo* experiments were performed blindly by three researchers. GraphPad Prism V11 software (Graphpad) was used for statistical analyses. The normality of all data was confirmed using Anderson-Darling or Shapiro-Wilk test. Error bars were determined by either SEM or SD. Statistical significance of data was assessed by either two-way ANOVA uncorrected Fisher's LSD multiple-comparisons test or unpaired two tailed Student's t-test or Kolmogorov-Smirnov or Fisher's exact test in 95% confidence interval. Survival curves were compared using log-rank Mantel-Cox test in 95% confidence interval. No statistical methods were used to pre-determine sample sizes for *in vivo*

experiments but our sample sizes are similar to those reported in previous publications. Mice of the indicated genotype were randomly assigned to groups. No data was excluded from any experimental group. EndNote 2025 was used for the organization of bibliography and in-text citations.

2.23 Data Availability

The MS proteomics data (Fig. 2e) have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD065049. Source data is provided with this paper. The RNA datasets generated and analysed during the current study are not publicly available due to ongoing scientific research but are available from the corresponding author upon reasonable request. No custom codes were developed in this study.

2.24 Declaration of Artificial Intelligence Usage

I hereby declare that artificial intelligence (AI) was partially utilized during the preparation of this dissertation. In particular, Google Gemini 3.5 Flash was employed to obtain recommendations for grammatical verification, syntax correction, and stylistic enhancement. In addition, Google Gemini 3.5 Flash was exclusively utilized to as a language-editing tool to refine wording and enhance the scientific writing; text segments derived from this model were partially integrated into the "Introduction" and "Materials and Methods" sections of this dissertation solely for the purpose of paraphrasing my own previously written literature review, and elaborated methods. They were not used for the generation of original scientific content, including novel scientific ideas, interpretations, conclusions or analysis.

Furthermore, Figures 1.2, 1.3, and 1.11 were adapted with the assistance of ChatGPT 5.5. I confirm that all AI-assisted contributions, including textual revisions and figure adaptations, were carefully reviewed and verified for their accuracy. I accept full responsibility for the content of this dissertation and for the appropriate use and integration of all AI-assisted materials.

3 Results

Lysine-11 ubiquitination drives type-I/III interferon induction by cGAS–STING and Toll-like receptors 3 and 4

<https://doi.org/10.1038/s41556-026-01886-z>

Declaration: This study underscores the differential regulation of several immune receptor complexes capable of inducing IFN production to mount robust antiviral and antibacterial immune responses. To date, signalling pathways downstream of these immune receptors have been extensively studied; however, the precise mechanism of TBK1 activation leading to IFN production via the phosphorylation of IRF3 remains controversial. This investigation initially focused on characterising the functional role of a previously uncharacterised E3 ubiquitin ligase, ANKIB1. The findings provide novel biochemical insights into the functionality of specific ANKIB1 domains and demonstrate its involvement to TBK1 activation downstream of various PRRs. Consequently, these data resolve existing discrepancies in the literature regarding the mechanisms governing TBK1 activation and its modulation across distinct immune receptor signalling networks. Beyond defining the functional contributions of ANKIB1, this study characterizes a previously unrecognised signalling axis downstream of cGAS-STING, TLR3, and TLR4. Furthermore, the study describes a novel signalling function of K11-Ub in immune response. Collectively, these critical biochemical insights expand our understanding of innate immunity and open new avenues for more selective therapeutic interventions in autoimmune diseases. This publication comprises all data generated within the scope of this dissertation. A subset of these data was previously included in the PhD thesis of Alexis Betrancourt, entitled “Characterisation of ANKIB1 as a new regulator of Toll-Like Receptor signalling” and submitted to the University of Cologne.

Author Contributions: Henning Walczak and Eva Rieser conceived the project. Alexis Betrancourt, **Muhammed Talha Cinko**, Henning Walczak, and Eva Rieser designed the study. Alexis Betrancourt generated ANKIB1 deficient HeLa, HT-29 cells and performed *in vitro* ubiquitination assays. **Muhammed Talha Cinko** generated mutant ANKIB1 constructs and performed ELISA experiments. Gene activation, immunoprecipitations and RT-PCR experiment were cooperatively and equally conducted by Alexis Betrancourt and **Muhammed Talha Cinko**. TUBE pulldown assays and subsequent DUB assays were performed by **Muhammed Talha Cinko** and Eva Rieser. Julian Pardo, Iratxe Uranga-Murillo, Maykel Arias, and Natacha Peña contributes to the design and execution of *in vivo* IAV, HSV-1 infection, *E.coli*-induced sepsis and sHLH experiments and disease monitoring. Rocio Martin and Antonio Alcamí contributed to the execution of HSV-1 infection experiment *in vivo*. RNA samples from *in vivo* experiments were prepared by Ana Beatriz Varanda and **Muhammed Talha Cinko**. Alexis Betrancourt, **Muhammed Talha Cinko**, Ana Beatriz Varanda, Lucia-Maria Kaps, and Bianca Buratti supported the study through the characterization of ANKIB1 catalytic domain. Ana Beatriz Varanda and Lucia-Maria Kaps performed RNA and cytokine analyses using the samples from

HSV-1 infected mice. Johannes Brägelmann, Kerstin Becker, and Ramona Casper performed the bioinformatic analysis of RNA sequencing data derived from HeLa cells and murine spleen. Long Fung Chau and Brian J. Ferguson designed and performed *in vitro* infection experiments with IAV, SeV, MVA and HSV-1. Diego de Miguel was cloned WT ANKIB1 gene to the different vectors, generated A549 ANKIB1 deficient cell line and contributed to the conceptualisation of the project. Data visualization and figure preparation were primarily conducted by Alexis Betrancourt and **Muhammed Talha Cinko**. Lucia-Maria Kaps and Ana Beatriz Varanda contributed to visualisation of RNA data analysis from the *in vivo* HSV-1 experiment. Johannes Brägelmann generated heat maps using RNA-seq data in HeLa cells. Alexis Betrancourt, **Muhammed Talha Cinko**, Eva Rieser, and Henning Walczak wrote the manuscript.

Author	Contribution to the Study
Alexis Betrancourt	42%
Muhammed Talha Cinko	42%
Ana Beatriz Varanda	5%
Maykel Arias, Iratxe Uranga- Murillo, Natacha Peña, Julian Pardo,	5%
Lucia-Maria Kaps & Bianca Buratti	4%
Long Fung Chau & Brian J.	1%
Johannes Brägelmann, Diego de Miguel, Kerstin Becker,	1%
Eva Rieser & Henning Walczak	Corresponding Authors

Lysine-11 ubiquitination drives type-I/III interferon induction by cGAS–STING and Toll-like receptors 3 and 4

Received: 21 October 2024

Accepted: 20 January 2026

Published online: 6 March 2026

 Check for updates

Alexis Betrancourt^{1,2,3,13}, M. Talha Cinko^{1,2,13}, Ana Beatriz Varanda^{1,2}, Maykel Arias^{4,5,6}, Iratxe Uranga-Murillo^{4,5,6}, Natacha Peña^{4,5,6}, Lucia-Maria Kaps^{1,2}, Long Fung Chau⁷, Bianca Buratti^{1,2}, Johannes Brägelmann^{8,9}, Diego de Miguel^{1,2,3,5}, Kerstin Becker¹⁰, Ramona Casper¹⁰, Rocio Martin¹¹, Antonio Alcami¹¹, Brian J. Ferguson¹², Julian Pardo^{4,5,6}, Eva Rieser^{1,2,3,12,14} ✉ & Henning Walczak^{1,2,3,14} ✉

Pattern recognition receptor (PRR)-induced interferon (IFN) is critical for effective immunity. The PRRs Toll-like receptor (TLR) 3, TLR4 and cyclic GMP–AMP synthase (cGAS), together with the stimulator of IFN genes (STING), signal through TANK-binding kinase 1 (TBK1), which activates the type-I/III IFN-inducing transcription factor interferon-response factor 3 (IRF3). The mechanism by which these PRRs activate TBK1 remains unresolved. Here we show that lysine-11 (K11)-linked ubiquitination drives TBK1 activation by these PRRs. The E3 ligase ANKIB1 attaches K11-linked ubiquitin chains to components of the TLR3- and cGAS–STING-induced signalosomes. This facilitates Optineurin recruitment to these complexes, in turn enabling recruitment and activation of TBK1 and IRF3, defining an uncharacterized signalling axis. In mice, ANKIB1 deficiency dampens IFN induction via TLR3 and cGAS–STING, reducing interferonopathy and compromising protection against HSV-1, respectively. Together, our results demonstrate an unanticipated and critical role for ANKIB1-generated K11-linked ubiquitination in the immune response activated by cGAS–STING, TLR3 and TLR4.

Interferon (IFN) production is a key defence mechanism of innate immunity. Different pattern recognition receptors (PRRs) detect distinct pathogen- and damage-associated molecular patterns during infection and during tissue damage, rapidly mobilizing innate defences^{1–3}. Toll-like receptors (TLRs) are archetypal and well-characterized PRRs⁴. The triggering of two of them, TLR3 and TLR4, results in the activation of TANK-binding kinase 1 (TBK1) in a biochemical context capable of directly activating IRF3, the transcription factor responsible for the induction of type-I and type-III IFNs⁵. This unique biochemical feature of the double-stranded (ds)RNA-sensing TLR3 and the lipopolysaccharide (LPS)-sensing TLR4 is shared with a small subset of other PRRs, most

notably the cytosolic DNA sensor cyclic GMP–AMP synthase (cGAS) and the two dsRNA-sensing RNA helicases retinoic acid-inducible gene 1 (RIG-I) and melanoma differentiation-associated protein 5 (MDA-5)^{6–9}. However, despite its critical role in innate immunity, the biochemical mechanism by which activation of these PRRs confers this capacity on TBK1 remains unknown.

TBK1 is also involved in other cellular processes, including inhibition of tumour necrosis factor (TNF)-induced cell death via RIPK1 phosphorylation¹⁰. We previously showed that, by enabling the recruitment of various kinases, linear ubiquitin (linUb) chains generated by HOIP, a component of the linUb chain assembly complex (LUBAC),

A full list of affiliations appears at the end of the paper. ✉e-mail: erieser@uni-koeln.de; h.walczak@uni-koeln.de

are responsible for full gene activation and cell-death resistance in TNFR1 and TLR3 signalling^{11–13}. While TBK1 is one such kinase in TNF signalling¹⁰, in TLR3 signalling LUBAC-generated linUb is dispensable for TBK1 activation¹³.

This unexpected observation, together with the fact that all proposed TBK1-recruiting adaptors in TLR3 signalling bind to polyubiquitin, including linUb^{10,14}, led us to hypothesize that another, possibly linUb-generating and therefore probably HOIP-related E3 ligase may be required for TLR3-induced TBK1 activation. On the basis of this, we next screened the HOIP-comprising RING-between-RING (RBR)-domain-containing E3 subfamily for the elusive E3 ligase.

This resulted in the discovery of ANKIB1 as the E3 ligase responsible for TBK1 activation downstream of TLR3. Yet ANKIB1 does not generate linUb chains but instead attaches K11-linked ubiquitin (K11-Ub) chains to various components of the TLR3 signalosome, thereby enabling Optineurin (OPTN) recruitment and initiating an ANKIB1–K11-Ub–OPTN–TBK1–IRF3 signalling axis that bridges TLR3 stimulation to IRF3 activation and IFN induction. Remarkably, this signalling axis also drives activation of IRF3 following stimulation of TLR4 and cGAS, together with the stimulator of IFN genes (STING). In vivo, ANKIB1 deficiency limits TLR3-induced IFN induction and, consequently, reduces lethality in a TLR3-driven interferonopathy model, whereas it increases vulnerability of mice to herpes simplex virus-1 (HSV-1) infection, known to depend on cGAS–STING-mediated IFN induction for survival, providing compelling evidence that ANKIB1-mediated K11 ubiquitination is crucial for innate immune signalling in vivo.

Results

TLR3-mediated TBK1 and IRF3 activation requires ANKIB1, an unrecognized component of the TLR3-SC, to promote type-I and type-III IFN induction

After confirming that HOIP and its linUb-generating activity were dispensable for TBK1 activation downstream of TLR3, but not TNFR1 (Fig. 1a), we screened the RBR-E3 subfamily for the E3 ligase responsible for TLR3-induced TBK1 activation. Candidate RBR-E3s we could exclude a priori were HOIP, HOIL-1¹⁵ and PARKIN because it is not expressed by HeLa cells¹⁶. Individual RNA-interference (RNAi)-mediated silencing of the remaining 11 RBR-E3 members revealed that only suppression of ANKIB1 substantially reduced TLR3-induced TBK1 activation, but not p65 phosphorylation (Extended Data Fig. 1a–c), implying a specific role for ANKIB1 in activation of TBK1 and not NF- κ B.

To test whether ANKIB1 could indeed be the hitherto elusive E3 ligase required for TLR3-induced TBK1 activation, we next generated ANKIB1-knockout (KO) cell lines and analysed their response to TNF and polyinosinic:polycytidylic acid (poly(I:C)) stimulation in comparison to HOIP-KO and wild-type (WT) cells. This demonstrated that TLR3-induced TBK1 activation was virtually abolished in ANKIB1-KO cells, whereas TNF-induced TBK1 activation remained intact (Fig. 1b). Conversely, HOIP-KO impaired TNF- but not poly(I:C)-induced TBK1 activation (Fig. 1b). Extended kinetic analyses across different KO and WT cell lines confirmed that ANKIB1-KO did not merely delay but profoundly impaired TLR3- but not TNF-induced TBK1 phosphorylation (Extended Data Fig. 2a–c). Thus, TBK1 phosphorylation is enabled by two distinct RBR-E3 ligases in different signalling pathways; whereas HOIP facilitates TNF-induced TBK1 activation, ANKIB1 is required for TLR3-induced TBK1 phosphorylation.

Assessing the role of ANKIB1 in TLR3-mediated IRF3 activation and IFN induction^{17,18} revealed that TLR3-induced IRF3 phosphorylation and the induction of both β (type-I) and λ (type-III) IFN gene expression almost completely depended on ANKIB1 (Fig. 1c–e). Stably re-expressing modified tandem affinity purification-tagged (moTAP)-ANKIB1 at near endogenous levels in ANKIB1-KO cells fully restored TLR3-induced TBK1 and IRF3 phosphorylation (Fig. 1f and Extended Data Fig. 2d) and type-I/III IFN production (Fig. 1g), underscoring the crucial role of ANKIB1 in this pathway. RNA-sequencing analysis

demonstrated that ANKIB1 is required for TLR3-mediated induction of type-I/III IFN genes and downstream IFN-stimulated genes. (Fig. 1h).

To epistatically place ANKIB1 in TLR3 signalling, we performed immunoprecipitation (IP) of moTAP-ANKIB1, which corroborated the TLR3-induced interaction of ANKIB1 with phosphorylated TBK1 (p-TBK1; Fig. 1i). To determine whether this interaction occurs at the TLR3 signalling complex (TLR3-SC) level, we generated TLR3-deficient HeLa cells expressing ectopic moTAP-TLR3. Apart from confirming recruitment of the known TLR3-SC components RIPK1 and HOIP^{13,19}, immunoprecipitation of moTAP-TLR3 also revealed ANKIB1 as forming part of the TLR3-SC but not the TNFR1-SC (Fig. 1j and Extended Data Fig. 2e). Thus, ANKIB1 constitutes a previously unrecognized component of the TLR3-SC that interacts with TBK1 upon receptor activation and is required for TLR3-induced activation of TBK1 and IRF3 and induction of type-I/III IFNs.

The RBR and UIM domains of ANKIB1 are crucial for TBK1 phosphorylation

Although ANKIB1 is a member of the RBR-E3 subfamily²⁰, its catalytic activity had not previously been demonstrated. In an in vitro ubiquitination assay, full-length recombinant ANKIB1 was capable of generating ubiquitin chains in the presence of the E2s UBE2L3 and UBE2D3, with higher activity observed with UBE2D3 (Fig. 2a), yet not with UBE2L6 (Extended Data Fig. 3a). The multimeric proteins formed by ANKIB1/UBE2D3 were degraded by the general deubiquitinase (DUB) USP2, confirming they were composed of ubiquitin polymers (Extended Data Fig. 3b).

To assess whether the E3 ligase activity of ANKIB1 is required for TBK1 activation, we employed a similar approach to the previously studied RBR-E3 ligases, all known to exert their catalytic activity via their respective RING2²¹. We therefore next generated ANKIB1 with mutations in the conserved cysteine residues (C519S/C522S/C532S/C537S/C540S/C545S/C548S) of its RING2 (ANKIB1-RING2^{mut}) (Extended Data Fig. 3c). Unexpectedly, ANKIB1-RING2^{mut} expression in ANKIB1-deficient cells restored TLR3-induced TBK1 and IRF3 phosphorylation (Extended Data Fig. 3d). As we suspected that the point mutations we introduced in the RING2 of ANKIB1 might not have aborted its activity to the same extent as was seen in previous studies for other RBR-E3s^{22–24}, we next expressed an ANKIB1 mutant lacking the entire RING2 domain (ANKIB1 Δ RING2) (Extended Data Fig. 3c), yet TBK1 and IRF3 activation were again restored to levels comparable to those observed in wt cells upon TLR3 stimulation (Extended Data Fig. 3e). To test whether ANKIB1 Δ RING2 bears residual catalytic activity, we performed in vitro ubiquitination assays. Despite lacking a RING2, this mutant RBR-E3 retained ubiquitin chain-forming activity with the more general E2 UBE2D3 but not with UBE2L3 (Extended Data Fig. 3f).

To fully abrogate any possible RBR-residing catalytic activity of ANKIB1, we next expressed mutant ANKIB1 lacking the entire RBR (ANKIB1 Δ RBR) in ANKIB1-KO cells (Extended Data Fig. 3c). This mutant failed to rescue TBK1 and IRF3 phosphorylation upon TLR3 activation, indicating that the catalytic activity of ANKIB1 indeed resides in its RBR and that the polyubiquitin chains it generates are essential for TBK1 activation (Fig. 2b). We next investigated whether the RBR domain is required for the recruitment of ANKIB1 to the TLR3-SC and/or its interaction with TBK1. Pull down (PD) revealed that the interaction of ANKIB1 with p-TBK1 was drastically reduced in absence of its RBR (Fig. 2c). By contrast, full-length ANKIB1 and ANKIB1 Δ RBR exhibited comparable interaction with TRAF3, a known component of the TLR3-SC^{25–27}. Thus, the RBR of ANKIB1 is required for its TLR3-induced interaction with TBK1 and TBK1 activation but not for TLR3-SC recruitment.

Since the ANKIB1-RBR but not its RING2 was required, we next generated ANKIB1-deficient cells expressing a RING1-mutant ANKIB1 (ANKIB1-RING1^{mut}) with mutations in several conserved residues (C333A/I335A/C336A/C351A/H353A) and, indeed, TLR3 stimulation failed to activate TBK1 in these cells (Fig. 2d). Hence, the RING1 of




Figure 1: TLR3-mediated TBK1 and IRF3 activation requires ANKIB1, a member of the TLR3-SC, to promote type-I and type-III IFN induction. **a**, HeLa WT, HOIP-deficient (HOIP^{-/-}), and HOIP^{-/-} cells reconstituted enzymatically inactive HOIP^{C885S} or in **b**, ANKIB1-deficient (ANK^{-/-}) cells were stimulated with either 10 μ g/mL poly(I:C) or 100 ng/mL TNF for the indicated times and the lysates were analysed by western blotting. **c**, HT-29 ANK^{-/-} and WT cells were stimulated with 10 μ g/mL poly(I:C) for the indicated times and the lysates were analysed by immunoblotting. **d**, **e** IFN β and IFN λ mRNAs levels were respectively assessed by RT-qPCR 6h after stimulation of HT-29 with 10 μ g/mL poly(I:C). $P=0.0199$ and $P<0.0001$, respectively. **f**, HeLa ANK^{-/-} cells that were reconstituted with either moTAP-ANKIB1 WT (ANK WT) or empty vector (empty vec.) and treated with 10 μ g/mL poly(I:C) for the indicated times. Lysates were analysed by western blotting or **g**, Total RNA were isolated for IFN β transcripts analysis by RT-qPCR after the stimulation of cells for respective time

points. $P = 0.4470$, $P = 0.3506$, $P < 0.0001$, $P = 0.0018$ and $P = 0.0099$, respectively. **h**, RNA sequencing analysis of HeLa cells reconstituted with either ANK WT or empty vector was performed after 10 $\mu\text{g/mL}$ poly(I:C) treatment for two hours ($n=2$). **i**, HeLa cells stably expressing ANK WT were stimulated with 15 $\mu\text{g/mL}$ poly(I:C) and ANKIB1 was pulled-down via its FLAG-tag. **j**, HeLa TLR3^{-/-} cells reconstituted moTAP-TLR3 were treated with 15 $\mu\text{g/mL}$ poly(I:C) as indicated. moTAP-TLR3 was pulled-down through its FLAG-tag. All graphs represent mean $\pm$ SEM of three independent experiments. P values were calculated by two-way ANOVA with uncorrected Fisher's LSD multiple-comparisons test in 95% confidence interval. * $P \leq 0.05$; ** $P \leq 0.01$; *** $P \leq 0.001$. For western blots, one representative of at least three independent experiments is displayed. Non-specific bands are marked with an asterisk.




Figure 2: The RBR and UIM domains of ANKIB1 are crucial for TBK1 phosphorylation. **a**, moTAP-ANKIB1 purified from HeLa cells was incubated with ubiquitin, E1, E2 UBE2D3 or UBE2L3 in ubiquitin buffer for 1h at 37°C and samples were analysed by western blotting. **b**, HeLa ANK^{-/-} cells reconstituted with either moTAP-ANKIB1 WT (ANK WT) or ΔRBR (ANK ΔRBR) mutant were stimulated with 10 μg/mL poly(I:C) as indicated. **c**, HeLa cells stably expressing either ANK WT or ANK ΔRBR were stimulated with 15 μg/ml poly(I:C) as indicated and ANKIB1 was pulled-down via its FLAG-tag. **d**, HeLa ANK^{-/-} cells reconstituted with either ANK WT or RING1 mutant C333A/ I335A/ C336A/ C351A/ H353A (ANK RING1^{mut}) were stimulated with 10 μg/mL poly(I:C) as indicated. The downstream pathways were analysed by immunoblotting. **e**, After performing an in-vitro ubiquitination assay of ANKIB1 in combination with either UBE2D3 or UBE2L3, the samples were digested with trypsin overnight and subjected to LC MS/MS analysis. Left panel represents intensity induced upon in vitro ubiquitin assay. Representative figure from two independent experiment. Right panel is a pie chart representing the intensity average of two independent experiments of the different ubiquitin linkages generated by ANKIB1 in combination with either UBE2D3 or UBE2L3. **f**, moTAP-ANKIB1 purified from HeLa cells was incubated with ubiquitin, E1, E2 UBE2D3 in ATP regeneration solution for 1h at 37°C followed by digestion of the sample with deubiquitinase Cezanne for 1h at 30°C. **g**, HeLa cells stably expressing either ANK WT or moTAP-ANKIB1 ΔUIM (ANK ΔUIM) were stimulated with 15 μg/ml poly(I:C) and ANKIB1 was pulled-down via its FLAG-tag. **h**, HT-29 cells reconstituted with either moTAP-ANKIB1 WT or empty vector were stimulated with 15 μg/ml poly(I:C) and ANKIB1 was pulled-down via its FLAG-tag. The samples were subjected to analysis by western blotting. For all western blots, one representative of at least three independent experiments is displayed.

ANKIB1 is required and sufficient for its catalytic function and essential for promoting TBK1 activation.

Using mass spectrometry, we next determined the ubiquitin linkage type(s) ANKIB1 generates in the presence of UBE2D3 or UBE2L3. Surprisingly, K11-Ub was the most abundant linkage type formed by ANKIB1 in these *in vitro* assays with K63-Ub and K6-Ub linkages also detectable, albeit at substantially lower levels (Fig. 2e). No other linkage types, including linUb (M1-Ub) and K48-Ub, were detected. Performing a DUB assay using Cezanne (OTUD7B)²⁸, a K11-Ub-specific DUB, resulted in the disappearance of the vast majority of ANKIB1-generated polyubiquitin chains (Fig. 2f). Thus, ANKIB1 preferentially generates K11-Ub chains and its catalytic activity facilitates TLR3-induced TBK1 activation, suggesting that ANKIB1-generated K11-Ub may be crucial for TBK1 recruitment and activation upon TLR3 stimulation.

Binding to ubiquitin or polyubiquitin chains is a well-established mechanism for recruiting proteins with the required specificity to signalling complexes^{29,30}. As the ANKIB1-RBR was not required for TLR3-SC recruitment, we next examined the role of ANKIB1's ubiquitin-interacting motif (UIM), a domain type previously reported to mediate polyubiquitin-chain binding (Extended Data Fig. 3c)³¹. Following poly(I:C) treatment, while wt-ANKIB1 interacted with known TLR3-SC components, including TRAF3 and HOIP, UIM-deficient ANKIB1 (ANKIB1ΔUIM) failed to associate with these components, implying this domain is essential for TLR3-SC recruitment of ANKIB1 (Fig. 2g).

As TBK1 is recruited to different immune receptor signalling complexes via distinct ubiquitin-binding adaptor proteins, we next sought to identify which ANKIB1-interacting protein(s) might function as TBK1 recruiter(s) in the TLR3 pathway. OPTN was previously reported as adaptor for TBK1 in TLR3 and TLR4, but not in TNFR1 signalling^{10,32}, whereas NAPI was previously proposed to serve as adaptor for TBK1 in TLR3 and TNFR1 signalling^{10,33}. To determine possible adaptor interactions, we performed ANKIB1 PD upon TLR3 stimulation followed by western blotting for these the different possible adaptors. This identified a selective interaction between ANKIB1 and OPTN but not NAPI (Fig. 2g,h). Hence, ANKIB1 is recruited to the TLR3-SC via its UIM domain and, once recruited, utilizes its RBR domain to mediate TBK1 activation, probably via OPTN as adaptor.

Optineurin requires ANKIB1-generated K11-Ub for recruitment to the TLR3-SC and serves as essential adaptor for TBK1

Recruitment of OPTN, along with recruitment and activation of TBK1, correlates with the presence of ANKIB1 at the TLR3-SC (Fig. 2g,h). However, other proteins, including TANK, NAPI and SINTBAD, have also been proposed as adaptors for TBK1 in TLR3 signalling^{34–36}. To assess the contribution of these adaptors to TBK1 activation by TLR3, we next investigated poly(I:C)-induced TBK1 activation in triple knockout (TKO) cells lacking these three adaptors. Remarkably, TLR3-induced activation of TBK1 and IRF3 was unaffected in these cells whereas, consistent with our prior observations¹⁰, TNF-induced TBK1 activation was completely lost in the absence of these three proteins (Fig. 3a). Owing to the association between OPTN and ANKIB1 at the TLR3-SC and prior evidence implicating OPTN as TBK1 adaptor in TLR3 signalling^{32,37,38}, we next generated quadruple knockout (QKO) cells lacking TANK, NAPI, SINTBAD and OPTN. In these QKO cells, TBK1 phosphorylation was completely abolished (Fig. 3b) upon poly(I:C) stimulation, indicating a critical role for OPTN as an adaptor in TBK1 recruitment. To test whether OPTN alone is sufficient and essential for TBK1 activation, we next generated OPTN single-KO cells. Strikingly, loss of OPTN alone recapitulated the phenotype of ANKIB1-deficient or QKO cells, with complete impairment of TBK1 and IRF3 activation in response to stimulation of TLR3 but not TNFR1 (Fig. 3c). Together, these results establish OPTN as the essential adaptor for TBK1 activation in TLR3 signalling.

Since the catalytic activity of ANKIB1 is required to promote TLR3-induced TBK1 activation (Fig. 2d) and because previous

studies have implicated the UBAN domain of OPTN in TBK1 recruitment during TLR3 signalling^{32,39}, we next tested whether ANKIB1 and its K11-Ub-generating activity are necessary for OPTN and TBK1 recruitment. A comparison of TLR3-SC formation in WT versus ANKIB1-KO cells revealed markedly reduced recruitment of p-TBK1 and OPTN in ANKIB1 deficiency (Fig. 3d).

To investigate whether its K11-Ub-generating capacity is also required, we purified the TLR3-SC, treated it with the K11-specific DUB Cezanne and analysed the resulting supernatant for proteins released from the complex. Strikingly, Cezanne-mediated hydrolysis of K11-Ub chains caused specific release of OPTN, but not NEMO, from the TLR3-SC (Fig. 3e). Hence, ANKIB1 and its K11-Ub-generating activity are essential for the recruitment of OPTN, which is, in turn, required for TBK1 activation upon TLR3 stimulation.

In summary, we define a signalling axis in which ANKIB1 is recruited to the TLR3-SC, where it catalyses the formation of K11-linked polyubiquitin chains, facilitating the recruitment of OPTN which, in turn, mediates the recruitment and activation of TBK1. Importantly, this previously unrecognized ANKIB1–K11-Ub–OPTN–TBK1 signalling axis is essential for TLR3-induced IRF3 activation and IFN production.

IFN induction by TLR4 and cGAS–STING is also driven by ANKIB1

We next investigated whether ANKIB1 plays a role in other PRRs known to induce type-I IFNs through TBK1 and IRF3. We first focused on the LPS-sensing TLR4, the only TLR capable of signalling through two pathways via distinct adaptors, a TRIF-dependent one that is similar to TLR3 signalling and an MyD88-dependent one. Importantly, only TRIF—but not MyD88—contains an IRF3-binding motif, which is essential for its recruitment, activation and subsequent induction of IFN genes^{9,25,40}. In ANKIB1-KO cells, LPS-induced IRF3 phosphorylation and type-I/III IFN induction were substantially reduced in comparison with WT cells. TBK1 phosphorylation, however, was only partially decreased (Fig. 4a–c). Thus, similar to TLR3 signalling, the TRIF-dependent arm of TLR4 signalling requires ANKIB1 for effective TBK1 activation and downstream IRF3-dependent IFN induction. By contrast, MyD88-dependent signalling can also activate TBK1 but does not require ANKIB1⁴⁰.

We next investigated the role of ANKIB1 in cGAS–STING signalling, which also relies on TBK1 and IRF3 for IFN induction. In ANKIB1-KO cells, stimulation with the STING activator 2'3'cyclic GMP–AMP (2'3'cGAMP) or the STING agonist ADU-S100 failed to induce robust phosphorylation of TBK1, IRF3 and STING (Fig. 4d and Extended Data Fig. 4a,b). Following STING activation, ANKIB1 PD revealed an interaction with activated STING, together with p-TBK1, suggesting that ANKIB1 is recruited to the STING-associated signalling complex (STING-SC) (Extended Data Fig. 4c). ANKIB1-deficient cells exhibited significantly reduced type-I/III IFN induction, not only following STING agonist treatment but also after infection with the cGAS-sensed poxvirus modified vaccinia virus Ankara (MVA) (Fig. 4e–g). Hence, ANKIB1 is also crucial for effective type-I/III IFN induction in TLR4 and cGAS–STING signalling.

Using cells expressing ANKIB1-RING1^{mut} and ANKIB1ΔUIM, we next tested the role of ANKIB1 catalytic activity and ubiquitin-binding capacity in cGAS–STING signalling. Both mutants failed to rescue TBK1 and IRF3 phosphorylation following STING stimulation, indicating that the E3 ligase activity and UIM of ANKIB1 are also essential for its function in cGAS–STING signalling (Fig. 4h and Extended Data Fig. 4d). Furthermore, ANKIB1 required its UIM for recruitment to the STING-SC, where it interacted with phosphorylated STING, TBK1 and OPTN (Fig. 4i).

By treating cells with the RIG-I ligand 3p-hpRNA, we next assessed whether the RIG-I helicase, which recognizes cytosolic dsRNA and activates IFN transcription through mitochondrial antiviral signalling protein (MAVS)-driven activation of TBK1 and IRF3⁴¹, may also require ANKIB1 for TBK1 activation. However, ANKIB1-KO cells exhibited TBK1 and IRF3 activation and type-I/III IFN induction similar to




Figure 3: Optineurin is the crucial adaptor protein for TBK1 activation and requires K11-Ub generated by ANKIB1 for TLR3-SC recruitment. **a**, HeLa WT cells and deficient for TANK/NAP1/SINTBAD (TKO) cells were stimulated with either 100 ng/mL TNF or 10 µg/mL poly(I:C) for the indicated times and the lysates were subjected to western blot analysis. **b**, HeLa WT cells and deficient for TANK/NAP1/SINTBAD/OPTN (QKO) cells were stimulated with 10 µg/mL poly(I:C) for the indicated times and the lysates were subjected to western blot analysis **c**, HeLa WT, Optineurin-deficient (OPTN^{-/-}), and ANK^{-/-} cells were stimulated with either 100 ng/mL TNF or 10 µg/mL poly(I:C) for the indicated times. The lysates were analysed by immunoblotting. **d**, HeLa ANKIB1 proficient and deficient moTAP-TLR3 cells were stimulated with 15 µg/ml poly(I:C). moTAP-TLR3 was pulled-down via its FLAG-tag and the analysis of co-immunoprecipitated proteins was determined by immunoblotting. **e**, HeLa moTAP-TLR3 cells were stimulated with 15 µg/ml poly(I:C) for the indicated time points. moTAP-TLR3 was pulled-down via its FLAG-tag. After washing, pulled-down

samples were incubated with or without Cezanne in DUB buffer for 1h at 30°C. Co-immunoprecipitated proteins and the resultant supernatant were subjected to western blotting analysis. For all panels, one representative of at least three independent experiments is displayed. Non-specific bands are marked with an asterisk.

Article

<https://doi.org/10.1038/s41556-026-01886-z>

WT controls (Fig. 4j–l), regardless of the 3p-hpRNA concentration used (Extended Data Fig. 4e,f). As further confirmation, we infected cells with Sendai virus (SeV) or influenza A virus (IAV), both of which are primarily sensed by RIG-I⁴². Upon infection, WT and ANKIB1-KO cells showed similar levels of TBK1 and IRF3 phosphorylation and MAVS protein levels remained unchanged (Extended Data Fig. 4g). Moreover, IFN β induction was similar in WT and ANKIB1-KO cells (Fig. 4m). These findings suggest that ANKIB1 may not have a prominent role for RIG-I-mediated activation of TBK1 and IRF3 and subsequent IFN production.

To explain the divergence in ANKIB1 requirement across different PRRs, we hypothesized that distinct PRRs may engage different adaptor proteins for TBK1 recruitment and activation. Supporting this, we found that, as in TLR3 signalling, the absence of OPTN strongly impaired STING-induced activation of TBK1 and IRF3, whereas co-deletion of TANK, NAP1 and SINTBAD did not (Fig. 4n and Extended Data Fig. 4h). Conversely, TBK1 and IRF3 phosphorylation were strongly impaired in TANK/NAP1/SINTBAD TKO but remained unchanged in OPTN-KO cells upon RIG-I activation (Fig. 4o and Extended Data Fig. 4i). Thus, ANKIB1 promotes IFN production downstream of PRRs that depend on OPTN for TBK1 and IRF3 activation, namely TLR3, TRIF-mediated TLR4, and cGAS–STING. Instead, activation of TBK1, IRF3 and IFN production induced by stimulation of RIG-I is primarily mediated via TANK, NAP1 and/or SINTBAD.

ANKIB1 promotes ubiquitination of TRIF, STING, NEMO, OPTN and itself

Having established that the catalytic activity of ANKIB1 is essential for TBK1 activation downstream of TLR3 and cGAS–STING, we aimed to identify its potential substrates within the TLR3- and STING-SCs. To this end, we performed total ubiquitin PDs using tandem ubiquitin-binding entities (TUBE) following poly(I:C) or 2'3'cGAMP treatment. In WT cells, the adaptor proteins TRIF and STING were strongly ubiquitinated upon stimulation, whereas their ubiquitination was considerably reduced in ANKIB1-KO and ANKIB1-RING1^{mut}-expressing cells (Fig. 5a,b). In addition, ubiquitination of NEMO and OPTN was also impaired in the absence of ANKIB1 or its catalytic activity (Fig. 5a,b), showing that the activity of ANKIB1 facilitates their ubiquitination. Intriguingly, ANKIB1 itself appeared to be constitutively ubiquitinated and underwent additional ubiquitination upon poly(I:C) or STING agonist treatment, while these ubiquitination events were absent in ANKIB1-RING1^{mut}-expressing cells (Fig. 5a,b), implying constitutive and PRR stimulation-dependent ANKIB1 auto-ubiquitination.

To identify the nature of the ubiquitin linkages involved, we performed TUBE PDs from poly(I:C)-treated cells followed by DUB assay using K63-specific AMSH, K11-specific Cezanne and non-linkage-specific USP2^{28,43,44}. TRIF ubiquitination was sensitive to both AMSH and Cezanne, indicating the presence of both K63- and

K11-Ub-linked chains (Fig. 5c). OPTN ubiquitination was predominantly reduced by AMSH and USP2, with a modest Cezanne effect, suggesting predominant K63-Ub of OPTN yet also the presence of K11-Ub. For NEMO, only the high-molecular-weight ubiquitin chains were cleaved by either DUB (Fig. 5c), suggesting the presence of complex, probably K63–K11-branched or mixed-linkage ubiquitin chains that resist complete processing by individual DUBs. By performing K11-Ub-specific PDs following TLR3 activation, TRIF was found to be K11-ubiquitinated in WT but not in ANKIB1-KO cells, providing further proof of TRIF as substrate of ANKIB1 (Fig. 5d). Together, these results identify TRIF, STING, NEMO, OPTN and ANKIB1 itself as targets of the K11-Ub chain-generating activity of ANKIB1. K11-Ub, placed on components of the TLR3- and STING-SCs enables OPTN recruitment, thereby promoting activation of TBK1, IRF3 and subsequent IFN induction.

ANKIB1 is crucial for IRF3-activating, IFN-inducing TBK1 activation in primary murine immune cells upon activation of TLR3/4 and cGAS–STING, but not RIG-I

To understand the relevance of ANKIB1 in primary cells and in vivo, we generated *Ankib1*^{−/−} mice. ANKIB1 deficiency was not embryonically lethal and did not result in any overt phenotype (Extended Data Fig. 5a). However, ANKIB1 is differentially expressed across tissues and particularly enriched in the spleen, lungs and, to a lesser extent, the colon and Peyer's patches (Extended Data Fig. 5b). To assess whether ANKIB1 deletion altered basal immune homeostasis or inflammation, we evaluated spleen morphology and immune cell composition. Both spleen/body weight ratio and immune cell numbers were comparable between control and *Ankib1*^{−/−} mice (Extended Data Fig. 5c,d). Histological characterization of liver, spleen, lungs and intestine did not show any prominent alterations between *Ankib1*^{−/−} and control mice (Extended Data Fig. 5e).

We next assessed the role of ANKIB1 in innate immune signalling by examining primary murine immune cells ex vivo. Consistent with our findings in human cell lines, stimulation of TLR3 led to substantially decreased TBK1 phosphorylation in bone marrow-derived macrophages (BMDMs) from *Ankib1*^{−/−} compared with *Ankib1*^{+/+} controls (Extended Data Fig. 5f). In TLR4-stimulated splenocytes, TBK1 phosphorylation was preserved—probably via MyD88-dependent signalling—yet IRF3 phosphorylation was abolished and STAT1 phosphorylation, a downstream readout of type-I IFN signalling, was largely diminished in *Ankib1*^{−/−} cells (Extended Data Fig. 5g). Similarly, STING stimulation induced robust TBK1 activation and IFN production in *Ankib1*^{+/+} primary murine immune cells but was substantially attenuated in *Ankib1*^{−/−} cells (Extended Data Fig. 5h). By contrast, RIG-I signalling remained intact in *Ankib1*^{−/−} cells, with comparable phosphorylation of TBK1, IRF3 and STAT1 to controls (Extended Data Fig. 5i). These observations were further confirmed by cytokine quantification: control BMDMs secreted high levels of IFN β upon TLR3, TLR4 or

Article

<https://doi.org/10.1038/s41556-026-01886-z>

STING stimulation, whereas *Ankib1*^{−/−} BMDMs showed blunted IFN β production upon TLR3 and TLR4 stimulation and a substantial decrease therein upon STING activation (Fig. 6a–c). By contrast, IFN β production in response to RIG-I stimulation was unaffected by ANKIB1 deficiency (Fig. 6d). These results demonstrate that ANKIB1 is a crucial driver of IRF3 activation and consequent IFN induction downstream of TLR3, TLR4 and cGAS–STING.

ANKIB1 is crucial for TLR3- and cGAS–STING-mediated IFN induction in vivo

During infection, type-I IFNs are critical for orchestrating an effective immune response^{45,46}. However, excessive or uncontrolled type-I IFN production can be detrimental, as seen in various so-called interferonopathies⁴⁷, such as Aicardi–Goutières syndrome and STING-associated vasculopathy with onset in infancy, as well as

lysates were analysed by immunoblotting. **i**, HeLa cells stably expressing either ANK WT or ANK Δ UIM treated with 10 μ g/mL 2'3' cGAMP. moTAP-ANKIB1 was pulled-down via its FLAG-tag. Immunoprecipitated proteins were analysed by immunoblotting. **j**, A549 WT and ANK^{-/-} cells were treated with 500 ng/mL 3p-hpRNA for the indicated times and subjected to western blot analysis. **k, l**, IFN β and IFN λ mRNAs were respectively measured by RT-qPCR 6h after stimulation of HeLa WT and ANK^{-/-} cells with 500 ng/mL 3p-hpRNA. $P=0.8597$ and $P=0.9458$, respectively. **m**, A549 WT and ANK^{-/-} cells were infected with Sendai virus (SeV) for the indicated times before IFN β transcripts were measured by RT-qPCR. $P=0.4326$ and $P=0.7257$, respectively. **n**, HeLa WT, OPTN^{-/-} and ANK^{-/-} cells were stimulated with 10 μ g/mL ADU-S100. The lysates were subjected to immunoblotting. **o**, HeLa WT and TKO cells were treated with 500 ng/mL 3p-hpRNA for the indicated times and the lysates were subjected to western blot analysis. All graphs represent mean $\pm$ SEM of three independent experiments. P values were determined by two-way ANOVA with uncorrected Fisher's LSD multiple-comparisons test in 95% confidence interval. * $P \leq 0.05$; ** $P \leq 0.01$; *** $P \leq 0.001$. For western blots, one representative of three independent experiments is shown. Non-specific bands are marked with an asterisk.




Figure 5: ANKIB1 promotes ubiquitination of TRIF, STING, NEMO, and OPTN. **a**, HeLa WT, ANK^{-/-} and ANK RING1^{mut} cells were stimulated with 15 µg/mL poly(I:C) for the indicated times. The ubiquitinated proteins were pulled down using GST-TUBE pre-coupled with glutathione beads. Co-precipitated proteins were analysed by western blot. **b**, HeLa WT, ANK^{-/-} and ANK RING1^{mut} cells were stimulated with 10 µg/mL 2'3'cGAMP for the indicated times. The ubiquitinated proteins were pulled down using GST-TUBE pre-coupled with glutathione beads. Co-precipitated proteins were analysed by western blot. **c**, HeLa WT cells were stimulated with 15 µg/mL poly(I:C) for 60 minutes. The ubiquitinated proteins were pulled down using GST-TUBE pre-coupled with glutathione beads and the beads were incubated with K48 tetra-ubiquitin chains before performing with de-ubiquitination assay using either 125nM AMSH (A), Cezanne (C) or 250 nM USP2 (U). The samples were analysed by western blot. **d**, HeLa WT, and ANK^{-/-} cells were stimulated with 15 µg/mL poly(I:C) for the indicated

times. K11-linked poly-ubiquitinated targets were co-precipitated using K11 2A3/2E6 antibody pre-coupled with protein G. Co-immunoprecipitated proteins were analysed by western blotting. For western blots, one representative of three independent experiments is displayed. Non-specific bands are marked with an asterisk.

Article

<https://doi.org/10.1038/s41556-026-01886-z>

secondary haemophagocytic lymphohistiocytosis (sHLH)^{47–52}. The latter is characterized by excessive macrophage activation, leading to hyperinflammation and multi-organ failure⁵³. As no natural pathogen is known to elicit IFN exclusively through TLR3, we employed an in vivo model of sHLH (Fig. 6e) in which TLR3-driven type-I IFN converts an otherwise sublethal TLR4 stimulation (Extended Data Fig. 6a) into a lethal challenge⁴⁷. Strikingly, ANKIB1 deficiency significantly protected from TLR3-driven sHLH, as 78% of *Ankib1*^{−/−} mice survived whereas all control mice succumbed to the challenge (Fig. 6f). RNA-sequencing of spleens collected after poly(I:C) treatment revealed that, while poly(I:C) induced robust type-I/III IFN expression in control mice, this response was largely absent in *Ankib1*^{−/−} mice (Fig. 6g). Importantly, while NF-κB target genes such as IL-6 and IL-1β were equally induced in both genotypes, IFN-stimulated genes were selectively upregulated in controls. Gene set enrichment analysis further showed a marked suppression of IFNα and IFNγ response signatures in *Ankib1*^{−/−} mice, whereas TNF, IL-6 and MAPK signalling pathways were not strongly affected (Fig. 6h and Extended Data Fig. 6b–e). Together, these results establish ANKIB1 as a key driver of TLR3-induced type-I/III IFN production and responses in vivo, and identify it as a critical mediator of TLR3-induced lethality in interferonopathy.

Given the established role of ANKIB1 in TRIF- but not MyD88-dependent TLR4 signalling, we next determined whether ANKIB1 deficiency influences TLR4-driven, MyD88-dependent pathology in vivo. To accomplish this, we employed an *E. coli*-induced sepsis model in which the lethality is driven by MyD88-dependent TLR4 signalling⁵⁴. Notably, ANKIB1-deficient and control mice exhibited comparable susceptibility to *E. coli*-induced lethality (Fig. 6i), indicating selective requirement for ANKIB1 in TRIF-dependent, but not MyD88-dependent, TLR4 signalling in vivo.

We next assessed the role of ANKIB1 in the context of viral infection. First, we used IAV as an RNA virus model, in which viral RNA is known to be primarily sensed by RIG-I, leading to a potent IFN response essential for host survival^{45,55,56}. In this model, weight loss and recovery were indistinguishable between control and *Ankib1*^{−/−} mice (Fig. 6j), providing in vivo confirmation that ANKIB1 is not essential for RIG-I signalling.

Finally, we intranasally infected mice with HSV-1 SC16, a DNA virus primarily sensed by the cGAS–STING pathway whose induction of IFN is indispensable for survival in this model^{57–59}. As expected, 75% of control mice survived infection (Fig. 6k). Remarkably, *Ankib1*^{−/−} mice exhibited severe susceptibility, with only 20% of the mice surviving the challenge (Fig. 6k), implicating ANKIB1 as a key regulator of antiviral defence against HSV-1. Interestingly, the susceptibility of *Ankib1*^{−/−} mice to HSV-1 infection is similar to that previously reported for *Optn*^{−/−} mice in the

same model⁶⁰, which, in both cases, is lower than expected for complete loss of cGAS–STING signalling⁵⁹. This result is probably reflective of a substantial, yet incomplete dependence of cGAS–STING-induced IFN induction on ANKIB1–OPTN signalling also in vivo, in line with our observations in human cell lines (Fig. 4n) and primary murine immune cells ex vivo (Fig. 6c and Extended Data Fig. 5h).

To determine the mechanism underlying this increased lethality, we collected brainstems—the primary site of HSV-1 replication in this model⁵⁹ at day 3 post infection and analysed cytokine expression. Notably, IFNβ response signalling was significantly downregulated in HSV-1-infected *Ankib1*^{−/−} compared with control mice (Fig. 6l). However, NF-κB target genes showed heterogeneous expression, indicating that ANKIB1 primarily affected IFN signalling. We also observed a 50% reduction in IFNβ levels in pulmonary tissues from infected mice, while NF-κB-driven cytokines such as IL-6 remained largely unchanged (Fig. 6m and Extended Data Fig. 6f). Consequently, immune activation and cytotoxic effector responses were also impaired, as evidenced by reduced granzyme B expression in the lungs and the analysis of the downregulated genes in the brainstems of *Ankib1*^{−/−} mice (Fig. 6n,o). Thus, ANKIB1 is an important driver of cGAS–STING-dependent IFN induction and antiviral immunity against HSV-1 infection in vivo.

In summary, the results demonstrate that ANKIB1 is crucial for IFN-dependent biological effects triggered by TLR3 and cGAS–STING in vivo, whereas this is not the case for RIG-I and the MyD88-dependent arm of TLR4.

Discussion

We here describe ANKIB1 and the product of this catalytic activity, K11-Ub, as previously unknown crucial drivers of TBK1 and IRF3 activation and type-I/III IFN induction downstream of TLR3, TLR4 and cGAS–STING. This is achieved via a hitherto unknown signalling axis comprised of ANKIB1–K11-Ub–OPTN–TBK1, which acts as a molecular bridge linking activation of TLR3, TLR4, and cGAS–STING to TBK1 activation, thereby enabling IRF3 activation and IFN induction. We provide evidence for the physiological relevance of ANKIB1 as the apical component of a previously unrecognized signalling axis in in vivo disease models of TLR3-dependent interferonopathy and cGAS–STING-mediated, IFN induction-dependent antiviral immunity.

Mechanistically, ANKIB1 is recruited to the TLR3-SC via its UIM domain, where it K11-ubiquitinates TRIF, NEMO, OPTN and itself. K11-Ub was previously shown to regulate cell cycle progression by enabling proteasomal degradation⁶¹, with more recent studies suggesting that, rather than acting alone, K11-Ub triggers proteasomal degradation in

Nature Cell Biology | Volume 28 | March 2026 | 608–621

617

Article

<https://doi.org/10.1038/s41556-026-01886-z>

concert with other chain types, including K48-Ub or K63-Ub⁶² with non-degradative signalling roles⁶³. We show that ANKIB1-generated K11-Ub is essential for the recruitment of OPTN to the TLR3-SC, which in turn serves as critical adaptor for TBK1 recruitment and activation, driving IRF3 phosphorylation and IFN production. Interestingly, Dynek et al. reported that K11-Ub confers a scaffold property to RIFK1 in TNFR1 signalling and that NEMO, which contains a UBA domain similar to that of OPTN, is able to bind to such K11-Ub⁶⁴.

We also identified a role for ANKIB1 in TRIF-dependent TLR4 signalling. TLR4 signals via both MyD88 and TRIF^{65,66}, with TRIF containing the IRF3-binding motif for IFN production^{9,40}. While TANK mediates TBK1 and IKKε activation in MyD88 signalling³⁴, it is dispensable for TBK1 and IRF3 activation downstream of TRIF. Our findings align with prior studies showing that OPTN—but not TANK—is essential for IFN production in TRIF-dependent TLR4 signalling^{32,37}. On the basis of our findings, we propose that the ANKIB1–K11-Ub–OPTN–TBK1 signalling

Nature Cell Biology | Volume 28 | March 2026 | 608–621

618




Figure 6: ANKIB1 is crucial for TLR3- and cGAS-STING-mediated IFN induction *in vivo*. **a**, Control and *Ankib1*^{-/-} BMDMs were stimulated with 5 μ g/mL poly(I:C) for 24h or **b**, with 200 ng/mL LPS for 4h or **c**, 5 μ g/mL ADU-S100 for 6h, **d**, 200 ng/mL 3p-hpRNA for 6h and the supernatants were collected to determine IFN β concentration by ELISA. The graphs represent mean $\pm$ SEM of three or four independent biological replicates. *P* values were determined by two-way ANOVA with uncorrected Fisher's LSD multiple-comparisons test in 95% confidence interval. *P* < 0.0001, *P* < 0.0001, *P* < 0.0001, and *P* = 0.6573, respectively. **e**, Workflow of the sHLH model was created in BioRender. Cinko, M. T. (2025) <https://biorender.com/z86e207>. **f**, 10 mg/kg poly(I:C) was injected intraperitoneally (i.p) to 8- to 12-week-old wt littermate control and *Ankib1*^{-/-} mice, followed 24 hours later by the intraperitoneal (i.p) administration of 5 mg/kg LPS. The survival rates of the mice were monitored for 5 days and the log-rank Mantel-Cox test was used to determine the statistical significance. *P*=

0.0018. **g**, Spleens of 9- to 10-week-old wt littermate control and *Ankib1*^{-/-} mice were harvested for RNA extraction after 10 mg/kg intraperitoneal poly(I:C) injection for 3 and 6 hours. RNA sequencing analysis was represented as a heatmap, using two independent biological replicates per group for each genotype. **h**, IFN- α response gene set enrichment analysis was performed using spleen samples for both, the 3 and the 6 hours time points. Statistical significance of the data was determined using Kolmogorov-Smirnov test. **i**, wt littermate control and *Ankib1*^{-/-} mice were challenged with 2×10^8 CFU *Escherichia coli* (*E. coli*)-induced sepsis. The survival rates of the mice were monitored for 5 days and the log-rank Mantel–Cox test was used to determine the statistical significance. $P=0.9001$. **j**, 8-10 weeks old wt littermate control and *Ankib1*^{-/-} mice were challenged with 1×10^6 PFU Influenza P8 virus (IAV). The weight loss of the mice was monitored for 15 days. Data shows mean $\pm$ SD of independent biological replicates. P values were determined by two-way ANOVA. $P=0.2721$. **k**, 12-16 weeks old male *Ankib1*^{-/-} (n=5) and wt littermate control mice (n=8) were challenged with 1×10^6 PFU HSV-1 SC16. The survival rates of the mice were monitored for 14 days and the log-rank Mantel–Cox test was used to determine the statistical significance. $P=0.0395$. **l**, Gene ontology analysis was performed using RNA samples from the brainstem of wt littermate control and *Ankib1*^{-/-} mice at 3 days post infection with HSV-1. **m, n**, The respective cytokines in lung homogenates of 12-week-old wt littermate control (n=4) and *Ankib1*^{-/-} (n=5) mice were measured at day 5 post-infection with HSV-1 SC16 by multiplex ELISA. $P=0.007$, and $P=0.0209$, respectively. ELISA graphs represent mean $\pm$ SD of independent biological replicates. P values were determined by unpaired two-tailed Student's test. * $P \leq 0.05$; ** $P \leq 0.01$; *** $P \leq 0.001$; **** $P \leq 0.0001$ **o**, Gene ontology analysis was performed using RNA samples from brainstems of wt littermate control and *Ankib1*^{-/-} mice at 5 days post infection with HSV-1.

axis we identified as responsible for IFN induction downstream of TRIF in TLR3 signalling operates likewise in TLR4 signalling.

Finally, we demonstrated a key role for ANKIB1 in cGAS–STING signalling. Prior studies reported a direct TBK1–STING interaction via a C-terminal TBK1-binding motif⁶⁷, whereas others highlighted a requirement for ubiquitination^{68–70}. Our results reconcile these models by showing that the ANKIB1–OPTN dependence of cGAS–STING-induced TBK1 activation and IFN induction is substantial yet incomplete. It is possible that ANKIB1–OPTN-independent, cGAS–STING-induced TBK1 activation is due to direct binding of TBK1 to STING, as previously shown^{7,67}; it remains to be shown, however, whether this is truly the case.

Consistent with previous work that OPTN deficiency impairs STING-induced IFN induction, thereby increasing susceptibility to HSV-1 infection^{60,71}, we show that OPTN is required for effective TBK1 activation downstream of STING. We identify STING, NEMO, OPTN and ANKIB1 itself as substrates of ANKIB1 and show, by using ANKIB1-RING^{mut} cells, that the catalytic activity of ANKIB1 enables OPTN and TBK1 recruitment, contributing substantially to IRF3 activation and type-I and type-III IFN production. By contrast, ANKIB1 and OPTN are dispensable for robust RIG-I–MAVS signalling, whereas TANK, NAPI and/or SINTBAD are required for it, as previously reported³⁶.

Interestingly, the biochemical mechanism of the catalytic activity of ANKIB1 is distinct from that of other RBR-E3s such as PARKIN or HOIP^{72,73} as it depends on the RBR-RING1 rather than the RBR-RING2. The identification of this currently unique mechanism for ANKIB1 among the RBR-E3s proposes the existence of two distinct types of RBR-E3s, one relying on RING2 and the other one on RING1. Structural studies will be required to determine how ANKIB1 accomplishes this.

We identify ANKIB1 as crucial driver of activation of TBK1, IRF3 and type-I/III IFN induction in signalling triggered by TLR3, TRIF-dependent TLR4 and cGAS–STING, but not RIG-I. Contrasting with the latter, it was recently reported that ANKIB1 would interfere with RIG-I-induced IFN induction, that is, exert the opposite function to the one we identified for ANKIB1 in TLR3, TLR4 and cGAS–STING but not RIG-I–MAVS signalling, by mediating the proteasomal degradation of MAVS through K48-linked ubiquitination⁷⁴. However, we neither observed such interference with RIG-I-induced IFN induction in ANKIB1-proficient cells nor did we detect proteasomal degradation of MAVS upon treatment of such cells with the RIG-I ligand 3p-hpRNA or by infection with the RIG-I-stimulating viruses IAV and SeV. We attribute this differential requirement to distinct biochemical mechanisms of TBK1 activation downstream of various PRRs. Whereas cGAS–STING and TRIF-dependent TLR3 and TLR4 signalling rely on OPTN-mediated TBK1 phosphorylation, which requires recruitment via ANKIB1-generated K11-linked ubiquitin chains, TBK1 activation downstream of RIG-I–MAVS primarily depends on the adaptor proteins TANK, NAPI and SINTBAD, whose recruitment, as we show, is ANKIB1-independent.

In summary, we here identify a previously unrecognized ANKIB1–K11-Ub–OPTN–TBK1 signalling axis as the crucial driver of IRF3-mediated IFN induction downstream of TLR3, TLR4 and cGAS–STING (Extended Data Fig. 5j). Notably, ANKIB1 deletion confers significant protection in an otherwise lethal TLR3-dependent interferonopathy mouse model. Future strategies aimed at inhibiting the catalytic function of ANKIB1 or degrading it altogether may open additional avenues for treating IFN-driven pathologies.

Online content

Any methods, additional references, Nature Portfolio reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41556-026-01886-z>.

References

- Muller, U. et al. Functional role of type I and type II interferons in antiviral defense. *Science* **264**, 1918–1921 (1994).
- Haller, O., Arnheiter, H., Gresser, I. & Lindenmann, J. Virus-specific interferon action. Protection of newborn Mx carriers against lethal infection with influenza virus. *J. Exp. Med.* **154**, 199–203 (1981).
- Durbin, J. E. et al. Type I IFN modulates innate and specific antiviral immunity. *J. Immunol.* **164**, 4220–4228 (2000).
- Kawai, T. & Akira, S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. *Nat. Immunol.* **11**, 373–384 (2010).
- Perry, A. K., Chow, E. K., Goodnough, J. B., Yeh, W. C. & Cheng, G. Differential requirement for TANK-binding kinase-1 in type I interferon responses to Toll-like receptor activation and viral infection. *J. Exp. Med.* **199**, 1651–1658 (2004).
- Tenover, B. R. et al. Multiple functions of the IKK-related kinase IKKε in interferon-mediated antiviral immunity. *Science* **315**, 1274–1278 (2007).
- Yum, S., Li, M., Fang, Y. & Chen, Z. J. TBK1 recruitment to STING activates both IRF3 and NF-κB that mediate immune defense against tumors and viral infections. *Proc. Natl Acad. Sci. USA* **118**, e2100225118 (2021).
- Tanaka, Y. & Chen, Z. J. STING specifies IRF3 phosphorylation by TBK1 in the cytosolic DNA signaling pathway. *Sci. Signal.* **5**, ra20 (2012).
- Liu, S. et al. Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation. *Science* **347**, aaa2630 (2015).
- Lafont, E. et al. TBK1 and IKKε prevent TNF-induced cell death by RIPK1 phosphorylation. *Nat. Cell Biol.* **20**, 1389–1399 (2018).
- Gerlach, B. et al. Linear ubiquitination prevents inflammation and regulates immune signalling. *Nature* **471**, 591–596 (2011).
- Haas, T. L. et al. Recruitment of the linear ubiquitin chain assembly complex stabilizes the TNF-R1 signaling complex and is required for TNF-mediated gene induction. *Mol. Cell* **36**, 831–844 (2009).
- Zingg, J. et al. LUBAC deficiency perturbs TLR3 signaling to cause immunodeficiency and autoinflammation. *J. Exp. Med.* **213**, 2671–2689 (2016).
- Li, F. et al. Structural insights into the ubiquitin recognition by OPTN (optineurin) and its regulation by TBK1-mediated phosphorylation. *Autophagy* **14**, 66–79 (2018).
- Peltzer, N. et al. LUBAC is essential for embryogenesis by preventing cell death and enabling haematopoiesis. *Nature* **557**, 112–117 (2018).
- Pawlyk, A. C. et al. Novel monoclonal antibodies demonstrate biochemical variation of brain parkin with age. *J. Biol. Chem.* **278**, 48120–48128 (2003).
- Hemmi, H. et al. The roles of two IκB kinase-related kinases in lipopolysaccharide and double stranded RNA signaling and viral infection. *J. Exp. Med.* **199**, 1641–1650 (2004).
- McWhirter, S. M. et al. IFN-regulatory factor 3-dependent gene expression is defective in Tbk1-deficient mouse embryonic fibroblasts. *Proc. Natl Acad. Sci. USA* **101**, 233–238 (2004).
- Cusson-Hermance, N., Khurana, S., Lee, T. H., Fitzgerald, K. A. & Kelliher, M. A. Rip1 mediates the Trif-dependent Toll-like receptor 3- and 4-induced NF-κB activation but does not contribute to interferon regulatory factor 3 activation. *J. Biol. Chem.* **280**, 36560–36566 (2005).
- Spratt, D. et al., Walden, H. & Shaw, G. RBR E3 ubiquitin ligases: new structures, new insights, new questions. *Biochem. J.* **458**, 421–437 (2014).
- Walden, H. & Rittinger, K. RBR ligase-mediated ubiquitin transfer: a tale with many twists and turns. *Nat. Struct. Mol. Biol.* **25**, 440–445 (2018).

22. Kamadurai, H. B. et al. Insights into ubiquitin transfer cascades from a structure of a UbcH5B approximately ubiquitin–HECT(NEDD4L) complex. *Mol. Cell* **36**, 1095–1102 (2009).
23. Eddins, M. J., Carlile, C. M., Gomez, K. M., Pickart, C. M. & Wolberger, C. Mms2–Ubc13 covalently bound to ubiquitin reveals the structural basis of linkage-specific polyubiquitin chain formation. *Nat. Struct. Mol. Biol.* **13**, 915–920 (2006).
24. Fallon, L. et al. A regulated interaction with the UIM protein Eps15 implicates parkin in EGF receptor trafficking and PI(3)K-Akt signalling. *Nat. Cell Biol.* **8**, 834–842 (2006).
25. Tseng, P.-H. et al. Different modes of ubiquitination of the adaptor TRAF3 selectively activate the expression of type I interferons and proinflammatory cytokines. *Nat. Immunol.* **11**, 70–75 (2009).
26. Häcker, H. et al. Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. *Nature* **439**, 204–207 (2005).
27. Oganessian, G. et al. Critical role of TRAF3 in the Toll-like receptor-dependent and -independent antiviral response. *Nature* **439**, 208–211 (2005).
28. Mevissen, T. E. T. et al. Molecular basis of Lys11-polyubiquitin specificity in the deubiquitinase Cezanne. *Nature* **538**, 402–405 (2016).
29. Rahighi, S. et al. Specific recognition of linear ubiquitin chains by NEMO is important for NF- κ B activation. *Cell* **136**, 1098–1109 (2009).
30. Dikic, I., Wakatsuki, S. & Walters, K. J. Ubiquitin-binding domains—from structures to functions. *Nat. Rev. Mol. Cell Biol.* **10**, 659–671 (2009).
31. Miller, S. L., Malotky, E. & O'Bryan, J. P. Analysis of the role of ubiquitin-interacting motifs in ubiquitin binding and ubiquitylation. *J. Biol. Chem.* **279**, 33528–33537 (2004).
32. Gleason, C. E., Ordureau, A., Gourlay, R., Arthur, J. S. C. & Cohen, P. Polyubiquitin binding to optineurin is required for optimal activation of tank-binding kinase 1 and production of interferon β . *J. Biol. Chem.* **286**, 35663–35674 (2011).
33. Sasai, M. et al. NAK-associated protein 1 participates in both the TLR3 and the cytoplasmic pathways in type I IFN induction. *J. Immunol.* **177**, 8676–8683 (2006).
34. Clark, K., Takeuchi, O., Akira, S. & Cohen, P. The TRAF-associated protein TANK facilitates cross-talk within the I κ B kinase family during Toll-like receptor signaling. *Proc. Natl Acad. Sci. USA* **108**, 17093–17098 (2011).
35. Goncalves, A. et al. Functional dissection of the TBK1 molecular network. *PLoS ONE* **6**, e23971 (2011).
36. Ryzhakov, G. & Randow, F. SINTBAD, a novel component of innate antiviral immunity, shares a TBK1-binding domain with NAP1 and TANK. *EMBO J.* **26**, 3180–3190 (2007).
37. Slowicka, K. et al. Optineurin deficiency in mice is associated with increased sensitivity to Salmonella but does not affect proinflammatory NF- κ B signaling. *Eur. J. Immunol.* **46**, 971–980 (2016).
38. Meena, N. P. et al. The TBK1-binding domain of optineurin promotes type I interferon responses. *FEBS Lett.* **590**, 1498–1508 (2016).
39. Munitic, I. et al. Optineurin insufficiency impairs IRF3 but Not NF- κ B activation in immune cells. *J. Immunol.* **191**, 6231–6240 (2013).
40. Kagan, J. C. et al. TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon- β . *Nat. Immunol.* **9**, 361–368 (2008).
41. Rehwinkel, J. & Gack, M. U. RIG-I-like receptors: their regulation and roles in RNA sensing. *Nat. Rev. Immunol.* **20**, 537–551 (2020).
42. Kato, H. et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. *Nature* **441**, 101–105 (2006).
43. McCullough, J., Clague, M. J. & Urbe, S. AMSH is an endosome-associated ubiquitin isopeptidase. *J. Cell Biol.* **166**, 487–492 (2004).
44. Ritorto, M. S. et al. Screening of DUB activity and specificity by MALDI-TOF mass spectrometry. *Nat. Commun.* **5**, 4763 (2014).
45. Hatesuer, B. et al. Deletion of Irf3 and Irf7 genes in mice results in altered interferon pathway activation and granulocyte-dominated inflammatory responses to influenza A infection. *J. Innate Immun.* **9**, 145–161 (2017).
46. Channappanavar, R. et al. Dysregulated Type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice. *Cell Host Microbe* **19**, 181–193 (2016).
47. Crow, Y. J. & Stetson, D. B. The type I interferonopathies: 10 years on. *Nat. Rev. Immunol.* **22**, 471–483 (2022).
48. Rice, G. I. et al. Mutations in ADAR1 cause Aicardi-Goutieres syndrome associated with a Type I interferon signature. *Nat. Genet.* **44**, 1243–1248 (2012).
49. Stetson, D. B., Ko, J. S., Heidmann, T. & Medzhitov, R. Trex1 prevents cell-intrinsic initiation of autoimmunity. *Cell* **134**, 587–598 (2008).
50. Liu, Y. et al. Activated STING in a vascular and pulmonary syndrome. *N. Engl. J. Med.* **371**, 507–518 (2014).
51. Huang, Z. et al. Type I interferon signature and cycling lymphocytes in macrophage activation syndrome. *J. Clin. Invest.* **133**, e165616 (2023).
52. Ohyagi, H. et al. Monocyte-derived dendritic cells perform hemophagocytosis to fine-tune excessive immune responses. *Immunity* **39**, 584–598 (2013).
53. Nguyen, T. T. T., Kim, Y. T., Jeong, G. & Jin, M. Immunopathology of and potential therapeutics for secondary hemophagocytic lymphohistiocytosis/macrophage activation syndrome: a translational perspective. *Exp. Mol. Med.* **56**, 559–569 (2024).
54. Roger, T. et al. Protection from lethal Gram-negative bacterial sepsis by targeting Toll-like receptor 4. *Proc. Natl Acad. Sci. USA* **106**, 2348–2352 (2009).
55. Arimori, Y. et al. Type I interferon limits influenza virus-induced acute lung injury by regulation of excessive inflammation in mice. *Antivir. Res.* **99**, 230–237 (2013).
56. Loo, Y. M. et al. Distinct RIG-I and MDA5 signaling by RNA viruses in innate immunity. *J. Virol.* **82**, 335–345 (2008).
57. Murphy, A. A., Rosato, P. C., Parker, Z. M., Khlenkov, A. & Leib, D. A. Synergistic control of herpes simplex virus pathogenesis by IRF-3, and IRF-7 revealed through non-invasive bioluminescence imaging. *Virology* **444**, 71–79 (2013).
58. Rosato, P. C. & Leib, D. A. Neuronal interferon signaling is required for protection against herpes simplex virus replication and pathogenesis. *PLoS Pathog.* **11**, e1005028 (2015).
59. Reinert, L. S. et al. Sensing of HSV-1 by the cGAS–STING pathway in microglia orchestrates antiviral defence in the CNS. *Nat. Commun.* **7**, 13348 (2016).
60. Ames, J. et al. OPTN is a host intrinsic restriction factor against neuroinvasive HSV-1 infection. *Nat. Commun.* **12**, 5401 (2021).
61. Matsumoto, M. L. et al. K11-linked polyubiquitination in cell cycle control revealed by a K11 linkage-specific antibody. *Mol. Cell* **39**, 477–484 (2010).
62. French, M. E., Koehler, C. F. & Hunter, T. Emerging functions of branched ubiquitin chains. *Cell Discov.* **7**, 6 (2021).
63. Boname, J. M. et al. Efficient internalization of MHC I requires lysine-11 and lysine-63 mixed linkage polyubiquitin chains. *Traffic* **11**, 210–220 (2010).
64. Dynek, J. N. et al. c-IAP1 and UbcH5 promote K11-linked polyubiquitination of RIP1 in TNF signalling. *EMBO J.* **29**, 4198–4209 (2010).
65. Hoebe, K. et al. Identification of Lps2 as a key transducer of MyD88-independent TIR signalling. *Nature* **424**, 743–748 (2003).
66. Yamamoto, M. et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. *Science* **301**, 640–643 (2003).

67. Zhao, B. et al. A conserved PLPLRT/SD motif of STING mediates the recruitment and activation of TBK1. *Nature* **569**, 718–722 (2019).
68. Tsuchida, T. et al. The ubiquitin ligase TRIM56 regulates innate immune responses to intracellular double-stranded DNA. *Immunity* **33**, 765–776 (2010).
69. Zhang, J., Hu, M. M., Wang, Y. Y. & Shu, H. B. TRIM32 protein modulates type I interferon induction and cellular antiviral response by targeting MITA/STING protein for K63-linked ubiquitination. *J. Biol. Chem.* **287**, 28646–28655 (2012).
70. Wang, Q. et al. The E3 ubiquitin ligase AMFR and INSIG1 bridge the activation of TBK1 kinase by modifying the adaptor STING. *Immunity* **41**, 919–933 (2014).
71. Prabakaran, T. et al. Attenuation of cGAS–STING signaling is mediated by a p62/SQSTM1-dependent autophagy pathway activated by TBK1. *EMBO J.* **37**, e97858 (2018).
72. Riley, B. E. et al. Structure and function of Parkin E3 ubiquitin ligase reveals aspects of RING and HECT ligases. *Nat. Commun.* **4**, 1982 (2013).
73. Smit, J. J. et al. The E3 ligase HOIP specifies linear ubiquitin chain assembly through its RING-IBR-RING domain and the unique LDD extension. *EMBO J.* **31**, 3833–3844 (2012).
74. Liu, W. et al. E3 ubiquitin ligase ANKIB1 attenuates antiviral immune responses by promoting K48-linked polyubiquitination of MAVS. *Cell Rep.* **43**, 114687 (2024).

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2026

¹Cell Death, Inflammation and Immunity Laboratory, Institute of Biochemistry I, Faculty of Medicine, University of Cologne, Cologne, Germany.

²Cell Death, Inflammation and Immunity Laboratory, CECAD Cluster of Excellence, University of Cologne, Cologne, Germany. ³Centre for Cell Death, Cancer and Inflammation, UCL Cancer Institute, University College London, London, UK. ⁴CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain. ⁵Aragón Health Research Institute (IIS Aragón), Zaragoza, Spain. ⁶Department of Microbiology, Paediatrics, Radiology and Preventive Medicine and Public Health, University of Zaragoza, Zaragoza, Spain. ⁷Department of Pathology, University of Cambridge, Cambridge, UK. ⁸Mildred Scheel School of Oncology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Translational Genomics, Cologne, Germany. ⁹Medical Clinic III for Oncology, Hematology, Immune-Oncology and Rheumatology, University Hospital of Bonn, Bonn, Germany.

¹⁰Cologne Centre for Genomics, Medical Faculty, University of Cologne, Cologne, Germany. ¹¹Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas, Universidad Autónoma de Madrid, Madrid, Spain. ¹²Institute of Biochemistry, Department of Chemistry, Faculty of Mathematics and Natural Sciences, University of Cologne, Cologne, Germany. ¹³These authors contributed equally: Alexis Betrancourt, M. Talha Cinko.

¹⁴These authors jointly supervised this work: Eva Rieser, Henning Walczak. ✉ e-mail: erieser@uni-koeln.de; h.walczak@uni-koeln.de

75. Draber, P. et al. LUBAC-recruited CYLD and A20 regulate gene activation and cell death by exerting opposing effects on linear ubiquitin in signaling complexes. *Cell Rep.* **13**, 2258–2272 (2015).
76. Hjerpe, R. et al. Efficient protection and isolation of ubiquitylated proteins using tandem ubiquitin-binding entities. *EMBO Rep.* **10**, 1250–1258 (2009).
77. Shrum, B. et al. A robust scoring system to evaluate sepsis severity in an animal model. *BMC Res. Notes* **7**, 233 (2014).
78. Wang, A. et al. Specific sequences of infectious challenge lead to secondary hemophagocytic lymphohistiocytosis-like disease in mice. *Proc. Natl Acad. Sci. USA* **116**, 2200–2209 (2019).
79. Uranga-Murillo, I. et al. Biological relevance of Granzymes A and K during *E. coli* sepsis. *Theranostics* **11**, 9873–9883 (2021).
80. Tyanova, S., Temu, T. & Cox, J. The MaxQuant computational platform for mass spectrometry-based shotgun proteomics. *Nat. Protoc.* **11**, 2301–2319 (2016).
81. Tyanova, S. et al. The Perseus computational platform for comprehensive analysis of (prote)omics data. *Nat. Methods* **13**, 731–740 (2016).

Acknowledgements

We thank all members of the Walczak group for useful technical advice and fruitful scientific discussions, particularly M. Wakid for her support in preparation of the final manuscript. We thank the CECAD animal facility for generating *Ankib1^{−/−}* mice. We also thank the members of the CECAD proteomics facility for valuable support and advice and K. Hofmann for valuable input and advice regarding ubiquitin linkage characterization.

H.W. is funded by the Alexander von Humboldt Foundation, a Wellcome Trust Investigator Award (no. 214342/Z/18/Z), a Medical Research Council Grant (no. MR/S00811X/1), a Cancer Research UK Programme grant (no. A27323), three collaborative research centre grants (SFB1399, project C06, SFB1530-455784452, SFB1399-413326622, project A03 and SFB1403-414786233) funded by the Deutsche Forschungsgemeinschaft (DFG) and the NRW Network grant CANTAR funded from the programme 'Netzwerke 2021', an initiative of the Ministry of Culture and Science of the State of Northrhine Westphalia. J.P. is funded by PID2020-113963RB-I00, ASPANOA, FARO, Carrera de la mujer de Monzón, CIBERINFEC/ISCIII (CB21/13/00087), CERTERA/ISCIII (CERT22/00004), FORTALECE/ISCIII (FORT23/00028/03) and Aragon Government (Group B29_23R). M.A. is funded by a Postdoctoral Juan de la Cierva Contract and postdoctoral CIBER contract and I.U.-M. received a PhD grant from the Aragón Government (no. BOA-2018-06-15-027). J.B. received funding from a Mildred Scheel Nachwuchszentrum grant 70113307 by the German Cancer Aid (Deutsche Krebshilfe), a collaborative research centre grant (SFB1399, Project C07) and the NRW Network grant CANTAR. RNA sequencing was supported by the DFG Research Infrastructure West German Genome Center (project no. 407493903) as part of the Next Generation Sequencing Competence Network (project no. 423957469). Next-generation sequence analyses were carried out at the production site Cologne (Cologne Center for Genomics). A.A. is funded by the Spanish Ministry of Science and Innovation and the European Union (European Regional Development's Funds, FEDER) (grant PID2021-128580OB-I00). B.J.F. is funded by UKRI BBSRC, BB/Y007212/1, UKRI MRC and UKRI430 grants. RNA sequencing was supported by the DFG Research Infrastructure West German Genome Center (project no. 407493903) as part of the Next Generation Sequencing Competence Network (project no. 423957469). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

Author contributions

H.W. and E.R. conceived the project. A.B., M.T.C., H.W. and E.R. designed the experiments and A.B., M.T.C. and E.R. performed the majority of the experiments, with J.P., I.U.M., M.A. and N.P. helping in designing and performing the in vivo experiments. R.M. and A.A. contributed to the in vivo experiments. A.B.V., L.M.K. and B.B. supported in vitro experiments. A.B.V. and L.M.K. performed RNA and cytokine analysis. J.B., K.B. and R.C. performed the bioinformatic analysis of the RNA sequencing. L.F.C. and B.J.F. designed and performed in vitro infection experiments. D.d.M. generated essential tools for the study. A.B., M.T.C., E.R. and H.W. wrote the manuscript.

Funding

Open access funding provided by Universität zu Köln.

Competing interests

The authors declare no competing interests.

Additional information


Extended data is available for this paper at <https://doi.org/10.1038/s41556-026-01886-z>.

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41556-026-01886-z>.

Correspondence and requests for materials should be addressed to Eva Rieser or Henning Walczak.


Peer review information *Nature Cell Biology* thanks Xuetao Cao, Ivan Dikic and Nan Yan for their contribution to the peer review of this work.

Reprints and permissions information is available at www.nature.com/reprints.




Extended Data Fig. 1 | ANKIB1 knockdown disrupts TLR3-induced TBK1 activation. **a-c** HeLa WT cells were transfected with either 20 nM non-targeting control siRNA (siCtrl) or 20 nM siRNA targeting the respective mRNAs of interest, individually for 48 hours or in **b**, 72 hours. Subsequently, they were stimulated with 10 µg/mL poly(I:C) as displayed and the lysates were subjected to western

blot analysis. The knockdown efficiency of the targets was assessed by RT-qPCR in **a**, **b** or immunoblotting in **c**. For the panel of the western blots and RT-qPCR, one representative experiment was displayed of three independent replicates. Non-specific bands were marked with an asterisk.




Extended Data Fig. 2 | ANKIB1 enables TBK1 activation in TLR3 pathway but does not act in TNF signalling. a, HT-29 ANK^{-/-} and WT cells were stimulated with 100 ng/mL TNF for the indicated times and subjected to western blot analysis. Non-specific bands were marked with an asterisk. **b**, HT-29 ANK^{-/-} and WT or in **c**, HeLa WT and ANK^{-/-} cells were treated with 10 µg/mL poly(I:C) for the indicated time points. **d**, ANKIB1 expression between HeLa WT, ANK^{-/-} cells, and HeLa

stably expressing moTAP-ANKIB1 WT cells. **e**, HeLa WT cells were stimulated with 1 µg/mL moTAP-TNF and subjected to the pull down via its Flag-tag. The purified TNFR1 and co-immunoprecipitated proteins were analysed by immunoblotting. One representative experiment of four independent replicates was shown for each western blot panel.




Extended Data Fig. 3 | Characterisation of ANKIB1's catalytic domain and its requirement for TLR3-induced TBK1 activation. **a**, Purified moTAP-ANKIB1 WT was incubated with ubiquitin, E1, and different combinations of E2 enzymes in ATP regeneration solution for 1 h at 37 °C. All samples were resolved by SDS-PAGE and subjected to anti-ubiquitin immunoblotting. **b**, moTAP-ANKIB1 WT purified from HeLa cells was subjected to in vitro ubiquitination assay with UBE2D3 for 1 h at 37 °C. Then, the reactants were incubated with or without general deubiquitinase USP2 for 1 h at 30 °C. The samples were resolved by SDS-PAGE and subjected to anti-ubiquitin immunoblotting. **c**, A schematic illustration of putative domains of ANKIB1 and its different mutant versions were created in BioRender. Cinko, M. T. (2025) <https://biorender.com/dm2lne6>. Ankyrin1/2 domains, catalytic RBR domain, Ariadne domain, ubiquitin interactive

motif (UIM), flexible linker, moTAP tag (2xStrep and 1xFlag). **d**, HeLa ANK^{-/-} reconstituted with either moTAP-ANKIB1 WT or RING2 mutant (C519S/ C522S/ C532S/ C537S/ C540S/ C545S/ C548S) (ANK RING2^{mutant}) were stimulated with 10 μg/mL poly(I:C) for the indicated time points. The lysates were analyzed by immunoblotting. **e**, HeLa ANK^{-/-} reconstituted with either moTAP-ANKIB1 WT or ΔRING2 (ANK ΔRING2) were stimulated with 10 μg/mL poly(I:C) for the indicated time points. The lysates were analyzed by immunoblotting. **f**, Purified moTAP-ANKIB1 WT and ΔRING2 were subjected to in vitro ubiquitination assay with UBE2D3 and UBE2L3 for 1 h at 37 °C. All samples were resolved by SDS-PAGE and subjected to anti-ubiquitin and ANKIB1 immunoblotting. For western blot, one representative experiment was displayed of three independent experiments.



Extended Data Fig. 4 | Contribution of ANKIB1 and the adaptor proteins in STING and RIG-I signalling. **a**, A549 WT and ANK^{-/-} or in **b**, HT-29 WT and ANK^{-/-} cells were treated with 10 μg/mL ADU-S100. The lysates were analysed by western blot. **c**, HeLa cells stably expressing moTAP ANK WT cells were treated with 10 μg/mL ADU S-100. moTAP-ANKIB1 was pulled-down via its Flag-tag. Immunoprecipitated proteins were analysed by immunoblotting. **d**, HeLa cells stably expressing either moTAP ANK WT or ANK ΔUIM cells were treated with 10 μg/mL 2'3'-cGAMP. The lysates were analysed by western blot. **e**, A549 WT and ANK^{-/-} were treated with either 50 ng/mL, 100 ng/mL or 200 ng/mL of 3p-hpRNA. The lysates were analysed by western blot. **f**, IFNβ mRNA was measured by RT-qPCR 6 h after stimulation of HeLa WT and ANK^{-/-} cells with


200 ng/mL 3p-hpRNA. $P = 0.0818$. **g**, A549 WT and ANK^{-/-} cells were either treated with 200 ng/mL 3p-hpRNA or infected with SeV/IAV for the indicated times and subjected to western blot analysis. **h**, HeLa WT and OPTN^{-/-} cells were treated with 200 ng/mL of 3p-hpRNA. The lysates were analysed by western blot. **i**, HeLa WT and TKO cells were treated with 10 μg/mL ADU S-100. The lysates were analysed by western blot. The graphs represent mean ± SEM of six independent experiments. P values were determined by two-way ANOVA with uncorrected Fisher's LSD test in 95% confidence interval. * $P \leq 0.05$; ** $P \leq 0.01$; *** $P \leq 0.001$; **** $P \leq 0.0001$. For western blot, one representative experiment of three independent replicates was displayed. Non-specific bands were marked with an asterisk.



Extended Data Fig. 5 | See next page for caption.

Extended Data Fig. 5 | Role of ANKIB1 *ex vivo* and characterisation of *Ankib1*^{−/−} mice. **a**, Mendelian frequencies obtained from inter-crossing *Ankib1*^{+/−} mice. **b**, ANKIB1 expression was evaluated in various mouse tissues by western blotting. One representative experiment of three independent biological replicates was shown. **c**, Graph represents the ratio in percent of spleen weight (g) to body weight (g) in littermate control (n = 11) and *Ankib1*^{+/−} (n = 12) mice. *P* = 0.5639. **d**, Number of immune cells isolated from spleen digestion in littermate control (n = 4) and *Ankib1*^{+/−} (n = 4) mice were measured by flow cytometry, using anti-CD45 staining. *P* = 0.5942. **e**, Representative images from various organs of 10-month-old littermate control and *Ankib1*^{+/−} mice stained with H&E. One representative image of three independent biological replicates per genotype was shown. **f**, *Ankib1*^{+/−} and *Ankib1*^{−/−} BMDMs were stimulated with 5 µg/mL poly(I:C) for the indicated times, and the lysates were assessed by western blotting. **g**, **h**, *Ankib1*^{+/−} and *Ankib1*^{−/−} splenocytes were treated with either 200 ng/mL LPS or 5 µg/mL ADU S-100 for the indicated times, and the lysates were analysed by western blotting. **i**, *Ankib1*^{+/−} and *Ankib1*^{−/−} BMDMs were stimulated with 200 ng/mL 3p-hpRNA for the indicated times, and the lysates were assessed

by western blotting. In all western blot panels, one representative experiment of four independent biological replicates was shown. Graphical data shows mean ± SD of independent biological replicates per genotype. Statistical analysis was performed by unpaired two tailed Student's *t*-test in 95% confidence interval. **j**, Representative scheme of the "Unrecognized signalling axis ANKIB1–K11-Ub–OPTN in the downstream of different PRRs" was created in BioRender. Cinko, M. T. (2025) <https://biorender.com/munm5yp>. ANKIB1 is a crucial module of TLR3, TLR4-TRIF and STING-SCs and once recruited, it generates K-11 Ub chains on various signalling proteins, facilitating OPTN-TBK1 recruitment, thereby activation of TBK1. Other types of ubiquitin linkages are present, such as K-63, as well as mixed ubiquitin chains. TBK1 phosphorylates the IRF3-binding motif of TRIF and STING, initially enabling the recruitment of IRF3 and later its phosphorylation by TBK1, which induces interferon production consequently (left panel). However, TLR4-MyD88 signalling arm and another IFN-inducing SC, MAVS-SC does not require ANKIB1-K11 Ub–OPTN signalling axis for TBK1 activation (right panel).



Extended Data Fig. 6 | Inflammatory response characterisation of *Ankib1*^{-/-} mice in sHLH and HSV-1 infection model. **a**, 5 mg/kg LPS were intraperitoneally administered to WT littermate control and *Ankib1*^{-/-} mice and the survival rate was monitored over days. *P* values were determined using log-rank Mantel-Cox test in 95% confidence interval. *P* > 0.9999. **b, c, d, e** Different gene enrichment set analysis were performed using RNA samples from the spleen of WT littermate control and *Ankib1*^{-/-} mice 3 and 6 hours after poly(I:C) injection. Statistical

significance of the data was determined using Kolmogorov-Smirnov test. **f**, The concentration of IL-6 in lung homogenates of WT littermate control (*n* = 4) and *Ankib1*^{-/-} (*n* = 5) mice was measured by ELISA at 5 days post infection with HSV-1. *P* = 0.8060. Data shows independent biological replicates per genotype. Statistical analysis was performed by unpaired two tailed Student's *t*-test in 95% confidence interval.

4 Discussion

In this study, ANKIB1 and its catalytic product, K11-Ub, were identified as previously unrecognised and essential regulators of TBK1 and IRF3 activation, thereby driving IFN-I and IFN-III production downstream of TLR3, TLR4, and cGAS–STING signalling. Mechanistically, these responses are mediated through a previously unidentified ANKIB1–K11-Ub–OPTN–TBK1 signalling axis that functions as a molecular bridge between upstream activation of TLR3, TLR4, and cGAS–STING and downstream TBK1 recruitment, IRF3 phosphorylation, and subsequent IFN induction. Furthermore, using *in-vivo* models of TLR3-dependent interferonopathy and cGAS–STING-mediated IFN-dependent antiviral immunity and the physiological relevance of ANKIB1 as an apical regulator of this newly identified signalling pathway is demonstrated.

Mechanistically, ANKIB1 is recruited to the TLR3 signalosome through its UIM domain, where it catalyses the K11-linked ubiquitination of TRIF, NEMO, OPTN, and itself. Although K11-linked ubiquitin chains have traditionally been associated with cell cycle regulation through the promotion of proteasomal degradation²⁰, accumulating evidence indicates that K11-Ub can also cooperate with other ubiquitin chain types, including K48-Ub and K63-Ub, to mediate either proteasomal degradation³⁷² or non-degradative signalling functions³⁷³. Our findings demonstrate that ANKIB1-mediated K11-linked Ub is indispensable for the recruitment of OPTN to the TLR3 signalosome. Following its recruitment, OPTN serves as the primary adaptor responsible for TBK1 recruitment and activation, thereby promoting downstream IRF3 phosphorylation and IFN production. This scaffolding function resembles the mechanism described, where it was demonstrated that K11-linked ubiquitin chains provide a structural scaffold for RIPK1 during TNFR1 signalling and that NEMO binds these K11-linked chains through its UBAN domain, which is structurally related to the UBAN domain of OPTN²².

Despite detecting both the K63- and K11-linked ubiquitination of NEMO, OPTN, and TRIF via DUB assay (Figure 5c), the hierarchical relationship between these ubiquitin chains types remains unclear. Likewise, it remains to be determined whether both ubiquitin chain types are generated by ANKIB1 or whether ANKIB1 is exclusively responsible for K11-linked Ub. Addressing these questions will require sequential pulldown and immunoprecipitation experiments to characterise the signalosome-specific Ub patterns of these proteins. For example, TUBE pulldown using eluates obtained from the TLR3 pulldown would enable characterisation of the ubiquitin landscape within the TLR3 signalosome. Furthermore, the precise Ub sites should be identified by di-Gly enrichment coupled with subsequent MS analysis. Functional characterisation of these Ub sites should then be performed through mutational analyses combined with assessment of TBK1–IRF3 activation, IFN production, and comprehensive signalosome proteomics by MS to determine how ANKIB1-mediated Ub regulates the recruitment of signalling components. In this regard, TRIF-Ub was almost completely abolished in the absence of ANKIB1 activity (Figure 5a), however whether ANKIB1 solely acts on TRIF-Ub or whether it attaches

only the first ubiquitin chains, allowing further ubiquitination of TRIF by other E3s remains elusive. Interestingly, basal OPTN Ub was reduced in ANKIB1-deficient cells and was further diminished in cells expressing ANKIB1 RING1mut in the absence of stimulation (Figure 5a, b), suggesting that ANKIB1 and OPTN may be functionally linked independently of immune receptor signalling. Given the established role of OPTN in autophagy³⁷⁴, these findings further raise the possibility that ANKIB1 may also participate in autophagy, although its potential function in this pathway, as well as the biological significance of OPTN Ub, remains to be elucidated. Moreover, the rationale underlying the additional Ub of OPTN by ANKIB1 following stimulation remains unclear. TBK1-mediated phosphorylation of OPTN has been reported to enhance the affinity of its UBAN domain for polyubiquitin chains³⁷⁵. Whether Ub and other specific PTMs of OPTN may further facilitate or enhance its interaction with K11-linked ubiquitin chains is not fully characterised. Yet, *in vitro* analyses have demonstrated that the OPTN UBAN domain exhibits a substantially high affinity for M1- and K63-linked ubiquitin chains⁷⁸. Therefore, detailed biochemical characterisation of the interaction between OPTN and K11-linked ubiquitin chains, together with the analysis of OPTN PTMs, will be essential to clarify these mechanisms.

In addition, residual TBK1 and IRF3 activation during TLR3 signalling in the absence of either OPTN or ANKIB1 were observed, whereas this residual signalling was abolished in cells simultaneously deficient for TANK, NAP1, SINTBAD, and OPTN (Figure 3b, c). These findings indicate that the majority of TBK1 recruitment and activation occurs through OPTN, whereas the remaining activity is mediated by other TBK1 adaptor proteins. Consistent with these observations, *Ankib1*-deficient mice were protected from TLR3-dependent interferonopathy in the sHLH model. However, previous studies have suggested splenic and liver macrophages as major contributors to disease-associated lethality, and it therefore remains elusive whether conditional deletion of *Ankib1* within specific immune cell populations would prolong survival relative to whole-body knockout or completely prevent disease-associated lethality.

It was further demonstrated that this ANKIB1-dependent mechanism extends to TRIF-dependent TLR4 signalling. Although TLR4 signals through both, the MyD88 and TRIF adaptor proteins^{170, 376}, only TRIF contains the IRF3-binding motif required for IFN induction^{194, 377}. During MyD88-dependent signalling, TANK mediates TBK1 and IKK ϵ activation¹⁷³. However, TANK is dispensable for TBK1 and IRF3 activation downstream of TRIF. Consistent with previous studies^{151, 378}, our data demonstrate that OPTN, rather than TANK, is essential for IFN production during TRIF-dependent TLR4 signalling. These findings suggest that the ANKIB1–K11-Ub–OPTN–TBK1 signalling axis identified downstream of TRIF in TLR3 signalling similarly mediates IFN induction downstream of TLR4. Nevertheless, additional biochemical evidence is required to fully validate this model. In particular, characterisation of the TLR4–TRIF signalosome in the presence and absence of ANKIB1, using either TRIF immunoprecipitation or ANKIB1 pulldown approaches, would provide valuable insight into TLR4–

TRIF or ANKIB1 interactome and TBK1 adaptor proteins. Furthermore, gene activation experiment using TKO, QKO, and OPTN knockout cells would further clarify the predominant role of OPTN in TLR4–TRIF-mediated TBK1 activation. In addition, despite markedly impaired IRF3 activation, TLR4–TRIF-dependent IFN β production was not completely abolished in Ankib1-deficient murine BMDMs (Figure 6b). As these cells constitutively express IRF5, and IRF5 has previously been shown to contribute to IFN β production following WNV infection²⁴³, it might be assumed that IRF5 similarly contributes to the residual IFN β production observed during TLR4 signalling, yet this requires further investigation.

Finally, a substantial, though incomplete, contribution of ANKIB1 to TBK1 activation within the cGAS–STING signalling pathway was demonstrated. Previous studies have proposed two distinct models for TBK1 activation downstream of STING, with one suggesting direct recruitment of TBK1 through the C-terminal TBK1-binding motif of STING^{203, 379} and the other proposing an essential requirement for Ub^{214, 215, 380}. Our findings combine both paradigms by demonstrating that cGAS–STING-dependent TBK1 activation and IFN induction are strongly, but not completely, dependent on the ANKIB1–OPTN signalling axis. It is therefore possible that the remaining ANKIB1–OPTN-independent signalling may result from direct TBK1 binding to STING²⁰³. However, this hypothesis requires further experimental validation. Also, consistent with previous studies demonstrating that OPTN deficiency impairs STING-induced IFN production and increases susceptibility to HSV-1 infection^{219, 381}, our findings confirm that OPTN is required for optimal TBK1 activation downstream of STING. Furthermore, STING, NEMO, OPTN, and ANKIB1 were identified as substrates of ANKIB1 (Figure 5b). Nonetheless, the ANKIB1-dependent Ub landscape of STING, OPTN, NEMO, and ANKIB1 itself should be comprehensively characterised using DUB assays along with *in-vitro* Ub assays validations.

As for the TLR3 signalosome, the hierarchical organisation of ANKIB1-dependent and ANKIB1-independent polyubiquitin chains also remains unclear within the STING signalosome. Sequential pulldown and immunoprecipitation approaches will therefore be essential to characterise the Ub status of individual signalling components within the complex. For example, TUBE pulldown using an eluate from STING immunoprecipitation would provide a comprehensive overview of the ubiquitin landscape associated with the STING signalosome. Moreover, the precise Ub sites should be identified by di-Gly enrichment analysis coupled with MS. Subsequent mutational and functional analyses of these Ub sites for each protein should be assessed by TBK1–IRF3 activation, IFN production, and signalosome composition by MS to define how ANKIB1-mediated Ub regulates the signalling readouts and the recruitment of specific signalling proteins. Notably, robust Ub of NEMO was detected only in WT cells, whereas its Ub was markedly reduced in the absence of functional ANKIB1. However, the functional consequences of defective NEMO Ub remain to be determined. One possible explanation is that defective NEMO Ub compromises NF- κ B signalling, thereby suggesting a previously unappreciated

link between ANKIB1 and cGAS–STING-mediated NF- κ B activation. Nevertheless, this study does not provide sufficient evidence to conclusively support this hypothesis.

In addition to these considerations, several mechanistic aspects regarding the function of ANKIB1 within the STING signalling pathway remain unresolved. In particular, the cellular compartment in which ANKIB1 associates with the STING signalosome and whether it contributes to STING trafficking remains to be elucidated. These questions could be addressed by monitoring the kinetics of cGAS–STING signalling using immunofluorescence microscopy or live-cell imaging with fluorescently tagged ANKIB1. Using ANKIB1 RING1mut-expressing cells showed that the catalytic activity of ANKIB1 is required for the recruitment of both OPTN and TBK1 and that it thereby promotes IRF3 activation and subsequent IFN-I and III production. Interestingly, TBK1 and STING activation were further reduced in ANKIB1 RING1mut-expressing cells than in ANKIB1-deficient cells (Figure 5b). This observation suggests that alternative signalling modules may partially compensate when ANKIB1 is absent rather than merely inactive, especially since. In ANKIB1 RING1mut-expressing cells, scaffolding activity or physical occupancy of ANKIB1 appears to interfere with alternative signalling module activation. Because of its catalytic inactivation, ANKIB1 cannot execute its function, thereby resulting in further dampening the signalling. This observation may have important implications when considering pharmacological inhibition of ANKIB1 as a potential therapeutic strategy.

The physiological relevance of ANKIB1 was demonstrated *in vivo*. *Ankib1*-deficient mice displayed markedly increased susceptibility to HSV-1-induced lethality. Mechanistically, these mice failed to mount robust IFN β responses in the brain and lung and exhibited impaired immune cell-mediated antiviral immunity. However, several mechanistic aspects are still elusive. For example, although our analyses demonstrated defective T-cell chemotaxis and reduced Granzyme B production, a potential contribution of impaired NK-cell chemotaxis cannot be excluded. To address this possibility, CD3 immunostaining should be performed in the lungs and brains of infected mice to evaluate T-cell infiltration. In addition, viral titres should be quantified in multiple tissues from WT and *Ankib1*-deficient mice to determine the extent of viral dissemination. Tissue pathology should also be evaluated by haematoxylin and eosin staining, together with TUNEL staining to assess tissue integrity, immune cell infiltration and cell death. Furthermore, tissue damage may be exacerbated by excessive neutrophil recruitment. Since IFN-III has previously been reported to negatively regulate neutrophil-mediated tissue damage³⁰⁸, it will be important to evaluate both, IFN-III production and neutrophil-mediated pathology in HSV-1-infected *Ankib1*-deficient mice as compared to WT mice.

Crucially, the newly characterised ANKIB1–K11-Ub–OPTN–TBK1 signalling module exhibits strict PRR specificity. Although ANKIB1 and OPTN are indispensable for the aforementioned cascades, their deficiency does not cause prominent perturbations in TBK1–IRF3 activation during RIG-I–MAVS signalling. Instead, as previously reported, RIG-I–MAVS signalling requires several other E3 ligases

alongside the adapters TANK, NAP1, and/or SINTBAD¹⁵⁰ (Figure 4o). This differential requirement underscores distinct biochemical mechanisms governing TBK1 activation across specific PRRs: whereas the cGAS–STING and TRIF-dependent TLR3/4 pathways rely on ANKIB1-generated K11-Ub chains to recruit OPTN and drive TBK1 phosphorylation, the RIG-I–MAVS pathway activates TBK1 independently of ANKIB1 through the recruitment of TANK, NAP1, and/or SINTBAD. Conversely, a recent study suggested that ANKIB1 restrains RIG-I-mediated IFN induction by promoting the K48-Ub and subsequent proteasomal degradation of MAVS¹⁹⁹. However, no perturbation of RIG-I-mediated IFN production was observed in ANKIB1-proficient cells, nor was the proteasomal degradation of MAVS detected following stimulation with the RIG-I ligand 3p-hpRNA or infection with RIG-I-stimulating IAV or SeV (Extended Data Figure 4g). Nevertheless, because TBK1 and IRF3 phosphorylation are not completely abolished in the absence of TANK, NAP1, and SINTBAD after RIG-I stimulation, an additional adapter likely contributes to TBK1 activation. The effect of a single OPTN deficiency on TBK1 activation may not be prominent due to the presence of other major contributors, suggesting that RIG-I–MAVS signalling could be highly redundant. To test this hypothesis, TKO and QKO HeLa cells must be evaluated for RIG-I-induced TBK1–IRF3 activation. Correspondingly, ANKIB1 might play a minor, OPTN-dependent role in RIG-I-induced TBK1 activation; however, an appropriate experimental setup must be designed to bypass major E3 ligases and evaluate this potential function of ANKIB1.

Despite comprehensive biochemical and functional analyses of these pathways and ANKIB1, various mechanistic aspects require still further investigation. Notably, despite the lack of detection of the ANKIB1 Δ UIM mutant with known components of the TLR3-SC following ANKIB1 pulldown, TBK1 is still activated upon TLR3 stimulation. It is possible that ANKIB1 utilises its unique domain architecture—specifically both its UBA-like domain and UIM domain, which are both capable of interacting with polyubiquitin chains—for recruitment and retention within the complex. In the absence of the UIM domain, ANKIB1 may be transiently recruited to the complex through its UBA-like domain to partially mediate the K11-Ub of proteins within the complex; however, it may not be stably retained, thereby allowing TBK1 activation to a certain, but incomplete, extent. To test this hypothesis, the recruitment capacities and impacts on TBK1–IRF3 activation of ANKIB1 Δ UBA, ANKIB1 Δ UIM, and ANKIB1 Δ UBA-UIM mutants must be evaluated within the TLR3, TLR4, and STING signalosomes via immunoblotting, pulldown assays and subsequent MS analysis. Additionally, which specific module is responsible for ANKIB1 recruitment in each signalosome remains to be elucidated. Evaluating the single or concomitant deficiency of RIPK1, TRAF2, TRAF3, and/or TRAF6—in addition to considering catalytically inactive mutants of TRAF2, TRAF3, and/or TRAF6—might provide mechanistic insights into TLR3/4 signalling. Furthermore, the binding affinities of the ANKIB1 UBA and UIM domains for different types and lengths of ubiquitin chains must be evaluated, alongside potential PTMs on ANKIB1 that alter its affinity for polyubiquitin chains. Moreover, TLR3, TLR4-TRIF, and STING signalosomes must be dissected via MS in the presence or absence of wild-type ANKIB1, or in the presence of

catalytically inactive ANKIB1, to determine compositional changes and identify additional ANKIB1-dependent factors within the complexes.

ANKIB1 is classified as an Ariadne E3 ligase, a family characterised by an autoinhibitory domain that blocks the interaction between the E2-binding region and the catalytic cysteine within the RING2 domain^{51, 358}. However, the catalytic mechanism of ANKIB1 is biochemically unique compared to other RBR E3 ubiquitin ligases. While characterised RBR-E3s, such as PARKIN or HOIP, rely strictly on their RBR-RING2 domains for the ligase activity^{47, 382}, the catalytic function of ANKIB1 exhibits remarkable flexibility and can still be executed in the absence of the RING2 domain. In this regard, E2 preference represents a critical parameter. Specifically, UBE2L3-ANKIB1-mediated ubiquitination selectively requires the RING2 domain of ANKIB1. Conversely, UBE2D3—a more general E2 enzyme typically associated with canonical RING-type E3 ligases³⁸³—can still mediate ubiquitination in tandem with an ANKIB1 Δ RING2 mutant to an extent comparable to wild-type ANKIB1 (Extended Data Figure 3f), suggesting that ANKIB1 can induce ubiquitination via its RING1 or IBR domains. Because the IBR domains of RBR E3 ligases are structurally similar to RING2 domains⁴⁶, ANKIB1 may possess a catalytically functional IBR domain. Generation of ANKIB1 Δ IBR-RING2 mutant and its analysis in TBK1-IRF3 activation and IFN-I/III production might provide further mechanistic insight for the required elements in the RBR domain of ANKIB1. Alternatively, the ANKIB1 RING1 domain may directly execute catalytic functions because the sequence analysis of the ANKIB1 RING1 domain revealed that it bears all essential cysteine, histidine, proline, and hydrophobic residues found in the catalytic domains of classical RING E3s, contrasting with other RBR E3s. Mutational analysis of these residues demonstrated that an ANKIB1 RING1mut variant fails to induce the ubiquitination of TRIF, STING, OPTN, NEMO, and itself, and cannot drive robust downstream TBK1-IRF3 activation following TLR3 or cGAS-STING stimulation. Notably, however, ANKIB1 RING1 lacks a linchpin residue—the structural element that typically allows the E2 enzyme to determine the type of ubiquitin chain formed. Whether the ANKIB1 RING1 domain can independently determine polyubiquitin chain topology or relies entirely on the E2 enzyme for this specificity requires further investigation. Furthermore, it is possible that ANKIB1 RING1mut is incapable of binding any E2 enzyme—a classical feature of RING1 domains in RBR E3s³⁸⁴, thereby blocking all potential downstream RING1-, IBR-, or RING2-dependent ubiquitination. It also cannot be excluded that ANKIB1 participates in other signalling networks, uniquely and differentially utilising its RING1, IBR, or RING2 domains for catalysis depending on the specific pathway. This is exemplified by the dispensability of the ANKIB1 RING2 domain for TBK1-IRF3 activation (Extended Data Figure 3d, e). Structural studies are needed to elucidate how ANKIB1 achieves this configuration. Moreover, because E3 ligases require an interaction with ubiquitin to transfer it to substrates, ANKIB1 may rely on its UBA-like domain for ubiquitin engagement; structural characterisation could shed light on both this ubiquitin interaction and the overall catalytic mechanism. Structurally, the identification of this atypical ANKIB1 RING1-

mediated mechanism suggests the existence of two distinct classes of RBR-E3 ligases, distinguished by their relative dependence on the RING1 or RING2 domains. Furthermore, whether the Ariadne domain of ANKIB1 maintains the protein in a fully autoinhibited state or simply masks the RING2, IBR-RING2 or RING1-IBR-RING2 domains must be assessed. How this autoinhibition is structurally resolved upon stimulation—and whether it requires an interaction partner (such as the HOIP–HOIL-1 engagement)⁴⁷ or a specific PTM, as exemplified by Parkin³⁸²—remains to be investigated. Intriguingly, generating an ANKIB1 Δ Ariadne mutant could be highly insightful for evaluating potential aberrant activation of ANKIB1 and its subsequent cellular consequences, potentially uncovering additional functions of the ligase.

Furthermore, how ANKIB1 interacts with its substrates remains elusive. The generation of ANKIB1 Δ ANK1, ANKIB1 Δ ANK2, and ANKIB1 Δ ANK1-ANK2 mutants might provide key insights, given that Ankyrin repeats are primarily reported to mediate protein-protein interaction, thereof substrate recognition in other proteins³⁵³. Additionally, which specific E2 enzymes cooperate with ANKIB1 in physiological and signalling contexts remains to be elucidated, and an *in vitro* ubiquitination assay could be utilised to perform a comprehensive E2 enzyme screen. Biochemically, autoubiquitination of ANKIB1 was detected under steady-state conditions, which was further enhanced upon either TLR3 or STING stimulation. Nevertheless, this autoubiquitination was detectable only via TUBE pulldown and not in whole-cell lysates (Figure 5a, b), indicating that only a minor fraction of ANKIB1 undergoes autoubiquitination, both with and without stimuli. Whether the presence of this baseline autoubiquitination denotes a catalytically active state for ANKIB1 remains unclear; if validated, the molecular function of ANKIB1 in the absence of stimuli must be investigated. Finally, although ANKIB1 is capable of generating K6-linked ubiquitin chains (Figure 2e), the functional role of ANKIB1-dependent K6-ubiquitination—either within these respective signalling pathways or independent homeostatic signalling—remains to be determined.

In summary, a previously unrecognised ANKIB1–K11-Ub–OPTN–TBK1 signalling axis is defined herein as a master driver of IRF3-mediated IFN-I/III induction downstream of TLR3, TLR4, and cGAS–STING (Extended Data Fig. 5j). Reflecting its physiological importance, the deletion of ANKIB1 confers significant protection in an otherwise lethal mouse model of TLR3-dependent interferonopathy, and ANKIB1 is required to mount a cGAS–STING-mediated antiviral immune response upon HSV-1 infection. Consequently, future therapeutic strategies directed at inhibiting the catalytic function of ANKIB1 or inducing its targeted degradation may offer promising avenues for the treatment of IFN-driven pathologies.

5 References

1. Walsh, C.T., Garneau-Tsodikova, S. & Gatto, G.J., Jr. Protein posttranslational modifications: the chemistry of proteome diversifications. *Angew Chem Int Ed Engl* **44**, 7342–7372 (2005).
2. Varshavsky, A. The early history of the ubiquitin field. *Protein Sci* **15**, 647–654 (2006).
3. Clague, M.J., Heride, C. & Urbe, S. The demographics of the ubiquitin system. *Trends Cell Biol* **25**, 417–426 (2015).
4. Ciechanover, A., Elias, S., Heller, H., Ferber, S. & Hershko, A. Characterization of the heat-stable polypeptide of the ATP-dependent proteolytic system from reticulocytes. *J Biol Chem* **255**, 7525–7528 (1980).
5. Ciechanover, A., Heller, H., Elias, S., Haas, A.L. & Hershko, A. ATP-dependent conjugation of reticulocyte proteins with the polypeptide required for protein degradation. *Proc Natl Acad Sci U S A* **77**, 1365–1368 (1980).
6. Wilkinson, K.D. The discovery of ubiquitin-dependent proteolysis. *Proc Natl Acad Sci U S A* **102**, 15280–15282 (2005).
7. Goldstein, G. *et al.* Isolation of a polypeptide that has lymphocyte-differentiating properties and is probably represented universally in living cells. *Proc Natl Acad Sci U S A* **72**, 11–15 (1975).
8. Wilkinson, K.D., Urban, M.K. & Haas, A.L. Ubiquitin is the ATP-dependent proteolysis factor I of rabbit reticulocytes. *J Biol Chem* **255**, 7529–7532 (1980).
9. Thrower, J.S., Hoffman, L., Rechsteiner, M. & Pickart, C.M. Recognition of the polyubiquitin proteolytic signal. *EMBO J* **19**, 94–102 (2000).
10. Callis, J. The ubiquitination machinery of the ubiquitin system. *Arabidopsis Book* **12**, e0174 (2014).
11. Kliza, K. & Husnjak, K. Resolving the Complexity of Ubiquitin Networks. *Front Mol Biosci* **7**, 21 (2020).
12. Messick, T.E. & Greenberg, R.A. The ubiquitin landscape at DNA double-strand breaks. *J Cell Biol* **187**, 319–326 (2009).
13. Vijay-Kumar, S., Bugg, C.E. & Cook, W.J. Structure of ubiquitin refined at 1.8 Å resolution. *J Mol Biol* **194**, 531–544 (1987).
14. Pickart, C.M. & Eddins, M.J. Ubiquitin: structures, functions, mechanisms. *Biochim Biophys Acta* **1695**, 55–72 (2004).
15. Swatek, K.N. & Komander, D. Ubiquitin modifications. *Cell Res* **26**, 399–422 (2016).
16. Xie, W. *et al.* Selective autophagy controls the stability of TBK1 via NEDD4 to balance host defense. *Cell Death Differ* **29**, 40–53 (2022).
17. Liu, Z. *et al.* Ubiquitylation of autophagy receptor Optineurin by HACE1 activates selective autophagy for tumor suppression. *Cancer Cell* **26**, 106–120 (2014).
18. Besche, H.C. *et al.* Autoubiquitination of the 26S proteasome on Rpn13 regulates breakdown of ubiquitin conjugates. *EMBO J* **33**, 1159–1176 (2014).
19. Yuan, W.C. *et al.* K33-Linked Polyubiquitination of Coronin 7 by Cul3-KLHL20 Ubiquitin E3 Ligase Regulates Protein Trafficking. *Mol Cell* **54**, 586–600 (2014).
20. Matsumoto, M.L. *et al.* K11-linked polyubiquitination in cell cycle control revealed by a K11 linkage-specific antibody. *Mol Cell* **39**, 477–484 (2010).
21. Xu, P. *et al.* Quantitative proteomics reveals the function of unconventional ubiquitin chains in proteasomal degradation. *Cell* **137**, 133–145 (2009).
22. Dynek, J.N. *et al.* c-IAP1 and Ubch5 promote K11-linked polyubiquitination of RIP1 in TNF signalling. *EMBO J* **29**, 4198–4209 (2010).

23. Draczkowski, P. *et al.* Structural basis of K11/K48-branched ubiquitin chain recognition by the human 26S proteasome. *Nat Commun* **16**, 9094 (2025).
24. Grice, G.L. *et al.* The Proteasome Distinguishes between Heterotypic and Homotypic Lysine-11-Linked Polyubiquitin Chains. *Cell Rep* **12**, 545–553 (2015).
25. Goto, E. *et al.* Contribution of lysine 11-linked ubiquitination to MIR2-mediated major histocompatibility complex class I internalization. *J Biol Chem* **285**, 35311–35319 (2010).
26. Gomez-Diaz, C. & Ikeda, F. Roles of ubiquitin in autophagy and cell death. *Semin Cell Dev Biol* **93**, 125–135 (2019).
27. Schulman, B.A. & Harper, J.W. Ubiquitin-like protein activation by E1 enzymes: the apex for downstream signalling pathways. *Nat Rev Mol Cell Biol* **10**, 319–331 (2009).
28. Damgaard, R.B. The ubiquitin system: from cell signalling to disease biology and new therapeutic opportunities. *Cell Death Differ* **28**, 423–426 (2021).
29. Groen, E.J.N. & Gillingwater, T.H. UBA1: At the Crossroads of Ubiquitin Homeostasis and Neurodegeneration. *Trends Mol Med* **21**, 622–632 (2015).
30. Gavin, J.M. *et al.* Mechanistic studies on activation of ubiquitin and di-ubiquitin-like protein, FAT10, by ubiquitin-like modifier activating enzyme 6, Uba6. *J Biol Chem* **287**, 15512–15522 (2012).
31. Stewart, M.D., Ritterhoff, T., Klevit, R.E. & Brzovic, P.S. E2 enzymes: more than just middle men. *Cell Res* **26**, 423–440 (2016).
32. Chua, N.K. *et al.* The E3-ome gene-centric compendium reveals the human E3 ligase landscape. *Cell* **189**, 2167–2188 e2127 (2026).
33. EngibodyBiotechnology, Vol. 2026 <https://engibody.com/products/Anti-UBA1-Antibody-AT15005.html> (2026).
34. Komander, D. & Rape, M. The ubiquitin code. *Annu Rev Biochem* **81**, 203–229 (2012).
35. Ohtake, F. *et al.* Ubiquitin acetylation inhibits polyubiquitin chain elongation. *EMBO Rep* **16**, 192–201 (2015).
36. Wauer, T. *et al.* Ubiquitin Ser65 phosphorylation affects ubiquitin structure, chain assembly and hydrolysis. *EMBO J* **34**, 307–325 (2015).
37. Swaney, D.L., Rodriguez-Mias, R.A. & Villen, J. Phosphorylation of ubiquitin at Ser65 affects its polymerization, targets, and proteome-wide turnover. *EMBO Rep* **16**, 1131–1144 (2015).
38. Hershko, A., Heller, H., Elias, S. & Ciechanover, A. Components of ubiquitin-protein ligase system. Resolution, affinity purification, and role in protein breakdown. *J Biol Chem* **258**, 8206–8214 (1983).
39. Bartel, B., Wunning, I. & Varshavsky, A. The recognition component of the N-end rule pathway. *EMBO J* **9**, 3179–3189 (1990).
40. Metzger, M.B., Hristova, V.A. & Weissman, A.M. HECT and RING finger families of E3 ubiquitin ligases at a glance. *J Cell Sci* **125**, 531–537 (2012).
41. Aravind, L. & Koonin, E.V. The U box is a modified RING finger - a common domain in ubiquitination. *Curr Biol* **10**, R132–134 (2000).
42. Christensen, D.E., Brzovic, P.S. & Klevit, R.E. E2-BRCA1 RING interactions dictate synthesis of mono- or specific polyubiquitin chain linkages. *Nat Struct Mol Biol* **14**, 941–948 (2007).
43. Williamson, A. *et al.* Identification of a physiological E2 module for the human anaphase-promoting complex. *Proc Natl Acad Sci U S A* **106**, 18213–18218 (2009).
44. Rotin, D. & Kumar, S. Physiological functions of the HECT family of ubiquitin ligases. *Nat Rev Mol Cell Biol* **10**, 398–409 (2009).
45. Pickart, C.M. Mechanisms underlying ubiquitination. *Annu Rev Biochem* **70**, 503–533 (2001).
46. Dove, K.K., Stieglitz, B., Duncan, E.D., Rittinger, K. & Klevit, R.E. Molecular insights into RBR E3 ligase ubiquitin transfer mechanisms. *EMBO Rep* **17**, 1221–1235 (2016).

47. Smit, J.J. *et al.* The E3 ligase HOIP specifies linear ubiquitin chain assembly through its RING-IBR-RING domain and the unique LDD extension. *EMBO J* **31**, 3833–3844 (2012).
48. Tokunaga, F. *et al.* SHARPIN is a component of the NF-kappaB-activating linear ubiquitin chain assembly complex. *Nature* **471**, 633–636 (2011).
49. Dove, K.K. & Klevit, R.E. RING-Between-RING E3 Ligases: Emerging Themes amid the Variations. *J Mol Biol* **429**, 3363–3375 (2017).
50. Smit, J.J. & Sixma, T.K. RBR E3-ligases at work. *EMBO Rep* **15**, 142–154 (2014).
51. Wenzel, D.M. & Klevit, R.E. Following Ariadne's thread: a new perspective on RBR ubiquitin ligases. *BMC Biol* **10**, 24 (2012).
52. Lee, D., Kim, M. & Cho, K.H. A design principle underlying the paradoxical roles of E3 ubiquitin ligases. *Sci Rep* **4**, 5573 (2014).
53. Hu, H. & Sun, S.C. Ubiquitin signaling in immune responses. *Cell Res* **26**, 457–483 (2016).
54. Snyder, N.A. & Silva, G.M. Deubiquitinating enzymes (DUBs): Regulation, homeostasis, and oxidative stress response. *J Biol Chem* **297**, 101077 (2021).
55. Lange, S.M., Armstrong, L.A. & Kulathu, Y. Deubiquitinases: From mechanisms to their inhibition by small molecules. *Mol Cell* **82**, 15–29 (2022).
56. Gersch, M. *et al.* Mechanism and regulation of the Lys6-selective deubiquitinase USP30. *Nat Struct Mol Biol* **24**, 920–930 (2017).
57. Sato, Y. *et al.* Structural basis for specific cleavage of Lys6-linked polyubiquitin chains by USP30. *Nat Struct Mol Biol* **24**, 911–919 (2017).
58. Abdul Rehman, S.A. *et al.* Mechanism of activation and regulation of deubiquitinase activity in MINDY1 and MINDY2. *Mol Cell* **81**, 4176–4190 e4176 (2021).
59. Ambroggio, X.I., Rees, D.C. & Deshaies, R.J. JAMM: a metalloprotease-like zinc site in the proteasome and signalosome. *PLoS Biol* **2**, E2 (2004).
60. Keusekotten, K. *et al.* OTULIN antagonizes LUBAC signaling by specifically hydrolyzing Met1-linked polyubiquitin. *Cell* **153**, 1312–1326 (2013).
61. Sato, Y. *et al.* Structures of CYLD USP with Met1- or Lys63-linked diubiquitin reveal mechanisms for dual specificity. *Nat Struct Mol Biol* **22**, 222–229 (2015).
62. Bingol, B. *et al.* The mitochondrial deubiquitinase USP30 opposes parkin-mediated mitophagy. *Nature* **510**, 370–375 (2014).
63. McCullough, J., Clague, M.J. & Urbe, S. AMSH is an endosome-associated ubiquitin isopeptidase. *J Cell Biol* **166**, 487–492 (2004).
64. Boone, D.L. *et al.* The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. *Nat Immunol* **5**, 1052–1060 (2004).
65. Bonacci, T. *et al.* Cezanne/OTUD7B is a cell cycle-regulated deubiquitinase that antagonizes the degradation of APC/C substrates. *EMBO J* **37** (2018).
66. Bremm, A., Moniz, S., Mader, J., Rocha, S. & Komander, D. Cezanne (OTUD7B) regulates HIF-1alpha homeostasis in a proteasome-independent manner. *EMBO Rep* **15**, 1268–1277 (2014).
67. Amarante-Mendes, G.P. *et al.* Pattern Recognition Receptors and the Host Cell Death Molecular Machinery. *Front Immunol* **9**, 2379 (2018).
68. Chan, F.K. Three is better than one: pre-ligand receptor assembly in the regulation of TNF receptor signaling. *Cytokine* **37**, 101–107 (2007).
69. Peltzer, N. & Walczak, H. Cell Death and Inflammation - A Vital but Dangerous Liaison. *Trends Immunol* **40**, 387–402 (2019).
70. Dondelinger, Y., Darding, M., Bertrand, M.J. & Walczak, H. Poly-ubiquitination in TNFR1-mediated necroptosis. *Cell Mol Life Sci* **73**, 2165–2176 (2016).
71. Silke, J. & Meier, P. Inhibitor of apoptosis (IAP) proteins-modulators of cell death and inflammation. *Cold Spring Harb Perspect Biol* **5** (2013).
72. Haas, T.L. *et al.* Recruitment of the linear ubiquitin chain assembly complex stabilizes the TNF-R1 signaling complex and is required for TNF-mediated gene induction. *Mol Cell* **36**, 831–844 (2009).

73. Gerlach, B. *et al.* Linear ubiquitination prevents inflammation and regulates immune signalling. *Nature* **471**, 591–596 (2011).
74. Webster, J.D. & Vucic, D. The Balance of TNF Mediated Pathways Regulates Inflammatory Cell Death Signaling in Healthy and Diseased Tissues. *Front Cell Dev Biol* **8**, 365 (2020).
75. Morrison, D.K. MAP kinase pathways. *Cold Spring Harb Perspect Biol* **4** (2012).
76. Tang, Y. *et al.* K63-linked ubiquitination regulates RIPK1 kinase activity to prevent cell death during embryogenesis and inflammation. *Nat Commun* **10**, 4157 (2019).
77. Totzke, J., Scarneo, S.A., Yang, K.W. & Haystead, T.A.J. TAK1: a potent tumour necrosis factor inhibitor for the treatment of inflammatory diseases. *Open Biol* **10**, 200099 (2020).
78. Herhaus, L. *et al.* Molecular Recognition of M1-Linked Ubiquitin Chains by Native and Phosphorylated UBA Domains. *J Mol Biol* **431**, 3146–3156 (2019).
79. Lafont, E. *et al.* TBK1 and IKKepsilon prevent TNF-induced cell death by RIPK1 phosphorylation. *Nat Cell Biol* **20**, 1389–1399 (2018).
80. Zhang, J., Clark, K., Lawrence, T., Pegg, M.W. & Cohen, P. An unexpected twist to the activation of IKKbeta: TAK1 primes IKKbeta for activation by autophosphorylation. *Biochem J* **461**, 531–537 (2014).
81. Kirisako, T. *et al.* A ubiquitin ligase complex assembles linear polyubiquitin chains. *EMBO J* **25**, 4877–4887 (2006).
82. Ujevic, A. *et al.* TBK1-associated adapters TANK and AZI2 protect mice against TNF-induced cell death and severe autoinflammatory diseases. *Nat Commun* **15**, 10013 (2024).
83. Micheau, O. & Tschopp, J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. *Cell* **114**, 181–190 (2003).
84. Feoktistova, M., Geserick, P. & Leverkus, M. Ripoptosome Analysis by Caspase-8 Coimmunoprecipitation. *Cold Spring Harb Protoc* **2016**, pdb prot087403 (2016).
85. Cho, Y.S. *et al.* Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. *Cell* **137**, 1112–1123 (2009).
86. He, S. *et al.* Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha. *Cell* **137**, 1100–1111 (2009).
87. Wu, J. *et al.* Mlkl knockout mice demonstrate the indispensable role of Mlkl in necroptosis. *Cell Res* **23**, 994–1006 (2013).
88. Upton, J.W., Kaiser, W.J. & Mocarski, E.S. Virus inhibition of RIP3-dependent necrosis. *Cell Host Microbe* **7**, 302–313 (2010).
89. Kaiser, W.J. *et al.* Toll-like receptor 3-mediated necrosis via TRIF, RIP3, and MLKL. *J Biol Chem* **288**, 31268–31279 (2013).
90. Feng, S. *et al.* Cleavage of RIP3 inactivates its caspase-independent apoptosis pathway by removal of kinase domain. *Cell Signal* **19**, 2056–2067 (2007).
91. Lin, Y., Devin, A., Rodriguez, Y. & Liu, Z.G. Cleavage of the death domain kinase RIP by caspase-8 prompts TNF-induced apoptosis. *Genes Dev* **13**, 2514–2526 (1999).
92. Feoktistova, M. *et al.* cIAPs block Ripoptosome formation, a RIP1/caspase-8 containing intracellular cell death complex differentially regulated by cFLIP isoforms. *Mol Cell* **43**, 449–463 (2011).
93. Weinlich, R. & Green, D.R. The two faces of receptor interacting protein kinase-1. *Mol Cell* **56**, 469–480 (2014).
94. Jaco, I. *et al.* MK2 Phosphorylates RIPK1 to Prevent TNF-Induced Cell Death. *Mol Cell* **66**, 698–710 e695 (2017).
95. Xu, D. *et al.* TBK1 Suppresses RIPK1-Driven Apoptosis and Inflammation during Development and in Aging. *Cell* **174**, 1477–1491 e1419 (2018).
96. Dondelinger, Y. *et al.* NF-kappaB-Independent Role of IKKalpha/IKKbeta in Preventing RIPK1 Kinase-Dependent Apoptotic and Necroptotic Cell Death during TNF Signaling. *Mol Cell* **60**, 63–76 (2015).

97. Komander, D., Clague, M.J. & Urbe, S. Breaking the chains: structure and function of the deubiquitinases. *Nat Rev Mol Cell Biol* **10**, 550–563 (2009).
98. Draber, P. *et al.* LUBAC-Recruited CYLD and A20 Regulate Gene Activation and Cell Death by Exerting Opposing Effects on Linear Ubiquitin in Signaling Complexes. *Cell Rep* **13**, 2258–2272 (2015).
99. Kupka, S., Reichert, M., Draber, P. & Walczak, H. Formation and removal of poly-ubiquitin chains in the regulation of tumor necrosis factor-induced gene activation and cell death. *FEBS J* **283**, 2626–2639 (2016).
100. Heger, K. *et al.* OTULIN limits cell death and inflammation by deubiquitinating LUBAC. *Nature* **559**, 120–124 (2018).
101. Takeuchi, O. & Akira, S. Pattern recognition receptors and inflammation. *Cell* **140**, 805–820 (2010).
102. Akira, S., Uematsu, S. & Takeuchi, O. Pathogen recognition and innate immunity. *Cell* **124**, 783–801 (2006).
103. Chen, R. *et al.* Pattern recognition receptors: function, regulation and therapeutic potential. *Signal Transduct Target Ther* **10**, 216 (2025).
104. Ohto, U. Activation and regulation mechanisms of NOD-like receptors based on structural biology. *Front Immunol* **13**, 953530 (2022).
105. Lu, Y. *et al.* Palmitoylation of NOD1 and NOD2 is required for bacterial sensing. *Science* **366**, 460–467 (2019).
106. Almeida-da-Silva, C.L.C., Savio, L.E.B., Coutinho-Silva, R. & Ojcius, D.M. The role of NOD-like receptors in innate immunity. *Front Immunol* **14**, 1122586 (2023).
107. Kienes, I. *et al.* DDX3X Links NLRP11 to the Regulation of Type I Interferon Responses and NLRP3 Inflammasome Activation. *Front Immunol* **12**, 653883 (2021).
108. Shi, J. *et al.* Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. *Nature* **526**, 660–665 (2015).
109. Yu, D. *et al.* The role of AIM2 in inflammation and tumors. *Front Immunol* **15**, 1466440 (2024).
110. Du, L., Wang, X., Chen, S. & Guo, X. The AIM2 inflammasome: A novel biomarker and target in cardiovascular disease. *Pharmacol Res* **186**, 106533 (2022).
111. Kang, R. *et al.* The Receptor for Advanced Glycation End Products Activates the AIM2 Inflammasome in Acute Pancreatitis. *J Immunol* **196**, 4331–4337 (2016).
112. Li, D. & Wu, M. Pattern recognition receptors in health and diseases. *Signal Transduct Target Ther* **6**, 291 (2021).
113. Ariizumi, K. *et al.* Identification of a novel, dendritic cell-associated molecule, dectin-1, by subtractive cDNA cloning. *J Biol Chem* **275**, 20157–20167 (2000).
114. Brown, G.D. & Gordon, S. Immune recognition. A new receptor for beta-glucans. *Nature* **413**, 36–37 (2001).
115. Li, K. & Underhill, D.M. C-Type Lectin Receptors in Phagocytosis. *Curr Top Microbiol Immunol* **429**, 1–18 (2020).
116. Brown, G.D., Willment, J.A. & Whitehead, L. C-type lectins in immunity and homeostasis. *Nat Rev Immunol* **18**, 374–389 (2018).
117. Sancho, D. & Reis e Sousa, C. Signaling by myeloid C-type lectin receptors in immunity and homeostasis. *Annu Rev Immunol* **30**, 491–529 (2012).
118. Reis e Sousa, C., Yamasaki, S. & Brown, G.D. Myeloid C-type lectin receptors in innate immune recognition. *Immunity* **57**, 700–717 (2024).
119. Wu, Y. *et al.* Spatiotemporal Immune Landscape of Colorectal Cancer Liver Metastasis at Single-Cell Level. *Cancer Discov* **12**, 134–153 (2022).
120. Brennan, J.J. & Gilmore, T.D. Evolutionary Origins of Toll-like Receptor Signaling. *Mol Biol Evol* **35**, 1576–1587 (2018).
121. Kim, H.J., Kim, H., Lee, J.H. & Hwangbo, C. Toll-like receptor 4 (TLR4): new insight immune and aging. *Immun Ageing* **20**, 67 (2023).

122. Costa, C. *et al.* Triggering Toll-Like Receptor 5 Signaling During Pneumococcal Superinfection Prevents the Selection of Antibiotic Resistance. *J Infect Dis* **230**, e1126–e1135 (2024).
123. Zinngrebe, J. *et al.* --LUBAC deficiency perturbs TLR3 signaling to cause immunodeficiency and autoinflammation. *J Exp Med* **213**, 2671–2689 (2016).
124. Lester, S.N. & Li, K. Toll-like receptors in antiviral innate immunity. *J Mol Biol* **426**, 1246–1264 (2014).
125. Ohto, U. *et al.* Structural basis of CpG and inhibitory DNA recognition by Toll-like receptor 9. *Nature* **520**, 702–705 (2015).
126. Kim, Y.M., Brinkmann, M.M., Paquet, M.E. & Ploegh, H.L. UNC93B1 delivers nucleotide-sensing toll-like receptors to endolysosomes. *Nature* **452**, 234–238 (2008).
127. Qi, R., Singh, D. & Kao, C.C. Proteolytic processing regulates Toll-like receptor 3 stability and endosomal localization. *J Biol Chem* **287**, 32617–32629 (2012).
128. Garcia-Cattaneo, A. *et al.* Cleavage of Toll-like receptor 3 by cathepsins B and H is essential for signaling. *Proc Natl Acad Sci U S A* **109**, 9053–9058 (2012).
129. Funami, K. *et al.* The cytoplasmic 'linker region' in Toll-like receptor 3 controls receptor localization and signaling. *Int Immunol* **16**, 1143–1154 (2004).
130. de Bouteiller, O. *et al.* Recognition of double-stranded RNA by human toll-like receptor 3 and downstream receptor signaling requires multimerization and an acidic pH. *J Biol Chem* **280**, 38133–38145 (2005).
131. Tatematsu, M. *et al.* A molecular mechanism for Toll-IL-1 receptor domain-containing adaptor molecule-1-mediated IRF-3 activation. *J Biol Chem* **285**, 20128–20136 (2010).
132. Chen, Y., Lin, J., Zhao, Y., Ma, X. & Yi, H. Toll-like receptor 3 (TLR3) regulation mechanisms and roles in antiviral innate immune responses. *J Zhejiang Univ Sci B* **22**, 609–632 (2021).
133. Xie, P. TRAF molecules in cell signaling and in human diseases. *J Mol Signal* **8**, 7 (2013).
134. Oganessian, G. *et al.* Critical role of TRAF3 in the Toll-like receptor-dependent and -independent antiviral response. *Nature* **439**, 208–211 (2006).
135. Sasai, M. *et al.* Direct binding of TRAF2 and TRAF6 to TICAM-1/TRIF adaptor participates in activation of the Toll-like receptor 3/4 pathway. *Mol Immunol* **47**, 1283–1291 (2010).
136. Jiang, Z., Mak, T.W., Sen, G. & Li, X. Toll-like receptor 3-mediated activation of NF-kappaB and IRF3 diverges at Toll-IL-1 receptor domain-containing adapter inducing IFN-beta. *Proc Natl Acad Sci U S A* **101**, 3533–3538 (2004).
137. Xie, X. *et al.* Cell type-specific function of TRAF2 and TRAF3 in regulating type I IFN induction. *Cell Biosci* **9**, 5 (2019).
138. Ajibade, A.A., Wang, H.Y. & Wang, R.F. Cell type-specific function of TAK1 in innate immune signaling. *Trends Immunol* **34**, 307–316 (2013).
139. Chang, M., Jin, W. & Sun, S.C. Peli1 facilitates TRIF-dependent Toll-like receptor signaling and proinflammatory cytokine production. *Nat Immunol* **10**, 1089–1095 (2009).
140. Emmerich, C.H. *et al.* Lys63/Met1-hybrid ubiquitin chains are commonly formed during the activation of innate immune signalling. *Biochem Biophys Res Commun* **474**, 452–461 (2016).
141. Guo, B. & Cheng, G. Modulation of the interferon antiviral response by the TBK1/IKKi adaptor protein TANK. *J Biol Chem* **282**, 11817–11826 (2007).
142. Song, G. *et al.* E3 ubiquitin ligase RNF128 promotes innate antiviral immunity through K63-linked ubiquitination of TBK1. *Nat Immunol* **17**, 1342–1351 (2016).
143. Liu, S. *et al.* Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation. *Science* **347**, aaa2630 (2015).
144. Mori, M. *et al.* Identification of Ser-386 of interferon regulatory factor 3 as critical target for inducible phosphorylation that determines activation. *J Biol Chem* **279**, 9698–9702 (2004).
145. Kawasaki, T. & Kawai, T. Toll-like receptor signaling pathways. *Front Immunol* **5**, 461 (2014).

146. Zhao, B. *et al.* Structural basis for concerted recruitment and activation of IRF-3 by innate immune adaptor proteins. *Proc Natl Acad Sci U S A* **113**, E3403–3412 (2016).
147. Necker-Brown, A. *et al.* Inducible gene expression of I κ B-kinase epsilon is dependent on nuclear factor-kappaB in human pulmonary epithelial cells. *Biochem J* **481**, 959–980 (2024).
148. Bakshi, S., Taylor, J., Strickson, S., McCartney, T. & Cohen, P. Identification of TBK1 complexes required for the phosphorylation of IRF3 and the production of interferon beta. *Biochem J* **474**, 1163–1174 (2017).
149. Fukasaka, M. *et al.* Critical role of AZI2 in GM-CSF-induced dendritic cell differentiation. *J Immunol* **190**, 5702–5711 (2013).
150. Ryzhakov, G. & Randow, F. SINTBAD, a novel component of innate antiviral immunity, shares a TBK1-binding domain with NAP1 and TANK. *EMBO J* **26**, 3180–3190 (2007).
151. Gleason, C.E., Ordureau, A., Gourlay, R., Arthur, J.S.C. & Cohen, P. Polyubiquitin binding to optineurin is required for optimal activation of TANK-binding kinase 1 and production of interferon beta. *J Biol Chem* **286**, 35663–35674 (2011).
152. Zhang, M. *et al.* TRAF-interacting protein (TRIP) negatively regulates IFN-beta production and antiviral response by promoting proteasomal degradation of TANK-binding kinase 1. *J Exp Med* **209**, 1703–1711 (2012).
153. Saitoh, T. *et al.* A20 is a negative regulator of IFN regulatory factor 3 signaling. *J Immunol* **174**, 1507–1512 (2005).
154. Kayagaki, N. *et al.* DUBA: a deubiquitinase that regulates type I interferon production. *Science* **318**, 1628–1632 (2007).
155. Wu, X. *et al.* Regulation of TRIF-mediated innate immune response by K27-linked polyubiquitination and deubiquitination. *Nat Commun* **10**, 4115 (2019).
156. Cao, Y., Sun, Y., Chang, H., Sun, X. & Yang, S. The E3 ubiquitin ligase RNF182 inhibits TLR-triggered cytokine production through promoting p65 ubiquitination and degradation. *FEBS Lett* **593**, 3210–3219 (2019).
157. Estornes, Y. *et al.* dsRNA induces apoptosis through an atypical death complex associating TLR3 to caspase-8. *Cell Death Differ* **19**, 1482–1494 (2012).
158. Newton, K. RIPK1 and RIPK3: critical regulators of inflammation and cell death. *Trends Cell Biol* **25**, 347–353 (2015).
159. Rebsamen, M., Meylan, E., Curran, J. & Tschopp, J. The antiviral adaptor proteins Cardif and Trif are processed and inactivated by caspases. *Cell Death Differ* **15**, 1804–1811 (2008).
160. Kuzmich, N.N. *et al.* TLR4 Signaling Pathway Modulators as Potential Therapeutics in Inflammation and Sepsis. *Vaccines (Basel)* **5** (2017).
161. Bai, Y. *et al.* ER-resident CCDC134 safeguards TLR4 maturation by maintaining gp96 stability. *Proc Natl Acad Sci U S A* **122**, e2512154122 (2025).
162. Wakabayashi, Y. *et al.* A protein associated with toll-like receptor 4 (PRAT4A) regulates cell surface expression of TLR4. *J Immunol* **177**, 1772–1779 (2006).
163. Tsukamoto, H., Fukudome, K., Takao, S., Tsuneyoshi, N. & Kimoto, M. Lipopolysaccharide-binding protein-mediated Toll-like receptor 4 dimerization enables rapid signal transduction against lipopolysaccharide stimulation on membrane-associated CD14-expressing cells. *Int Immunol* **22**, 271–280 (2010).
164. Zanoni, I. *et al.* CD14 controls the LPS-induced endocytosis of Toll-like receptor 4. *Cell* **147**, 868–880 (2011).
165. Kawagoe, T. *et al.* Sequential control of Toll-like receptor-dependent responses by IRAK1 and IRAK2. *Nat Immunol* **9**, 684–691 (2008).
166. Pereira, M. *et al.* The IRAK4 scaffold integrates TLR4-driven TRIF and MYD88 signaling pathways. *Cell Rep* **40**, 111225 (2022).
167. Ikeda, F. *et al.* SHARPIN forms a linear ubiquitin ligase complex regulating NF-kappaB activity and apoptosis. *Nature* **471**, 637–641 (2011).

168. Sasaki, Y. *et al.* Defective immune responses in mice lacking LUBAC-mediated linear ubiquitination in B cells. *EMBO J* **32**, 2463–2476 (2013).
169. Stierschneider, A. & Wiesner, C. Shedding light on the molecular and regulatory mechanisms of TLR4 signaling in endothelial cells under physiological and inflamed conditions. *Front Immunol* **14**, 1264889 (2023).
170. Yamamoto, M. *et al.* Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. *Science* **301**, 640–643 (2003).
171. Zhong, B. *et al.* Ubiquitin-specific protease 25 regulates TLR4-dependent innate immune responses through deubiquitination of the adaptor protein TRAF3. *Sci Signal* **6**, ra35 (2013).
172. Tseng, P.H. *et al.* Different modes of ubiquitination of the adaptor TRAF3 selectively activate the expression of type I interferons and proinflammatory cytokines. *Nat Immunol* **11**, 70–75 (2010).
173. Clark, K., Takeuchi, O., Akira, S. & Cohen, P. The TRAF-associated protein TANK facilitates cross-talk within the I κ B kinase family during Toll-like receptor signaling. *Proc Natl Acad Sci USA* **108**, 17093–17098 (2011).
174. Clark, K. *et al.* Novel cross-talk within the IKK family controls innate immunity. *Biochem J* **434**, 93–104 (2011).
175. Saikh, K.U. MyD88 and beyond: a perspective on MyD88-targeted therapeutic approach for modulation of host immunity. *Immunol Res* **69**, 117–128 (2021).
176. Aziz, M., Jacob, A. & Wang, P. Revisiting caspases in sepsis. *Cell Death Dis* **5**, e1526 (2014).
177. Sarkar, A. *et al.* Caspase-1 regulates Escherichia coli sepsis and splenic B cell apoptosis independently of interleukin-1 β and interleukin-18. *Am J Respir Crit Care Med* **174**, 1003–1010 (2006).
178. Chen, R. *et al.* cAMP metabolism controls caspase-11 inflammasome activation and pyroptosis in sepsis. *Sci Adv* **5**, eaav5562 (2019).
179. Feng, Y. *et al.* MyD88 and Trif signaling play distinct roles in cardiac dysfunction and mortality during endotoxin shock and polymicrobial sepsis. *Anesthesiology* **115**, 555–567 (2011).
180. Vanden Berghe, T. *et al.* Simultaneous targeting of IL-1 and IL-18 is required for protection against inflammatory and septic shock. *Am J Respir Crit Care Med* **189**, 282–291 (2014).
181. Heipertz, E.L., Harper, J. & Walker, W.E. STING and TRIF Contribute to Mouse Sepsis, Depending on Severity of the Disease Model. *Shock* **47**, 621–631 (2017).
182. Thoresen, D. *et al.* The molecular mechanism of RIG-I activation and signaling. *Immunol Rev* **304**, 154–168 (2021).
183. Chiang, J.J. *et al.* Viral unmasking of cellular 5S rRNA pseudogene transcripts induces RIG-I-mediated immunity. *Nat Immunol* **19**, 53–62 (2018).
184. Choi, J.H. *et al.* DUSP11-mediated control of 5'-triphosphate RNA regulates RIG-I sensitivity. *Genes Dev* **34**, 1697–1712 (2020).
185. Cadena, C. *et al.* Ubiquitin-Dependent and -Independent Roles of E3 Ligase RIPLET in Innate Immunity. *Cell* **177**, 1187–1200 e1116 (2019).
186. Gack, M.U. *et al.* TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. *Nature* **446**, 916–920 (2007).
187. Sun, Z., Ren, H., Liu, Y., Teeling, J.L. & Gu, J. Phosphorylation of RIG-I by casein kinase II inhibits its antiviral response. *J Virol* **85**, 1036–1047 (2011).
188. Wies, E. *et al.* Dephosphorylation of the RNA sensors RIG-I and MDA5 by the phosphatase PP1 is essential for innate immune signaling. *Immunity* **38**, 437–449 (2013).
189. Lang, X. *et al.* TRIM65-catalized ubiquitination is essential for MDA5-mediated antiviral innate immunity. *J Exp Med* **214**, 459–473 (2017).
190. Rehwinkel, J. & Gack, M.U. RIG-I-like receptors: their regulation and roles in RNA sensing. *Nat Rev Immunol* **20**, 537–551 (2020).

191. Venkataraman, T. *et al.* Loss of DExD/H box RNA helicase LGP2 manifests disparate antiviral responses. *J Immunol* **178**, 6444–6455 (2007).
192. Ren, Z. *et al.* Regulation of MAVS Expression and Signaling Function in the Antiviral Innate Immune Response. *Front Immunol* **11**, 1030 (2020).
193. Liu, S. *et al.* MAVS recruits multiple ubiquitin E3 ligases to activate antiviral signaling cascades. *Elife* **2**, e00785 (2013).
194. Fang, R. *et al.* MAVS activates TBK1 and IKKepsilon through TRAFs in NEMO dependent and independent manner. *PLoS Pathog* **13**, e1006720 (2017).
195. Xue, B. *et al.* TRIM21 Promotes Innate Immune Response to RNA Viral Infection through Lys27-Linked Polyubiquitination of MAVS. *J Virol* **92** (2018).
196. Jin, S. *et al.* Tetherin Suppresses Type I Interferon Signaling by Targeting MAVS for NDP52-Mediated Selective Autophagic Degradation in Human Cells. *Mol Cell* **68**, 308–322 e304 (2017).
197. Zhong, B. *et al.* The E3 ubiquitin ligase RNF5 targets virus-induced signaling adaptor for ubiquitination and degradation. *J Immunol* **184**, 6249–6255 (2010).
198. Yoo, Y.S. *et al.* The mitochondrial ubiquitin ligase MARCH5 resolves MAVS aggregates during antiviral signalling. *Nat Commun* **6**, 7910 (2015).
199. Liu, W. *et al.* E3 ubiquitin ligase ANKIB1 attenuates antiviral immune responses by promoting K48-linked polyubiquitination of MAVS. *Cell Rep* **43**, 114687 (2024).
200. Rongvaux, A. *et al.* Apoptotic caspases prevent the induction of type I interferons by mitochondrial DNA. *Cell* **159**, 1563–1577 (2014).
201. Dvorkin, S., Cambier, S., Volkman, H.E. & Stetson, D.B. New frontiers in the cGAS-STING intracellular DNA-sensing pathway. *Immunity* **57**, 718–730 (2024).
202. Zhang, C. *et al.* Structural basis of STING binding with and phosphorylation by TBK1. *Nature* **567**, 394–398 (2019).
203. Zhao, B. *et al.* A conserved PLPLRT/SD motif of STING mediates the recruitment and activation of TBK1. *Nature* **569**, 718–722 (2019).
204. Hopfner, K.P. & Hornung, V. Molecular mechanisms and cellular functions of cGAS-STING signalling. *Nat Rev Mol Cell Biol* **21**, 501–521 (2020).
205. Abe, T. & Barber, G.N. Cytosolic-DNA-mediated, STING-dependent proinflammatory gene induction necessitates canonical NF-kappaB activation through TBK1. *J Virol* **88**, 5328–5341 (2014).
206. Balka, K.R. *et al.* TBK1 and IKKepsilon Act Redundantly to Mediate STING-Induced NF-kappaB Responses in Myeloid Cells. *Cell Rep* **31**, 107492 (2020).
207. Fang, R. *et al.* NEMO-IKKbeta Are Essential for IRF3 and NF-kappaB Activation in the cGAS-STING Pathway. *J Immunol* **199**, 3222–3233 (2017).
208. Ergun, S.L., Fernandez, D., Weiss, T.M. & Li, L. STING Polymer Structure Reveals Mechanisms for Activation, Hyperactivation, and Inhibition. *Cell* **178**, 290–301 e210 (2019).
209. Zhang, Y. *et al.* Spatiotemporal Regulation of STING Activity by Linear Ubiquitination Governs Antiviral Immunity. *Adv Sci (Weinh)* **12**, e2417660 (2025).
210. Gui, X. *et al.* Autophagy induction via STING trafficking is a primordial function of the cGAS pathway. *Nature* **567**, 262–266 (2019).
211. Fischer, T.D. *et al.* STING induces HOIP-mediated synthesis of M1 ubiquitin chains to stimulate NF-kappaB signaling. *EMBO J* **44**, 141–165 (2025).
212. Dobbs, N. *et al.* STING Activation by Translocation from the ER Is Associated with Infection and Autoinflammatory Disease. *Cell Host Microbe* **18**, 157–168 (2015).
213. Mukai, K. *et al.* Activation of STING requires palmitoylation at the Golgi. *Nat Commun* **7**, 11932 (2016).
214. Zhang, J., Hu, M.M., Wang, Y.Y. & Shu, H.B. TRIM32 protein modulates type I interferon induction and cellular antiviral response by targeting MITA/STING protein for K63-linked ubiquitination. *J Biol Chem* **287**, 28646–28655 (2012).

215. Wang, Q. *et al.* The E3 ubiquitin ligase AMFR and INSIG1 bridge the activation of TBK1 kinase by modifying the adaptor STING. *Immunity* **41**, 919–933 (2014).
216. Ni, G., Konno, H. & Barber, G.N. Ubiquitination of STING at lysine 224 controls IRF3 activation. *Sci Immunol* **2** (2017).
217. Qin, Y. *et al.* RNF26 temporally regulates virus-triggered type I interferon induction by two distinct mechanisms. *PLoS Pathog* **10**, e1004358 (2014).
218. Zhang, L. *et al.* The deubiquitinase CYLD is a specific checkpoint of the STING antiviral signaling pathway. *PLoS Pathog* **14**, e1007435 (2018).
219. Prabakaran, T. *et al.* Attenuation of cGAS-STING signaling is mediated by a p62/SQSTM1-dependent autophagy pathway activated by TBK1. *EMBO J* **37** (2018).
220. Liu, B. *et al.* Human STING is a proton channel. *Science* **381**, 508–514 (2023).
221. Corrales, L. *et al.* Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. *Cell Rep* **11**, 1018–1030 (2015).
222. Decout, A., Katz, J.D., Venkatraman, S. & Ablasser, A. The cGAS-STING pathway as a therapeutic target in inflammatory diseases. *Nat Rev Immunol* **21**, 548–569 (2021).
223. Demaria, O. *et al.* STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity. *Proc Natl Acad Sci U S A* **112**, 15408–15413 (2015).
224. Wang, H. *et al.* cGAS is essential for the antitumor effect of immune checkpoint blockade. *Proc Natl Acad Sci U S A* **114**, 1637–1642 (2017).
225. Nagano, Y. & Kojima, Y. [Immunizing property of vaccinia virus inactivated by ultraviolet rays]. *C R Seances Soc Biol Fil* **148**, 1700–1702 (1954).
226. Isaacs, A. & Lindenmann, J. Virus interference. I. The interferon. *Proc R Soc Lond B Biol Sci* **147**, 258–267 (1957).
227. Isaacs, A., Lindenmann, J. & Valentine, R.C. Virus interference. II. Some properties of interferon. *Proc R Soc Lond B Biol Sci* **147**, 268–273 (1957).
228. Boehmer, D. & Zanoni, I. Interferons in health and disease. *Cell* **188**, 4480–4504 (2025).
229. Li, S.F. *et al.* Type I Interferons: Distinct Biological Activities and Current Applications for Viral Infection. *Cell Physiol Biochem* **51**, 2377–2396 (2018).
230. Chuah, J.J.M. & Campbell, N.K. IFNepsilon, IFNomega and IFNlambda: interferons defending the mucosa. *Curr Opin Immunol* **89**, 102456 (2024).
231. Hermant, P., Francius, C., Clotman, F. & Michiels, T. IFN-epsilon is constitutively expressed by cells of the reproductive tract and is inefficiently secreted by fibroblasts and cell lines. *PLoS One* **8**, e71320 (2013).
232. Fung, K.Y. *et al.* Expression of Interferon Epsilon in Mucosal Epithelium is Regulated by Elf3. *Mol Cell Biol* **44**, 334–343 (2024).
233. Harris, B.D., Schreiter, J., Chevrier, M., Jordan, J.L. & Walter, M.R. Human interferon- ϵ and interferon-kappa exhibit low potency and low affinity for cell-surface IFNAR and the poxvirus antagonist B18R. *J Biol Chem* **293**, 16057–16068 (2018).
234. Klein, K., Habiger, C., Iftner, T. & Stubenrauch, F. A TGF-beta- and p63-Responsive Enhancer Regulates IFN-kappa Expression in Human Keratinocytes. *J Immunol* **204**, 1825–1835 (2020).
235. Hillyer, P. *et al.* Expression profiles of human interferon-alpha and interferon-lambda subtypes are ligand- and cell-dependent. *Immunol Cell Biol* **90**, 774–783 (2012).
236. Ngo, C., Garrec, C., Tomasello, E. & Dalod, M. The role of plasmacytoid dendritic cells (pDCs) in immunity during viral infections and beyond. *Cell Mol Immunol* **21**, 1008–1035 (2024).
237. Dowling, J.W. & Forero, A. Beyond Good and Evil: Molecular Mechanisms of Type I and III IFN Functions. *J Immunol* **208**, 247–256 (2022).
238. Honda, K., Takaoka, A. & Taniguchi, T. Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors. *Immunity* **25**, 349–360 (2006).
239. Russell-Harde, D. *et al.* Reconstitution of a high affinity binding site for type I interferons. *J Biol Chem* **270**, 26033–26036 (1995).

240. Negishi, H., Taniguchi, T. & Yanai, H. The Interferon (IFN) Class of Cytokines and the IFN Regulatory Factor (IRF) Transcription Factor Family. *Cold Spring Harb Perspect Biol* **10** (2018).
241. Iversen, M.B. & Paludan, S.R. Mechanisms of type III interferon expression. *J Interferon Cytokine Res* **30**, 573–578 (2010).
242. Mishra, B. *et al.* IL-10 targets IRF transcription factors to suppress IFN and inflammatory response genes by epigenetic mechanisms. *Nat Immunol* **26**, 748–759 (2025).
243. Lazear, H.M. *et al.* IRF-3, IRF-5, and IRF-7 coordinately regulate the type I IFN response in myeloid dendritic cells downstream of MAVS signaling. *PLoS Pathog* **9**, e1003118 (2013).
244. Barbalat, R., Lau, L., Locksley, R.M. & Barton, G.M. Toll-like receptor 2 on inflammatory monocytes induces type I interferon in response to viral but not bacterial ligands. *Nat Immunol* **10**, 1200–1207 (2009).
245. Odendall, C., Voak, A.A. & Kagan, J.C. Type III IFNs Are Commonly Induced by Bacteria-Sensing TLRs and Reinforce Epithelial Barriers during Infection. *J Immunol* **199**, 3270–3279 (2017).
246. Pandey, A.K. *et al.* NOD2, RIP2 and IRF5 play a critical role in the type I interferon response to Mycobacterium tuberculosis. *PLoS Pathog* **5**, e1000500 (2009).
247. Watanabe, T. *et al.* NOD1 contributes to mouse host defense against Helicobacter pylori via induction of type I IFN and activation of the ISGF3 signaling pathway. *J Clin Invest* **120**, 1645–1662 (2010).
248. del Fresno, C. *et al.* Interferon-beta production via Dectin-1-Syk-IRF5 signaling in dendritic cells is crucial for immunity to C. albicans. *Immunity* **38**, 1176–1186 (2013).
249. Gringhuis, S.I. *et al.* Fungal sensing by dectin-1 directs the non-pathogenic polarization of T(H)17 cells through balanced type I IFN responses in human DCs. *Nat Immunol* **23**, 1735–1748 (2022).
250. Kesavardhana, S. *et al.* ZBP1/DAI ubiquitination and sensing of influenza vRNPs activate programmed cell death. *J Exp Med* **214**, 2217–2229 (2017).
251. Lee, D. *et al.* Inborn errors of OAS-RNase L in SARS-CoV-2-related multisystem inflammatory syndrome in children. *Science* **379**, eabo3627 (2023).
252. Ferguson, B.J., Mansur, D.S., Peters, N.E., Ren, H. & Smith, G.L. DNA-PK is a DNA sensor for IRF-3-dependent innate immunity. *Elife* **1**, e00047 (2012).
253. Klein, B. *et al.* Epidermal ZBP1 stabilizes mitochondrial Z-DNA to drive UV-induced IFN signaling in autoimmune photosensitivity. *Sci Immunol* **10**, eado1710 (2025).
254. Ivashkiv, L.B. & Donlin, L.T. Regulation of type I interferon responses. *Nat Rev Immunol* **14**, 36–49 (2014).
255. Schoggins, J.W. Interferon-Stimulated Genes: What Do They All Do? *Annu Rev Virol* **6**, 567–584 (2019).
256. Kreins, A.Y. *et al.* Human TYK2 deficiency: Mycobacterial and viral infections without hyper-IgE syndrome. *J Exp Med* **212**, 1641–1662 (2015).
257. Forero, A. *et al.* Differential Activation of the Transcription Factor IRF1 Underlies the Distinct Immune Responses Elicited by Type I and Type III Interferons. *Immunity* **51**, 451–464 e456 (2019).
258. Francois-Newton, V. *et al.* USP18-based negative feedback control is induced by type I and type III interferons and specifically inactivates interferon alpha response. *PLoS One* **6**, e22200 (2011).
259. Freitas, B.T., Scholte, F.E.M., Bergeron, E. & Pegan, S.D. How ISG15 combats viral infection. *Virus Res* **286**, 198036 (2020).
260. Lu, G. *et al.* ISG15 enhances the innate antiviral response by inhibition of IRF-3 degradation. *Cell Mol Biol (Noisy-le-grand)* **52**, 29–41 (2006).
261. Piganis, R.A. *et al.* Suppressor of cytokine signaling (SOCS) 1 inhibits type I interferon (IFN) signaling via the interferon alpha receptor (IFNAR1)-associated tyrosine kinase Tyk2. *J Biol Chem* **286**, 33811–33818 (2011).

262. Fenner, J.E. *et al.* Suppressor of cytokine signaling 1 regulates the immune response to infection by a unique inhibition of type I interferon activity. *Nat Immunol* **7**, 33–39 (2006).
263. Stanifer, M.L., Pervolaraki, K. & Boulant, S. Differential Regulation of Type I and Type III Interferon Signaling. *Int J Mol Sci* **20** (2019).
264. Pillai, P.S. *et al.* Mx1 reveals innate pathways to antiviral resistance and lethal influenza disease. *Science* **352**, 463–466 (2016).
265. Loske, J. *et al.* Pre-activated antiviral innate immunity in the upper airways controls early SARS-CoV-2 infection in children. *Nat Biotechnol* **40**, 319–324 (2022).
266. Wong, A.C. *et al.* Serotonin reduction in post-acute sequelae of viral infection. *Cell* **186**, 4851–4867 e4820 (2023).
267. McNab, F., Mayer-Barber, K., Sher, A., Wack, A. & O'Garra, A. Type I interferons in infectious disease. *Nat Rev Immunol* **15**, 87–103 (2015).
268. Kretzschmar, G. *et al.* Normalized Interferon Signatures and Clinical Improvements by IFNAR1 Blocking Antibody (Anifrolumab) in Patients with Type I Interferonopathies. *J Clin Immunol* **45**, 31 (2024).
269. Crow, Y.J. & Casanova, J.L. Human life within a narrow range: The lethal ups and downs of type I interferons. *Sci Immunol* **9**, eadm8185 (2024).
270. Thomas, K.E., Galligan, C.L., Newman, R.D., Fish, E.N. & Vogel, S.N. Contribution of interferon-beta to the murine macrophage response to the toll-like receptor 4 agonist, lipopolysaccharide. *J Biol Chem* **281**, 31119–31130 (2006).
271. Boxx, G.M. & Cheng, G. The Roles of Type I Interferon in Bacterial Infection. *Cell Host Microbe* **19**, 760–769 (2016).
272. Kotov, D.I. *et al.* Early cellular mechanisms of type I interferon-driven susceptibility to tuberculosis. *Cell* **186**, 5536–5553 e5522 (2023).
273. Berry, M.P. *et al.* An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. *Nature* **466**, 973–977 (2010).
274. Robinson, N. *et al.* Type I interferon induces necroptosis in macrophages during infection with *Salmonella enterica* serovar Typhimurium. *Nat Immunol* **13**, 954–962 (2012).
275. Zhang, H., Zoued, A., Liu, X., Sit, B. & Waldor, M.K. Type I interferon remodels lysosome function and modifies intestinal epithelial defense. *Proc Natl Acad Sci U S A* **117**, 29862–29871 (2020).
276. Stetson, D.B. & Medzhitov, R. Type I interferons in host defense. *Immunity* **25**, 373–381 (2006).
277. Montoya, M. *et al.* Type I interferons produced by dendritic cells promote their phenotypic and functional activation. *Blood* **99**, 3263–3271 (2002).
278. Ito, T. *et al.* Differential regulation of human blood dendritic cell subsets by IFNs. *J Immunol* **166**, 2961–2969 (2001).
279. Kolumam, G.A., Thomas, S., Thompson, L.J., Sprent, J. & Murali-Krishna, K. Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. *J Exp Med* **202**, 637–650 (2005).
280. Gil, M.P., Salomon, R., Louten, J. & Biron, C.A. Modulation of STAT1 protein levels: a mechanism shaping CD8 T-cell responses in vivo. *Blood* **107**, 987–993 (2006).
281. Heer, A.K. *et al.* TLR signaling fine-tunes anti-influenza B cell responses without regulating effector T cell responses. *J Immunol* **178**, 2182–2191 (2007).
282. Coro, E.S., Chang, W.L. & Baumgarth, N. Type I IFN receptor signals directly stimulate local B cells early following influenza virus infection. *J Immunol* **176**, 4343–4351 (2006).
283. Alspach, E., Lussier, D.M. & Schreiber, R.D. Interferon gamma and Its Important Roles in Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity. *Cold Spring Harb Perspect Biol* **11** (2019).
284. Yang, R. *et al.* Human T-bet Governs Innate and Innate-like Adaptive IFN-gamma Immunity against *Mycobacteria*. *Cell* **183**, 1826–1847 e1831 (2020).

285. Shimasaki, N., Jain, A. & Campana, D. NK cells for cancer immunotherapy. *Nat Rev Drug Discov* **19**, 200–218 (2020).
286. Berg, R.E., Crossley, E., Murray, S. & Forman, J. Memory CD8⁺ T cells provide innate immune protection against *Listeria monocytogenes* in the absence of cognate antigen. *J Exp Med* **198**, 1583–1593 (2003).
287. Miyagi, T. *et al.* High basal STAT4 balanced by STAT1 induction to control type 1 interferon effects in natural killer cells. *J Exp Med* **204**, 2383–2396 (2007).
288. Nguyen, K.B. *et al.* Coordinated and distinct roles for IFN- α β , IL-12, and IL-15 regulation of NK cell responses to viral infection. *J Immunol* **169**, 4279–4287 (2002).
289. Rusinova, I. *et al.* Interferome v2.0: an updated database of annotated interferon-regulated genes. *Nucleic Acids Res* **41**, D1040–1046 (2013).
290. Michalska, A., Blaszczyk, K., Wesoly, J. & Bluysen, H.A.R. A Positive Feedback Amplifier Circuit That Regulates Interferon (IFN)-Stimulated Gene Expression and Controls Type I and Type II IFN Responses. *Front Immunol* **9**, 1135 (2018).
291. Schroder, K., Hertzog, P.J., Ravasi, T. & Hume, D.A. Interferon- γ : an overview of signals, mechanisms and functions. *J Leukoc Biol* **75**, 163–189 (2004).
292. Steimle, V., Siegrist, C.A., Mottet, A., Lisowska-Grospierre, B. & Mach, B. Regulation of MHC class II expression by interferon- γ mediated by the transactivator gene CIITA. *Science* **265**, 106–109 (1994).
293. Kang, K. *et al.* Interferon- γ Represses M2 Gene Expression in Human Macrophages by Disassembling Enhancers Bound by the Transcription Factor MAF. *Immunity* **47**, 235–250 e234 (2017).
294. Lee, A.J. & Ashkar, A.A. The Dual Nature of Type I and Type II Interferons. *Front Immunol* **9**, 2061 (2018).
295. Califano, D. *et al.* IFN- γ increases susceptibility to influenza A infection through suppression of group II innate lymphoid cells. *Mucosal Immunol* **11**, 209–219 (2018).
296. Casanova, J.L., MacMicking, J.D. & Nathan, C.F. Interferon- γ and infectious diseases: Lessons and prospects. *Science* **384**, ead12016 (2024).
297. Stoljar, A. *et al.* Impaired Aire-dependent IFN signaling in the thymus precedes the protective autoantibodies to IFN α . *J Exp Med* **222** (2025).
298. Dolowschiak, T. *et al.* IFN- γ Hinders Recovery from Mucosal Inflammation during Antibiotic Therapy for Salmonella Gut Infection. *Cell Host Microbe* **20**, 238–249 (2016).
299. Monack, D.M., Mueller, A. & Falkow, S. Persistent bacterial infections: the interface of the pathogen and the host immune system. *Nat Rev Microbiol* **2**, 747–765 (2004).
300. Laidlaw, S.M. & Dustin, L.B. Interferon λ : opportunities, risks, and uncertainties in the fight against HCV. *Front Immunol* **5**, 545 (2014).
301. Osterlund, P.I., Pietila, T.E., Veckman, V., Kotenko, S.V. & Julkunen, I. IFN regulatory factor family members differentially regulate the expression of type III IFN (IFN- λ) genes. *J Immunol* **179**, 3434–3442 (2007).
302. Broggi, A., Granucci, F. & Zanoni, I. Type III interferons: Balancing tissue tolerance and resistance to pathogen invasion. *J Exp Med* **217** (2020).
303. Bolen, C.R., Ding, S., Robek, M.D. & Kleinstein, S.H. Dynamic expression profiling of type I and type III interferon-stimulated hepatocytes reveals a stable hierarchy of gene expression. *Hepatology* **59**, 1262–1272 (2014).
304. Schnepf, D. *et al.* Selective Janus kinase inhibition preserves interferon- λ -mediated antiviral responses. *Sci Immunol* **6** (2021).
305. Watling, D. *et al.* Complementation by the protein tyrosine kinase JAK2 of a mutant cell line defective in the interferon- γ signal transduction pathway. *Nature* **366**, 166–170 (1993).
306. Blumer, T., Coto-Llerena, M., Duong, F.H.T. & Heim, M.H. SOCS1 is an inducible negative regulator of interferon λ (IFN- λ)-induced gene expression in vivo. *J Biol Chem* **292**, 17928–17938 (2017).

307. Hernandez, P.P. *et al.* Interferon-lambda and interleukin 22 act synergistically for the induction of interferon-stimulated genes and control of rotavirus infection. *Nat Immunol* **16**, 698–707 (2015).
308. Rivera, A. Interferon Lambda's New Role as Regulator of Neutrophil Function. *J Interferon Cytokine Res* **39**, 609–617 (2019).
309. Philip, D.T. *et al.* Interferon lambda restricts herpes simplex virus skin disease by suppressing neutrophil-mediated pathology. *mBio* **15**, e0262323 (2024).
310. Mordstein, M. *et al.* Interferon-lambda contributes to innate immunity of mice against influenza A virus but not against hepatotropic viruses. *PLoS Pathog* **4**, e1000151 (2008).
311. Mahlakoiv, T., Hernandez, P., Gronke, K., Diefenbach, A. & Staeheli, P. Leukocyte-derived IFN-alpha/beta and epithelial IFN-lambda constitute a compartmentalized mucosal defense system that restricts enteric virus infections. *PLoS Pathog* **11**, e1004782 (2015).
312. Nice, T.J. *et al.* Interferon-lambda cures persistent murine norovirus infection in the absence of adaptive immunity. *Science* **347**, 269–273 (2015).
313. Stanifer, M.L. *et al.* Critical Role of Type III Interferon in Controlling SARS-CoV-2 Infection in Human Intestinal Epithelial Cells. *Cell Rep* **32**, 107863 (2020).
314. Tummers, B. & Green, D.R. Caspase-8: regulating life and death. *Immunol Rev* **277**, 76–89 (2017).
315. Horn, S. *et al.* Caspase-10 Negatively Regulates Caspase-8-Mediated Cell Death, Switching the Response to CD95L in Favor of NF-kappaB Activation and Cell Survival. *Cell Rep* **19**, 785–797 (2017).
316. Schug, Z.T., Gonzalez, F., Houtkooper, R.H., Vaz, F.M. & Gottlieb, E. BID is cleaved by caspase-8 within a native complex on the mitochondrial membrane. *Cell Death Differ* **18**, 538–548 (2011).
317. Xu, G. & Shi, Y. Apoptosis signaling pathways and lymphocyte homeostasis. *Cell Res* **17**, 759–771 (2007).
318. Vogler, M. *et al.* The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy. *Signal Transduct Target Ther* **10**, 91 (2025).
319. Danial, N.N. & Korsmeyer, S.J. Cell death: critical control points. *Cell* **116**, 205–219 (2004).
320. Chen, L. *et al.* Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. *Mol Cell* **17**, 393–403 (2005).
321. Zou, H., Henzel, W.J., Liu, X., Lutschg, A. & Wang, X. Apaf-1, a human protein homologous to *C. elegans* CED-4, participates in cytochrome c-dependent activation of caspase-3. *Cell* **90**, 405–413 (1997).
322. Deveraux, Q.L., Takahashi, R., Salvesen, G.S. & Reed, J.C. X-linked IAP is a direct inhibitor of cell-death proteases. *Nature* **388**, 300–304 (1997).
323. Chai, J. *et al.* Structural and biochemical basis of apoptotic activation by Smac/DIABLO. *Nature* **406**, 855–862 (2000).
324. Trapani, J.A. Target cell apoptosis induced by cytotoxic T cells and natural killer cells involves synergy between the pore-forming protein, perforin, and the serine protease, granzyme B. *Aust N Z J Med* **25**, 793–799 (1995).
325. Degterev, A. *et al.* Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. *Nat Chem Biol* **1**, 112–119 (2005).
326. Dong, J. *et al.* Exploring necroptosis: mechanistic analysis and antitumor potential of nanomaterials. *Cell Death Discov* **11**, 211 (2025).
327. Dhuriya, Y.K. & Sharma, D. Necroptosis: a regulated inflammatory mode of cell death. *J Neuroinflammation* **15**, 199 (2018).
328. Vandenabeele, P., Galluzzi, L., Vanden Berghe, T. & Kroemer, G. Molecular mechanisms of necroptosis: an ordered cellular explosion. *Nat Rev Mol Cell Biol* **11**, 700–714 (2010).
329. Gong, Y.N., Guy, C., Crawford, J.C. & Green, D.R. Biological events and molecular signaling following MLKL activation during necroptosis. *Cell Cycle* **16**, 1748–1760 (2017).

330. Cai, Z. *et al.* Plasma membrane translocation of trimerized MLKL protein is required for TNF-induced necroptosis. *Nat Cell Biol* **16**, 55–65 (2014).
331. Jiao, H. *et al.* Publisher Correction: Z-nucleic-acid sensing triggers ZBP1-dependent necroptosis and inflammation. *Nature* **580**, E10 (2020).
332. He, S., Liang, Y., Shao, F. & Wang, X. Toll-like receptors activate programmed necrosis in macrophages through a receptor-interacting kinase-3-mediated pathway. *Proc Natl Acad Sci U S A* **108**, 20054–20059 (2011).
333. Roberts, J.Z., Crawford, N. & Longley, D.B. The role of Ubiquitination in Apoptosis and Necroptosis. *Cell Death Differ* **29**, 272–284 (2022).
334. Liu, Z. *et al.* Oligomerization-driven MLKL ubiquitylation antagonizes necroptosis. *EMBO J* **40**, e103718 (2021).
335. Gong, Y.N. *et al.* ESCRT-III Acts Downstream of MLKL to Regulate Necroptotic Cell Death and Its Consequences. *Cell* **169**, 286–300 e216 (2017).
336. Kelley, N., Jeltema, D., Duan, Y. & He, Y. The NLRP3 Inflammasome: An Overview of Mechanisms of Activation and Regulation. *Int J Mol Sci* **20** (2019).
337. Lopez-Castejon, G. Control of the inflammasome by the ubiquitin system. *FEBS J* **287**, 11–26 (2020).
338. Yu, P. *et al.* Pyroptosis: mechanisms and diseases. *Signal Transduct Target Ther* **6**, 128 (2021).
339. Broz, P. & Dixit, V.M. Inflammasomes: mechanism of assembly, regulation and signalling. *Nat Rev Immunol* **16**, 407–420 (2016).
340. Kayagaki, N. *et al.* NINJ1 mediates plasma membrane rupture during lytic cell death. *Nature* **591**, 131–136 (2021).
341. Li, Z. *et al.* Enhancing Gasdermin-induced tumor pyroptosis through preventing ESCRT-dependent cell membrane repair augments antitumor immune response. *Nat Commun* **13**, 6321 (2022).
342. De Schutter, E. *et al.* Plasma membrane perforation by GSDME during apoptosis-driven secondary necrosis. *Cell Mol Life Sci* **79**, 19 (2021).
343. Sarhan, J. *et al.* Caspase-8 induces cleavage of gasdermin D to elicit pyroptosis during Yersinia infection. *Proc Natl Acad Sci U S A* **115**, E10888–E10897 (2018).
344. Zhang, Z. *et al.* Gasdermin E suppresses tumour growth by activating anti-tumour immunity. *Nature* **579**, 415–420 (2020).
345. Zhou, Z. *et al.* Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells. *Science* **368** (2020).
346. Exconde, P.M. *et al.* The tetrapeptide sequence of IL-18 and IL-1 β regulates their recruitment and activation by inflammatory caspases. *Cell Rep* **42**, 113581 (2023).
347. Yi, Y.S. Caspase-11 non-canonical inflammasome: a critical sensor of intracellular lipopolysaccharide in macrophage-mediated inflammatory responses. *Immunology* **152**, 207–217 (2017).
348. Kayagaki, N. *et al.* Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling. *Nature* **526**, 666–671 (2015).
349. Mouton-Liger, F. *et al.* Parkin deficiency modulates NLRP3 inflammasome activation by attenuating an A20-dependent negative feedback loop. *Glia* **66**, 1736–1751 (2018).
350. Siu, K.L. *et al.* Severe acute respiratory syndrome coronavirus ORF3a protein activates the NLRP3 inflammasome by promoting TRAF3-dependent ubiquitination of ASC. *FASEB J* **33**, 8865–8877 (2019).
351. Rodgers, M.A. *et al.* The linear ubiquitin assembly complex (LUBAC) is essential for NLRP3 inflammasome activation. *J Exp Med* **211**, 1333–1347 (2014).
352. Guarda, G. *et al.* Type I interferon inhibits interleukin-1 production and inflammasome activation. *Immunity* **34**, 213–223 (2011).
353. Kane, E.I. & Spratt, D.E. Structural Insights into Ankyrin Repeat-Containing Proteins and Their Influence in Ubiquitylation. *Int J Mol Sci* **22** (2021).

354. Mueller, T.D. & Feigon, J. Solution structures of UBA domains reveal a conserved hydrophobic surface for protein-protein interactions. *J Mol Biol* **319**, 1243–1255 (2002).
355. Mace, P.D. *et al.* Structures of the cIAP2 RING domain reveal conformational changes associated with ubiquitin-conjugating enzyme (E2) recruitment. *J Biol Chem* **283**, 31633–31640 (2008).
356. Budhidarmo, R., Nakatani, Y. & Day, C.L. RINGs hold the key to ubiquitin transfer. *Trends Biochem Sci* **37**, 58–65 (2012).
357. Cotton, T.R. & Lechtenberg, B.C. Chain reactions: molecular mechanisms of RBR ubiquitin ligases. *Biochem Soc Trans* **48**, 1737–1750 (2020).
358. Duda, D.M. *et al.* Structure of HHARI, a RING-IBR-RING ubiquitin ligase: autoinhibition of an Ariadne-family E3 and insights into ligation mechanism. *Structure* **21**, 1030–1041 (2013).
359. Miller, S.L., Malotky, E. & O'Bryan, J.P. Analysis of the role of ubiquitin-interacting motifs in ubiquitin binding and ubiquitylation. *J Biol Chem* **279**, 33528–33537 (2004).
360. Wright, M.H., Heal, W.P., Mann, D.J. & Tate, E.W. Protein myristoylation in health and disease. *J Chem Biol* **3**, 19–35 (2010).
361. Wang, Y. *et al.* A20 protein regulates lipopolysaccharide-induced acute lung injury by downregulation of NF-kappaB and macrophage polarization in rats. *Mol Med Rep* **16**, 4964–4972 (2017).
362. Sharma, A. & Dey, P. A machine learning approach to unmask novel gene signatures and prediction of Alzheimer's disease within different brain regions. *Genomics* **113**, 1778–1789 (2021).
363. Zhu, X. *et al.* Circular RNA circANKIB1 promotes the progression of osteosarcoma by regulating miR-217/PAX3 axis. *J Bone Oncol* **27**, 100347 (2021).
364. Du, J. *et al.* E2 variants for probing E3 ubiquitin ligase activities. *Proc Natl Acad Sci U S A* **123**, e2524899122 (2026).
365. Hai, L.Y. *et al.* HSPA6 Promotes Ferroptosis in Triple-Negative Breast Cancer by Rewiring Lipid Metabolism to Potentiate Membrane Lipid Peroxidation. *Int J Biol Sci* **22**, 4168–4193 (2026).
366. Hjerpe, R. *et al.* Efficient protection and isolation of ubiquitylated proteins using tandem ubiquitin-binding entities. *EMBO Rep* **10**, 1250–1258 (2009).
367. Shrum, B. *et al.* A robust scoring system to evaluate sepsis severity in an animal model. *BMC Res Notes* **7**, 233 (2014).
368. Wang, A. *et al.* Specific sequences of infectious challenge lead to secondary hemophagocytic lymphohistiocytosis-like disease in mice. *Proc Natl Acad Sci U S A* **116**, 2200–2209 (2019).
369. Uranga-Murillo, I. *et al.* Biological relevance of Granzymes A and K during E. coli sepsis. *Theranostics* **11**, 9873–9883 (2021).
370. Tyanova, S., Temu, T. & Cox, J. The MaxQuant computational platform for mass spectrometry-based shotgun proteomics. *Nat Protoc* **11**, 2301–2319 (2016).
371. Tyanova, S. *et al.* The Perseus computational platform for comprehensive analysis of (prote)omics data. *Nat Methods* **13**, 731–740 (2016).
372. French, M.E., Koehler, C.F. & Hunter, T. Emerging functions of branched ubiquitin chains. *Cell Discov* **7**, 6 (2021).
373. Boname, J.M. *et al.* Efficient internalization of MHC I requires lysine-11 and lysine-63 mixed linkage polyubiquitin chains. *Traffic* **11**, 210–220 (2010).
374. Qiu, Y. *et al.* Emerging views of OPTN (optineurin) function in the autophagic process associated with disease. *Autophagy* **18**, 73–85 (2022).
375. Richter, B. *et al.* Phosphorylation of OPTN by TBK1 enhances its binding to Ub chains and promotes selective autophagy of damaged mitochondria. *Proc Natl Acad Sci U S A* **113**, 4039–4044 (2016).

- 376. Hoebe, K. *et al.* Identification of Lps2 as a key transducer of MyD88-independent TIR signalling. *Nature* **424**, 743–748 (2003).
- 377. Kagan, J.C. *et al.* TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-beta. *Nat Immunol* **9**, 361–368 (2008).
- 378. Slowicka, K. *et al.* Optineurin deficiency in mice is associated with increased sensitivity to Salmonella but does not affect proinflammatory NF-kappaB signaling. *Eur J Immunol* **46**, 971–980 (2016).
- 379. Yum, S., Li, M., Fang, Y. & Chen, Z.J. TBK1 recruitment to STING activates both IRF3 and NF-kappaB that mediate immune defense against tumors and viral infections. *Proc Natl Acad Sci USA* **118** (2021).
- 380. Tsuchida, T. *et al.* The ubiquitin ligase TRIM56 regulates innate immune responses to intracellular double-stranded DNA. *Immunity* **33**, 765–776 (2010).
- 381. Ames, J. *et al.* OPTN is a host intrinsic restriction factor against neuroinvasive HSV-1 infection. *Nat Commun* **12**, 5401 (2021).
- 382. Riley, B.E. *et al.* Structure and function of Parkin E3 ubiquitin ligase reveals aspects of RING and HECT ligases. *Nat Commun* **4**, 1982 (2013).
- 383. Roman-Trufero, M. & Dillon, N. The UBE2D ubiquitin conjugating enzymes: Potential regulatory hubs in development, disease and evolution. *Front Cell Dev Biol* **10**, 1058751 (2022).
- 384. Martino, L., Brown, N.R., Masino, L., Esposito, D. & Rittinger, K. Determinants of E2-ubiquitin conjugate recognition by RBR E3 ligases. *Sci Rep* **8**, 68 (2018).

6 Appendix

6.1 Abbreviations

A20	TNF- α -Induced Protein 3
ABIN	A20 Binding Inhibitor of NF- κ B
Ac	Acetyl group
AGS	Aicardi-Goutières Syndrome
AIM2	Absent in Melanoma 2
ALRs	AIM2-Like Receptors
AMFR	Autocrine Motility Factor Receptor
APC/C	Anaphase promoting complex
ANKIB1	Ankyrin Repeat and IBR Domain-Containing Protein 1
AP-2	Activating Protein-2
APAF1	Apoptotic Protease Activating Factor 1
APC	Antigen-Presenting Cell
APS-1	Autoimmune polyendocrine syndrome type 1
ASC	Apoptosis-Associated Speck-Like Protein Containing a CARD
ATP	Adenosine Triphosphate
BAFF	B-Cell Activating Factor
BAK	BCL-2 Homologous Antagonist/Killer
BAX	BCL-2-Associated X Protein
Bcl-2	B-Cell Lymphoma 2
BID	BH3-Interacting Domain Death Agonist
BH3	Bcl-2 Homology 3
CARD	Caspase Recruitment Domain
Caspase	Cysteiny-Aspartate Specific Protease
c-FLIP	Cellular FLICE-Inhibitory Protein
cGAS	Cyclic GMP-AMP Synthase
cIAP1/2	Cellular Inhibitor of Apoptosis Proteins 1/2
CLP	Cecal Ligation and Puncture
CLR	C-Type Lectin Receptor
CLRs	C-Type Lectin Receptors

COVID-19	Coronavirus Disease 2019
CTLDs	C-Type Lectin-Like Domains
CYLD	Cylindromatosis
DAI	DNA-Induced Activator of IFN
DAMP	Damage-Associated Molecular Pattern
DD	Death Domain
DDM	n-Dodecyl- β -D-Maltopyranoside
DC	Dendritic Cell
Dectin-1	Dendritic Cell-Associated C-Type Lectin-1
DED	Death Effector Domain
DISC	Death-Inducing Signalling Complex
DIABLO	Direct IAP-Binding Protein with Low pI
DMEM	Dulbecco's Modified Eagle's Medium
DNA-PKcs	DNA-dependent protein kinase catalytic subunit
DR	Death Receptor
dRING	degenerate RING
dsRNA	Double-Stranded Ribonucleic Acid
DUB	Deubiquitinase
E1	Ubiquitin-Activating Enzyme
E2	Ubiquitin-Conjugating Enzyme
E3	Ubiquitin Ligase
E. coli	Escherichia coli
EMCV	Encephalomyocarditis Virus
ER	Endoplasmic Reticulum
ERK	Extracellular Signal-Regulated Kinase
ERGIC	ER-Golgi Intermediate Compartment
ESCRT	Endosomal Sorting Complex Required for Transport
FADD	Fas-Associated Death Domain
FasL	Fas Ligand
FBS	Fetal Bovine Serum
GM-CSF	Granulocyte-Macrophage Colony-Stimulating Factor

GSDMD/E	Gasdermin D/E
HECT	Homologous to the E6-AP Carboxyl Terminus
HIF1- α	Hypoxia-Inducible Factor 1-alpha
HOIL-1	Heme-Oxidized IRP2 Ubiquitin Ligase 1
HOIP	HOIL-1-Interacting Protein
HRP	Horseradish Peroxidase
IAP	Inhibitor of Apoptosis Protein
IBR	In-Between Ring
IEC	Intestinal Epithelial Cell
IFN	Interferon
IFN-I	Type I Interferon
IFN-II	Type II Interferon
IFN-III	Type III Interferon
IFNAR	Interferon α/β Receptor
IFNAR1/2	Interferon Alpha/Beta Receptor Subunits 1/2
IFNLR	Interferon Lambda Receptor
IL	Interleukin
IL10RB	IL-10 Receptor Subunit Beta
IKK	I κ B Kinase
INSIG1	Insulin-Induced Gene 1
IP	Immunoprecipitation
IRAK	IL-1 Receptor-Associated Kinase
IRF3/5/7	Interferon Regulatory Factor 3/5/7
ISG	Interferon-Stimulated Gene
ISGs	Interferon-Stimulated Genes
ISRE	Interferon-Stimulated Response Element
I κ B	Inhibitor of NF- κ B
JAK1/2	Janus Kinase1/2
JAMM	JAB1/MPN/MOV34 Metalloprotease
kDa	Kilodalton
KO	Knockout

LBP	LPS-Binding Protein
LGP	Laboratory of Genetics and Physiology
LPS	Lipopolysaccharide
LRR	Leucine-Rich Repeat
LUBAC	Linear Ubiquitin Chain Assembly Complex
MAPK	Mitogen-Activated Protein Kinase
MD2	Myeloid Differentiation 2
MDA5	Melanoma Differentiation-Associated Protein 5
MHC	Major Histocompatibility Complex
MK2	MAPK-Activated Protein Kinase 2
MLKL	Mixed Lineage Kinase Domain-Like
MOMP	Mitochondrial Outer Membrane Permeabilisation
M.tb	Mycobacterium tuberculosis
mTOR	Mechanistic Target of Rapamycin
MyD88	Myeloid Differentiation Primary Response 88
MS	Mass Spectrometry
MW	Molecular Weight
NALP	NACHT-, LRR-, and PYD-Containing Protein
NAP1	Nucleosome Assembly Protein 1
NF- κ B	Nuclear Factor κ B
NINJ1	Nerve Injury-Induced Protein 1
NK	Natural Killer
NLR	NOD-Like Receptor
NLRP3	NLR family pyrin domain containing 3
NOD1	Nucleotide-Binding Oligomerisation Domain Containing 1
OAS1	Oligoadenylate Synthetase 1
OPTN	Optineurin
OTULIN	OTU Deubiquitinase with Linear Linkage Specificity
PAMP	Pathogen-Associated Molecular Pattern
PBS	Phosphate-Buffered Saline
pDCs	Plasmacytoid Dendritic Cells

PDL-1	Programmed Cell Death Ligand 1
PEI	Polyethyleneimine
PKR	Protein Kinase R
Poly(I:C)	Polyinosinic:Polycytidylic Acid
PRR	Pattern Recognition Receptor
PTM	Post-Translational Modification
PYD	Pyrin Domain
QKO	Quadruple Knock out
RBR	RING-Between-RING
RIG-I	Retinoic Acid-Inducible Gene I
RIP	Receptor-Interacting Protein
RHIM	RIP Homotypic Interaction Motif
RING	Really Interesting New Gene
RLR	RIG-I-Like Receptor
RNF	RING Finger Protein
RNA	Ribonucleic Acid
RPMI	Roswell Park Memorial Institute
ROS	Reactive Oxygen Species
SARS-CoV-2	Severe Acute Respiratory Syndrome Coronavirus 2
SHARPIN	SHANK-Associated RH Domain-Interacting Protein
siRNA	Small Interfering RNA
SMAC	Second Mitochondria-Derived Activator of Caspases
SOCS1	Suppressor of Cytokine Signalling 1
STAT1/2	Signal Transducer and Activator of Transcription 1/2
STING	Stimulator of Interferon Genes
SAVI	STING-Associated Vasculopathy with Onset in Infancy
TAB2/3	TAK1-Binding Protein 2/3
TAK1	Transforming Growth Factor- β -Activated Kinase 1
TANK	TRAF Family Member-Associated NF- κ B Activator
TAP	Tandem Affinity Purification
TBK1	TANK-Binding Kinase 1

TCR	T Cell Receptor
THP-1	Tohoku Hospital Pediatrics-1
TIR	Toll/Interleukin-1 Receptor
TIRAP	TIR Domain-Containing Adaptor Protein
TKO	Triple Knock out
TLR3/4	Toll-Like Receptor 3/4
TNF	Tumour Necrosis Factor
TNFR	TNF Receptor
TNFR1-SC	TNFR1 Signalling Complex
TRADD	TNFR1-Associated Death Domain Protein
TRAF2/3/5/6	TNF Receptor-Associated Factor 2/3/5/6
TRAIL	TNF-Related Apoptosis-Inducing Ligand
TRAIL1/2	TNF-Related Apoptosis-Inducing Ligand Receptors 1/2
TRAM	TRIF-Related Adaptor Molecule
TRIF	TIR-Domain-Containing Adapter-Inducing Interferon- β
TYK2	Tyrosine Kinase 2
UB	Ubiquitination
UBAN	Ubiquitin-Binding Domain in ABINs and NEMO
UBD	Ubiquitin-Binding Domain
UIM	Ubiquitin-Interacting Motif
UNC93B1	Unc-93 Homolog B1
USP	Ubiquitin-Specific Protease
USP18	Ubiquitin-Specific Peptidase 18
WNV	West Nile Virus
WT	Wild Type
XIAP	X-Linked Inhibitor of Apoptosis Protein
ZBP1	Z-DNA-Binding Protein 1

6.2 List of the Figures

Figure 1.1: Structural Architecture of Ubiquitin and Modalities of Ubiquitination.....9

Figure 1.2: Diversity of Polyubiquitin Chain Topologies and Their Established Biological Functions.....10

Figure 1.3: General Overview of Ubiquitination Mechanism.....	11
Figure 1.4: Comparative Schematic of E3 Ubiquitin Ligase Classes.....	15
Figure 1.5: Schematic Overview of Tumour Necrosis Factor Receptor 1 (TNFR1) Signalling Complexes and Regulatory Mechanisms.....	20
Figure 1.6: Toll-like receptor 3 (TLR3) signalling pathway.....	29
Figure 1.7: MyD88 and TRIF-dependent TLR4 signalling pathway.....	33
Figure 1.8: Schematic representation of RIG-I/MAVS pathway.....	37
Figure 1.9: Overview of cGAS-STING pathway.....	40
Figure 1.10: A comprehensive overview of the extrinsic and intrinsic apoptotic pathways.....	52
Figure 1.11: Domain architecture of ANKIB1, and its conservation scores of its residues.....	57
Figure 1.12: Alignment of the RING domain sequences across different RBR and RING type E3 ligases.....	58
Figure 1.13: Alignment of the RING2 domain sequences across different RBR E3 ligases.....	59
Main Figures	
Figure 1: TLR3-mediated TBK1 and IRF3 activation requires ANKIB1, a member of the TLR3-SC, to promote type-I and type-III IFN induction.....	69
Figure 2: The RBR and UIM domains of ANKIB1 are crucial for TBK1 phosphorylation.....	70
Figure 3: Optineurin is the crucial adaptor protein for TBK1 activation and requires K11-Ub generated by ANKIB1 for TLR3-SC recruitment.....	73
Figure 4: Type-I/III IFN induction by TLR4 and cGAS-STING, but not RIG-I, depends on ANKIB1.....	75
Figure 5: ANKIB1 promotes ubiquitination of TRIF, STING, NEMO, OPTN and itself.....	77
Figure 6: ANKIB1 is crucial for TLR3- and cGAS-STING-mediated IFN induction <i>in vivo</i>	79
Extended Data Figure 1: ANKIB1 knockdown disrupt TLR3-induced TBK1 activation.....	85
Extended Data Figure 2: ANKIB1 enables TBK1 activation in TLR3 pathway but does not act in TNF signalling.....	86
Extended Data Figure 3: Characterisation of ANKIB1's catalytic domain and its requirement for TLR3-induced TBK1 activation.....	87
Extended Data Figure 4: Contribution of ANKIB1 and the adaptor proteins in STING and RIG-I signalling.....	88
Extended Data Figure 5: Role of ANKIB1 <i>ex vivo</i> and characterisation of <i>Ankib1</i> ^{-/-} mice.....	89
Extended Data Figure 6: Inflammatory response characterisation of <i>Ankib1</i> ^{-/-} mice in sHLH and HSV-1 infection model.....	91